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This thesis focuses on the evaluation of the optimal allocation and duration of adjuvant chemotherapy 
in stage II colon cancer. Using decision-analytic modelling, we evaluated the cost-effectiveness of 
different strategies to allocate adjuvant chemotherapy in stage II colon cancer patients. In addition, 
we evaluated the optimal treatment duration in these patients.  
This chapter briefly describes colon cancer epidemiology and the importance of optimizing treatment 
strategies in stage II colon cancer. Subsequently, it explains why adjuvant chemotherapy allocation is 
considered as a medical dilemma in stage II colon cancer by discussing treatment effectiveness, the 
selection of high-risk patients, the optimal treatment duration and the health risks of adjuvant 
chemotherapy. Furthermore, the advantages of decision-analytic modelling to address the challenge 
of adjuvant chemotherapy allocation and optimal treatment duration in stage II colon cancer are 
discussed. Finally, the aims and outline of this thesis are described. 
Colon cancer 
Colon cancer is the fourth most commonly diagnosed cancer worldwide, after lung-, breast- and 
prostate cancer, with around 1.1 million new cases and 0.6 million deaths in 2018.1 The incidence of 
colon cancer varies widely by world region and is highest in western countries, which is probably due 
to differences in lifestyle compared to non-Western countries.1 Worldwide, the incidence and 
mortality rates are higher in men compared to women.  
In the Netherlands, colon cancer is an important health problem as well. The incidence has more than 
doubled in the last thirty years; from 4,600 new cases in 1989 to 9,800 cases in 2018.2 The average age 
of a colon cancer patient is 69 years at the moment of diagnosis. In addition, more than 30% of all 
newly diagnosed patients are aged 75 or older.2 Thus, colon cancer mainly affects elderly patients. 
Given the aging population in the Netherlands in combination with an unfavourable change in lifestyle, 
such as a decrease in physical activity and an increase in alcohol consumption, the risk to develop colon 
cancer is increasing. On the other hand, the Dutch colorectal cancer screening program was introduced 
in 2014, which hopefully will ensure a decrease in colon cancer mortality in the long term.  
Shift in colon cancer stage distribution 
Using the tumor-node-metastasis (TNM) system, four disease stages are distinguished to classify the 
extensiveness of colon cancer.3 In this thesis, we focus on stage II colon cancer, which means that the 
tumor has grown through the colon wall, but has not spread to regional lymph nodes or distant organs. 
The proportion of stage II colon cancer patients was 26% in 2018 in the Netherlands. Due to the 
introduction of the Dutch national colorectal cancer screening program, the proportion of stage II 
colon cancer patients slightly decreased. To illustrate, in 2013 28% of the colon cancer patients were 
diagnosed with stage II disease.4  
Medical dilemma’s in stage II colon cancer treatment 
The standard treatment of stage II colon cancer patients is surgical resection. The overall prognosis 
after surgical resection is relatively good. To illustrate, the QUASAR trial reported in 2007 5-year 
survival rates of 76% and 80% for disease-free survival (DFS) and overall survival (OS), respectively.5 
However, the stage II colon cancer population is heterogeneous regarding the risk to develop a 
recurrence. Therefore, adjuvant chemotherapy is recommended in national and international 
guidelines to optimize survival probabilities for those patients with a high risk of recurrence.6-8 
Notwithstanding these recommendations, there are still three important knowledge gaps. Firstly, 
8
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despite the large number of RCTs that have evaluated adjuvant treatment effectiveness in colon cancer 
patients, the effectiveness in the stage II population remains unclear, mainly due to insufficient power 
in the studies for the stage II population. Furthermore, over the years the number of examined regional 
lymphnodes per patients increased as this provides important information about the patients’ 
prognosis, which resulted in a migration of disease stage.9 That is, a patient that was classified as stage 
II before the increasing number of evaluated lymphnodes, could possibly be classified as stage III in a 
more recently conducted study. Secondly, there is no consensus on which high-risk features should be 
taken into account to select stage II colon cancer patients for adjuvant chemotherapy. Thirdly, there is 
less convincing data for the optimal duration of adjuvant treatment in stage II colon cancer patients 
compared to stage III colon cancer. Moreover, when deliberating on the optimal treatment choice in 
stage II colon cancer, it is important to explicitly take into account the fact that there are also health 
risks associated with adjuvant chemotherapy. To guide the clinical decision making process, the 
potential health gain of adjuvant treatment should be carefully balanced against the potential harms. 
Summarizing, the identification of patients that require adjuvant chemotherapy as well as the optimal 
treatment duration remains challenging. Below the three knowledge gaps are discussed in more detail.  
The effect of adjuvant chemotherapy in stage II colon cancer 
The treatment effect of adjuvant chemotherapy in stage II colon cancer has been evaluated in several 
randomized clinical trials (RCTs) during the last decades. IMPACT was the first collaboration that 
conducted a pooled analysis of 1,016 patients with stage II colon cancer from 5 RCTs, which compared 
a fluorouracil-leucovorin (FU-LV) treated group to a control group. The group that was treated with 
FU-LV demonstrated a small, statistically non-significant improvement in 5-year DFS and OS. The DFS 
rates were 76% versus 73% and the OS rates were 82% versus 80% for the FU-LV group compared to 
the control group, respectively.10 Subsequently, in 2004 another meta-analysis was conducted in which 
3,302 patients were included with stage II or III colon cancer from 7 RCTs (the 5 RCTs included in 
IMPACT and two additional RCTs), which compared FU-LV to a control group. In a stage II colon cancer 
subgroup analysis (n=1,440), a small but significant difference of 4% (76% versus 72%, p=0.049) was 
found for DFS and a small non-significant difference of 1% in OS (81% versus 80%, p=0.113).11  
In 2007, results of the QUASAR trial became available. In the QUASAR trial, 3,239 resected stage I (1%), 
II (91%) and III (8%) patients were included of which 71% was diagnosed with colon cancer and 29% 
with rectal cancer. Patients were randomized to a FU-LV arm (with or without levamisole) or a control 
arm. The QUASAR trial demonstrated a relative risk of recurrence of 0.78 (95% CI, 0.67-0.91) and a 
relative risk of OS of 0.82 (95% CI, 0.70-0.95) for FU-LV treated patients compared to observation. The 
authors reported an improvement in OS of 3.6% for FU-LV compared to observation within 5-year 
follow-up, which was assessed as having limited clinical impact.5 After the QUASAR trial, the MOSAIC 
and NSABP-07 trials were conducted to evaluate the benefit of the addition of oxaliplatin to FU-LV 
(FOLFOX) in stage II and III colon cancer. In the secondary analysis of stage II colon cancer patients only 
(n=899), the MOSAIC trial reported a statistically non-significant improvement in DFS with a hazard 
ratio (HR) of 0.84 (95%CI: 0.62-1.14) for FOLFOX compared to FU-LV. However, the HR for OS was 1 
(95% CI: 0.70-1.41), indicating equal survival probabilities in both groups.12 In the NSABP C-07 trial, 
2,409 patients (29% stage II and 71% stage III) were included. In a separate stage II analysis (n=695), 
HRs of 0.94 (95% CI: 0.70-1.26) and 1.04 (95%: 0.72-1.50) for DFS and OS, respectively, were found 
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Overall, none of the conducted trials demonstrates a strong improvement in DFS or OS for FU-LV 
treated patients compared to controls or for FOLFOX compared to FU-LV. It should be taken into 
account though that none of the trials were adequately powered to determine the treatment effect in 
stage II colon cancer, as the primary objective of these studies was to evaluate DFS and OS in the stage 
III population or in a mixed population of colon and rectal cancer patients. 
Selection of high-risk stage II patients for adjuvant chemotherapy 
The selection of high-risk stage II colon cancer patients for adjuvant chemotherapy is an ongoing 
debate, both nationally and internationally. Until 2014, the Dutch guidelines recommended to consider 
fluoropyrimidine (FU-LV or capecitabine) combined with oxaliplatin (FOLFOX) for patients with at least 
one clinical or pathological high-risk feature, i.e. T4 stage, <10 lymph nodes evaluated, high degree of 
differentiation, presentation with perforation or obstruction and vascular invasion.14,15 These 
guidelines were informed by the initial findings of the MOSAIC trial, which showed that prescribing 
FOLFOX to patients with high-risk features positively influenced disease-free survival compared to 
prescribing FU-LV alone.12,14 In 2014, the guideline included, in addition to above mentioned high-risk 
features, that patients with a Microsatellite Instable (MSI) status were no longer eligible for 
chemotherapy, given the much better OS and DFS compared to patients with a microsatellite stable 
(MSS) status.16-21 Subsequently, the Dutch Society for Medical Oncology indicated in 2018 that only 
stage II colon cancer patients with pT4 and MSS tumors should be considered for adjuvant 
chemotherapy.22 This guideline adjustment was mainly based on the long term findings of the MOSAIC 
trial and findings from several retrospective studies, which assessed survival benefits associated with 
adjuvant chemotherapy among stage II colon cancer patients having one or more high-risk features.22-
28 To illustrate, a retrospective analysis of 5,160 stage II colon cancer patients included in the California 
cancer registry showed that adjuvant chemotherapy was only associated with an increase in OS in the 
patient group with pT4 as the only high-risk factor (HR 0.51, 95% CI: 0.34-0.78) or in the group with a 
pT4 stage in combination with other high-risk factors (HR 0.31, 95% CI: 0.11-0.90).28  
Current international guideline recommendations, such as the European Society for Medical Oncology 
(ESMO) and American Society for Clinical Oncology (ASCO), deviate from the Dutch guidelines. The 
ESMO recommends to consider fluoropyrimidine for patients with 1 clinical high-risk feature, i.e. T4 
stage, <12 examined lymph nodes, primary tumor perforation, poor tumor differentiation or MSS 
status. Patients with a MSS status in combination with a T4 stage or more than one abovementioned 
risk factor should be considered for fluoropyrimidine in combination with oxaliplatin.8 The ASCO 
suggests to discuss the risks and benefits of adjuvant treatment with patients with a MSS status in 
combination with at least one of the following clinical high-risk features; extramural vascular invasion, 
poor tumor differentiation, pT4 stage, obstructive tumors, mucinous tumors, <12 examined lymph 
nodes, and tumor budding.7,29 
The inclusion of abovementioned high-risk factors in the national and international guidelines are 
mainly based on the chance to develop a recurrence, i.e. prognostic value.11,23-26,28 So far there are no 
indications that there are differences in efficacy of adjuvant chemotherapy for clinical and pathological 
factors, i.e. predictive value. To illustrate, a pooled study of 7 RCTs that included stage II and III colon 
cancer patients showed that treatment effect was consistent across sex, tumor location, age, and 
tumor grade.11 Only for MSI status both a prognostic and predictive effect was found. That is, besides 
a better prognosis compared to patients with an MSS status, patients with an MSI status also had less 
benefit of adjuvant treatment with FU-LV.30 
10
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In addition to the clinical and pathological features included in the current guidelines, interest in the 
prognostic and predictive value of molecular markers is currently increasing. There is accumulating 
evidence for the prognostic value of specific aberrations, such as mutations in BRAF and KRAS.20,22,31-36 
Therefore, it has been suggested that these molecular markers may enable improved patient selection 
for adjuvant treatment. A pooled analysis of the NSABP C-07 and NSABP C-08 trials showed reduced 
OS in stage II and III colon cancer patients with a BRAF mutation (HR 1.46, 95% CI: 1.20-1.79) compared 
to those without a mutation. In addition, the researchers reported a significant association between 
BRAF mutation and MSI/MSS tumor status. To illustrate, the highest OS was found in patients with 
BRAF wild-type combined with MSI status, with 5-year OS of 89.7%, whereas the worst OS was found 
in patients with a BRAF mutation combined with MSS status, with 5-year OS of 69.1%.36 Another 
retrospective study showed that stage II and III colon cancer patients with MSI tumor status but 
without any mutation in BRAF and/or KRAS had a 5-year DFS of 93% (95% CI: 84-100%), while patients 
with tumor mutations in either BRAF or KRAS had a 5-year DFS of 76% (95% CI: 67-85%).33 Furthermore, 
results of the QUASAR trial showed a significantly higher risk of developing a recurrence for patients 
with a KRAS mutation compared to patients without this mutation (HR 1.4, 95% CI: 1.12-1.74).17 In 
contrast to the NSABP trials, no associations were found between BRAF status and survival rates in the 
QUASAR trial. Possible reasons for the different findings between the NSABP analysis and the QUASAR 
trial are the differences in patient population; QUASAR included rectal cancer patients (29%) as well 
as colon cancer patients and the NSABP trials mainly included stage III patients (≈70%) rather than 
stage II patients. Although knowledge of the prognostic value of BRAF and/or KRAS is increasing, so far 
there are no indications for a predictive effect for these markers.31,37 
In the abovementioned studies, the prognostic value of the mutation status for specific biomarkers 
was evaluated. However, these individual aberrations do not take into account the interconnectivity 
with other genetic features. For this purpose, the consensus molecular subtypes (CMS) for colorectal 
cancer were introduced in 2015.38,39 The CMS classification distinguishes four subtypes, each with a 
collection of specific genetic characteristics, defined as CMS1 to CMS4. A pooled study of 1,785 stage 
I-IV colorectal cancer patients showed an increased risk of developing a recurrence for patients with a 
CMS4 classification compared to patients with a CMS1 to CMS3 classification with HRs of 1.77 (95% CI: 
1.34-2.34), 1.70 (95% CI: 1.39-2.06) and 1.74 (95% CI: 1.29-2.33), respectively.38 In addition to the 
strong prognostic value of CMS, some studies suggested that patients classified as CMS4 may be 
resistant for adjuvant chemotherapy.40,41 
Overall, the potential value of using BRAF, KRAS and CMS status to improve adjuvant chemotherapy 
selection in colon cancer patients is described by several studies.22,31-33,38,42-44 Although the literature is 
promising, evidence on how to incorporate these features in daily clinical decision making by carefully 
weighting the harms and benefits of adjuvant chemotherapy in different selections of the population 
is limited.  
Duration of adjuvant chemotherapy in stage II colon cancer 
Until recently, in the Netherlands the standard prescribed adjuvant chemotherapy regimen for high-
risk stage II colon cancer patients was six months fluoropyrimidine in combination with oxaliplatin.12-
14 However, based on the findings from the International Duration Evaluation of Adjuvant therapy 
(IDEA) collaboration, there is currently a discussion in the field regarding the optimal duration of 
oxaliplatin-based chemotherapy in stage II colon cancer. The SCOT and TOSCA trial, both part of the 
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cancer patients.45,46 In the SCOT trial, a HR for recurrence of 0.99 (95% CI: 0.75-1.31) for a 3-month 
oxaliplatin-based treatment regimen compared to 6 months was reported for stage II colon cancer. 
This finding indicates non-inferiority of a 3 months treatment duration compared to a 6 months 
treatment duration.46 In contrast, the TOSCA trial reported a significant HR for recurrence of 1.42 
(95%CI: 1.06-1.90) when comparing 3 months of oxaliplatin-based treatment to 6 months in stage II 
colon cancer.45 A likely explanation for the conflicting findings in the SCOT and TOSCA trials is the 
different proportion of stage II patients that were treated with FOLFOX (fluorouracil, leucovorin and 
oxaliplatin) and CAPOX (capecitabine and oxaliplatin). To illustrate, the ratio FOLFOX/CAPOX was 
33%/67% in the SCOT trial and 64%/26% in the TOSCA trial. This argumentation was supported by a 
pooled analysis of all stage II colon cancer patients included in the IDEA trials. This analysis was 
conducted separately for CAPOX and FOLFOX and the results strongly suggest non-inferiority for 3 
versus 6 months when treating with CAPOX, whereas 3 months of FOLFOX is inferior to 6 months of 
FOLFOX.47,48 
In response to the pooled findings of the SCOT and TOSCA trials, the Dutch guidelines have been 
updated in 2019. The recommended treatment duration for stage II colon cancer patients was adjusted 
from 6 to 3 months for CAPOX. For FOLFOX this adjustment has not been made, given the conflicting 
findings. However, an extensive weighting of the benefits and harms of shortening the adjuvant 
treatment duration in Dutch stage II colon cancer patients is lacking. 
Harms of adjuvant chemotherapy 
Treatment with adjuvant chemotherapy can lead to serious side effects. The most common side effects 
of fluoropyrimidine treatment are anaemia (66.9%), nausea (61.1%), diarrhoea (48.4%), neutropenia 
(39.9%), stomatitis (39.6%) and vomiting (24.0%).14 These percentages correspond to the percentage 
of patients who reported at least mild complaints (grade 1). Results from the MOSAIC and NSABP C-07 
trial showed significantly higher rates for abovementioned side effects, except for stomatitis, when 
oxaliplatin is prescribed in addition to the fluoropyrimidine.14,49,50 In addition, oxaliplatin may cause 
neurotoxicity, which means that the nerves are damaged, causing discomfort in patients’ daily life.50 
Neurotoxicity complaints can persist for a long time after treatment has stopped. To illustrate, in the 
NSABP C-07 trial, 10% of the patients reported neurotoxicity complaints two years after treatment.50 
From the SCOT and TOSCA trial, it is known that the severity of the side effects is strongly related to 
the duration of treatment. Patients were less likely to experience side effects when treated for 3 
months compared to a 6 months treatment regimen. Especially the risk of neurotoxicity was lower; in 
the SCOT trial, 58% of the patients treated for 6 months reported moderate to severe (grade ≥ 2) 
neurotoxicity compared to 25% of the patients that were treated for 3 months.46 In addition to the 
differences in side effects, shortening the treatment duration resulted in a significantly better quality 
of life for patients treated for 3 months compared to patients treated for 6 months.51  
In conclusion, the decision whether or not to treat a patient with adjuvant chemotherapy should not 
only focus on health benefits in terms of recurrence risk, but also on the impact of treatment on quality 
of life. To carefully weigh health benefits and harms against each other and support both clinical and 
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Evaluating the optimal treatment allocation and duration of adjuvant chemotherapy using a decision 
model 
To support decision making on the optimal allocation and duration of adjuvant chemotherapy in stage 
II colon cancer, while doing justice to the delicate balance between quantity and quality of life, a 
comprehensive synthesis of the existing evidence is required. As described above, many studies 
already focused on treatment effectiveness, treatment duration and selection of high-risk patients. 
Among these studies are many RCTs, which are considered as the highest level of evidence.52 Despite 
this body of evidence, it remains difficult to determine the optimal treatment duration and allocation 
for stage II colon cancer patients. The findings of different studies are contradictory, mainly due to a 
lack of power and the lack of sub-analyses for the stage II population. In addition to the balance 
between the patients’ quantity and quality of life, it is also important to take the (long-term) costs 
associated with treatment into account in the decision making process. Bearing in mind the rising 
health care costs as a result of the aging population, it is essential to allocate treatment as efficiently 
as possible in the coming decades and to treat patients no longer than necessary. 
To support the deliberation on adjuvant chemotherapy and make an explicit trade-off between the 
benefits, harms and costs, a consistent and coherent framework is needed that combines the evidence 
for different aspects of the decision problem. Medical decision models meet these requirements and 
are frequently used to balance the costs and benefits of medical decisions in so called cost-
effectiveness studies.  
Despite all the recent developments in the field, the cost-effectiveness of different risk-based 
strategies for selecting high-risk stage II colon cancer patients for adjuvant chemotherapy has not been 
assessed so far. By developing a decision model in which pathological-, clinical- and biomarker-based 
subgroups are included, a range of risk-based allocation strategies as well as strategies differing in 
treatment duration can be evaluated. The most important steps in the development of a decision 
model will be briefly introduced in the next section .  
Development of a decision model  
To parametrize a decision model, it is recommended to use the best available evidence.53,54 Although 
RCTs and meta-analyses are considered as the highest level of evidence, patients included in RCTs may 
not be representative for the specific population of interest.55 To illustrate, stage II colon cancer 
patients are underrepresented in RCTs that focus on treatment effectiveness of adjuvant 
chemotherapy, and if stage II patients are included, there is often no information available about the 
patient characteristics for the stage II population. Since there are generally strong in- and exclusion 
criteria for RCTs, the patient characteristics in the RCTs probably deviate from daily clinical practice. As 
a consequence, the treatment effect estimated in RCTs may not be representative for the entire 
population. An alternative is to estimate treatment effect using observational data, but this requires 
specific and complex statistical methods and extensive baseline information from the patients.56,57 
Compared to RCTs, observational data are often closer to clinical practice, but due to the non-
randomized nature of the study design, results from observational studies are considered as lower 
quality of evidence.58,59 
Model validation is also an important step in the model development process. As a first step clinical 
experts should critically assess the model structure to ensure agreement with up-to-date medical 
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Subsequently, internal validity of the model is assessed by comparing a model’s predictions to the data 
used for model development.53 Finally, the quality of the decision model and trust in the model’s 
predictions increases by demonstrating good model performance in an external population. However, 
external model validations are not frequently conducted in model-based cost-effectiveness studies, 
mainly due to the lack of available data.60  
Aim and outline of the thesis 
The aim of this thesis is to evaluate the optimal allocation and duration of adjuvant chemotherapy in 
stage II colon cancer patients. For this evaluation, further insight regarding the effectiveness of 
treatment in the stage II population and the impact of chemotherapy on quality of life is required. 
Therefore, the impact of adjuvant chemotherapy in stage II colon cancer patients was studied in 
Chapter 2 using pooled summary survival data of 9 RCTs. Subsequently, the pooled RCT estimate was 
compared to estimates in an observational cohort of the Netherlands Cancer Registry (NCR) using 
propensity score methods. In Chapter 3, the influence of chemotherapy on a patient's quality of life 
was described. Furthermore, the influence of neurotoxicity on quality of life of adjuvantly-treated 
patients was examined. For these analyses, data from the Prospective Dutch Colorectal Cancer Cohort 
(PLCRC) was used. Using the results of Chapter 2 and Chapter 3, in combination with data of the 
Netherlands Cancer Registry, the Personalized Adjuvant TreaTment in Early stage coloN cancer 
(PATTERN) model was developed. The development of the PATTERN model, which allow the evaluation 
of strategies for the allocation of adjuvant chemotherapy as well as treatment duration in stage II colon 
cancer patients, is described in Chapter 4. The PATTERN model was used to conduct the cost-
effectiveness studies described in Chapter 5, Chapter 6 and Chapter 7. In chapter 5, we evaluated the 
cost-effectiveness of a 3-month adjuvant chemotherapy regimen compared to a 6-months regimen in 
high-risk stage II colon cancer patients. In Chapter 6, the cost-effectiveness of different (biomarker-
based) treatment allocation strategies was evaluated in stage II colon cancer whereas in Chapter 7 we 
compared a CMS-based treatment allocation strategy to a biomarker-based strategy as well as 
treatment allocation according to the Dutch guideline. Chapter 8 summarizes the main findings 
presented in this thesis. In addition, we discuss clinical and methodological issues and provide 
recommendations for future research. 
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CHAPTER 2




There is an ongoing discussion regarding the impact of adjuvant chemotherapy in stage II colon cancer. 
We therefore estimated adjuvant treatment effect in stage II colon cancer using pooled disease-free 
survival (DFS) data from randomized clinical trials (RCT approach) and compared this to real-world data 
(RWD approach) estimates. First, we estimated the treatment effect in RCTs by (i) searching relevant 
trials reporting DFS data, (ii) generating patient-level data from reported DFS data and (iii) estimating 
treatment effect in the patient-level data. Second, the treatment effect was estimated in an 
observational cohort of 1,947 patients provided by the Netherlands Cancer Registry using three 
propensity score methods; matching, weighting and stratification. In the RCT approach, patient-level 
data of 4,489 patients (events: 853) were generated from nine trials which compared two of the 
following treatment arms: control, 5FU/LV or FOLFOX. A Cox model was used to estimate a hazard 
ratio (HR) of 0.77 (0.43;1.10) for 5FU/LV vs. control and 0.93 (0.72;1.15) for FOLFOX vs. 5FU/LV. In the 
RWD approach, HRs for any adjuvant treatment vs. control were 0.95 (0.50;1.80), 0.88 (0.24;3.21) and 
1.05 (0.04;2.06) using matching, weighting and stratification, respectively. There was no significant 
difference with the estimates from the RCT approach (interaction test, p > 0.10). The RCT data suggest 
a clinically relevant benefit of adjuvant chemotherapy in terms of DFS, but the estimate did not reach 
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Introduction 
There is an ongoing clinical dilemma of whether or not to provide adjuvant treatment to stage II colon 
cancer patients after surgery. High-risk patients who are eligible for adjuvant treatment are identified 
according to the European Society for Medical Oncology guidelines based on clinical and pathological 
factors. The most commonly used high-risk factors include pT4 stage, less than 10–12 lymph nodes 
evaluated, the presence of perforation and/or obstruction, extramural vascular invasion, perineural 
invasion, poorly or undifferentiated tumor and mismatch repair status.1 
Such guideline recommendations are developed using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach. GRADE assigns most value to randomized clinical 
trials (RCTs) and meta-analyses, because of the methodologically strong character.2 An essential 
advantage of RCTs is the unbiased estimation of the treatment effect due to randomized allocation 
which can balance both observed and unobserved confounders. This randomized allocation is often 
combined with strict inclusion and exclusion criteria to minimize bias in the evaluation of treatment 
response.3,4 Because of this strict patient selection in RCTs, the patient population may differ in daily 
clinical practice. Thus, treatment effect in clinical practice may be different from an RCT-based 
treatment effect.3,5,6 
Observational studies without patient selection, although lower on the GRADE scale, are closer to 
clinical practice. In particular, after the introduction of electronic medical records, more and more 
scientists and decision makers are arguing for the use of observational studies in addition to RCTs.4,7 
Nationwide registries are an example of such observational studies and often contain many patients. 
However, comparing treatment groups in observational studies is challenging because selection bias 
arises as a result of the non-random treatment allocation.4,8 For that reason, appropriate statistical 
methodology to correct for confounding by indication should be applied.9 Even then, cautious 
interpretation of the results is necessary. Despite these limitations, observational studies could give 
important insights into real-world effectiveness of treatment regimens.4,10,11 
In the field of colon cancer, the literature is contradictory regarding treatment effects based on RCTs 
compared to those based on real-world oncology registry data. For example, Iwashyna et al.12 
concluded that a comparable adjuvant treatment effect is found in real-world data (RWD) and RCTs in 
stage III colon cancer patients. On the other hand, Meyerhardt et al.13 concluded that in metastatic 
colorectal cancer patients, treatment effect based on RCTs seems much stronger than the effect 
estimated using registry data. The authors speculate that the main explanation for this difference in 
effect is uncorrectable heterogeneity between the populations at baseline. 
In patients diagnosed with stage II colon cancer, results from RCTs were not supportive of prescribing 
adjuvant chemotherapy to all patients.14–19 For example, the IMPACT meta-analysis showed in a pooled 
analysis a HR of 0.83 (90% CI 0.72;1.07) for disease-free survival (DFS) and a HR of 0.86 (90% CI 
0.68;1.07) for overall survival (OS) for fluoropyrimidine monotherapy compared to no treatment.19 
Combination regimens in which oxaliplatin is given in addition to fluoropyrimidine were not included 
in IMPACT, although these combination regimens are nowadays recommended in Dutch and 
international guidelines.1,20 Furthermore, the trials included in IMPACT were not optimally designed to 
determine the treatment effect in stage II colon cancer as patients with rectal cancer or stage III disease 
were included as well, leading to relatively few stage II colon cancer patients.21 
2
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Therefore, the aim of our study was to estimate adjuvant treatment effects in stage II colon cancer 
patients using pooled DFS data from RCTs. Given the dilemma regarding applicability of outcomes from 
RCTs to the real-world population, our secondary aim was to compare the RCT estimates to estimates 
based on a national oncology registry. 
Methods 
To estimate treatment effect in stage II colon cancer patients, two approaches were used which we 
refer to as the “RCT approach” and “RWD approach.” In the RCT approach, we estimated the treatment 
effect in RCT data using the following three steps: (i) systematically searching relevant trials for which 
aggregated data on DFS was reported for stage II colon cancer patients, (ii) generating patient-level 
data from reported aggregated data and (iii) estimating a hazard ratio (HR) for treatment effect in the 
obtained patient-level data. In the RWD approach, treatment effects for DFS were estimated in an 
observational cohort of 1,947 patients provided by the Netherlands Cancer Registry (NCR). Three 
methods were used to estimate the treatment effects: (i) propensity score matching (matching), (ii) 
inverse propensity score weighting (weighting) and (iii) propensity score stratification (stratification). 
All treatment effects were estimated using both parametric and semiparametric survival analyses. The 
semiparametric estimates were considered as main analysis. Appendix Table 1 describes the rationale, 
methods and results for the parametric analyses. 
RCT approach 
Systematical search for relevant trials 
Studies that used a RCT design were included when they compared an adjuvant treatment arm to 
another adjuvant treatment arm or to a control group, and when stage II colon cancer patients were 
at least a subgroup of the included patients. In line with the Dutch and international guidelines 
applicable during the literature search, the included adjuvant treatment regimens had to have a 
duration of at least 6 months.1,20 Only studies published after 1987 in Western countries were taken 
into account. Finally, a Kaplan–Meier curve stratified for stage II colon cancer patients with DFS as 
outcome had to be reported, as well as the associated numbers at risk. 
For the identification of studies, we conducted a systematic search in MEDLINE, EMBASE and the 
Cochrane library similar to the search described in the Cochrane review by Figueredo et al.22 Reference 
lists of relevant studies were also searched and there were no language restrictions. A more detailed 
description of our search strategy is provided in Appendix 2. Inclusion criteria were applied by one 
researcher (GJ) to titles and abstracts. Full texts were obtained for hits that were considered relevant 
by one researcher (GJ). When in doubt, the eligibility was established by discussion (GJ, MG and VC). 
All authors agreed on the included studies before data extraction. Reasons for exclusion were 
documented and are presented in the PRISMA flow diagram (Figure 1).23,24 The main reasons for 
excluding studies were a population that did not include stage II colon cancer patients or not reporting 
a stratified Kaplan–Meier curve for stage II patients. Of each included trial, the following characteristics 
were extracted: time period, country, stage II sample size, treatment regimens and 5-year DFS (Tables 
1 and 2). DFS was defined as the length of time after surgery during which no recurrence was detected. 
Generating patient-level data  
DFS for stage II patients was extracted from the included publications. First, all data points from the 
Kaplan–Meier curves for DFS that were required to reproduce the figure were read using GetData 
22
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Graph Digitizer 2.26.25 Then, a curve fitting approach developed by Hoyle and Henley26 was used to 
generate the patient-level data including data on treatment (yes/no), recurrence (yes/no) and time to 
recurrence. To maintain the randomization of the original trials, the extracted patient-level data for all 
included studies were pooled in two separate analyses: (i) an analysis of the trials that compared 
fluoropyrimidine monotherapy to a control arm and (ii) an analysis of the trials that compared 
fluoropyrimidine in combination with oxaliplatin to fluoropyrimidine monotherapy. The first analysis 
was considered as the main outcome. To assess whether the study populations in the pooled RCTs 
were homogeneous, we compared 5-year DFS using an interaction test.27  
Estimating a HR for treatment effect  
Then, HRs for DFS were estimated by adding treatment as a covariate in a Cox model. To account for 
the potential heterogeneity between trials a multilevel Cox regression was conducted. Literature 
suggests that a HR of 0.80 or less may be considered clinically meaningful.28 Therefore, this threshold 
value was used to judge clinical relevance. All survival models were estimated using the “coxme” 
package in Rstudio version 3.4.2.29 
 
 
Figure 1. Flowchart of study selection. 
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RWD approach 
Real-world observational cohort  
The treatment effect was also estimated in a real-world observational cohort from the NCR. The 
dataset consisted of 1,947 patients diagnosed with Stage II colon cancer between 2002 and 2008.30 
The majority of patients had a pT3 stage (90.0%), less than 10 evaluated lymph nodes (53.9%) and a 
well/moderate tumor differentiation (83.3%). About 114 patients received adjuvant treatment (5.9%) 
and 1,833 did not (94.1%). Treatment regimens were fluoropyrimidine monotherapy (33.3%) or 
fluoropyrimidine with oxaliplatin (66.7%). Data were available on patient and tumor characteristics, 
time to recurrence and death. Follow-up duration of the patients was at least 36 months, with a 
maximum of 179 months. The median follow-up duration was 53 months for DFS. Recurrences could 
either be diagnosed due to symptoms or during regular follow-up visits. This follow-up consists of 
consultations every half-year during the first 2–3 years after surgery and yearly thereafter until 5 years 
after surgery. In these consultations, either an ultrasound scan of the liver or CT scan of the abdomen 
is made. Also, the CEA values are determined at each visit.20 The baseline characteristics of the cohort 
are shown in columns 2–4 of Table 3. 
Propensity score risk adjustments  
Due to the nonrandomized nature of the cohort, comparisons between patients who received adjuvant 
chemotherapy with non-recipients are potentially biased due to differences between both groups at 
baseline, that is, confounding by indication. The use of specialized methods is necessary to correct for 
confounding by indication. Although there are several methods available, there is no consensus on a 
gold standard.8 Therefore, three methods were used to estimate the treatment effects: (i) propensity 
score matching (matching), (ii) inverse propensity score weighting (weighting) and (iii) propensity score 
stratification (stratification). The choice for these methods is in line with Austin et al. (2013) and Gayat 
et al. (2012) who showed that these methods have a good performance for time-to-event data.31,32 
Propensity score estimation using observed confounders that are determined prior to treatment 
administration allows for unbiased estimation of treatment effects under the assumption of no 
unobserved confounding.33 This assumption cannot be formally tested. However, the most relevant 
clinical and pathological correlates of treatment assignment and survival, as reported in the literature, 
were available in our dataset (i.e., gender, age, pT stage, differentiation grade, lymph nodes evaluated 
and tumor site).34 
The propensity score represents the probability that a patient would receive adjuvant treatment. 
Propensity scores were determined on the basis of a logistic regression model in which the dependent 
variable was administration of adjuvant treatment and the independent variables were all available 
factors potentially associated with administration of adjuvant treatment (gender, age, pT stage, 
number of evaluated lymph nodes, grade of differentiation and tumor site). Interactions between 
treatment and any of these factors were included as well. A backward variable selection based on 
Akaike Information Criterium (AIC) was done to select the most relevant covariates in the propensity 
score model. 
Survival models  
First, the naïve treatment effect, that is, without correcting for confounding by indication, was 
estimated in the observational cohort. Second, HRs for DFS were estimated including a correction for 
24
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confounding by indication by matching, weighting and stratification. In the matching method, patients 
who did receive adjuvant treatment were 1:1 matched based on the propensity score to patients who 
did not receive adjuvant treatment. A caliper score was used to determine the maximum deviation in 
propensity score for matched pairs. In the inverse propensity score weighting method treatment 
effects were estimated by weighting the individuals based on the propensity score. In the stratification 
method, the sample was stratified into five mutually exclusive subclasses based on the propensity 
score. A detailed description of the confounding by indication methods is provided in Appendix 3. 
Model selection.  
For each Cox model, a forward covariate selection was performed. All multivariate survival models 
included the covariates that were significant in one or more survival models to ensure comparability 
of the results: age, pT stage, evaluated lymph nodes, tumor site and differentiation grade. 
Comparison RCT approach and RWD approach 
An interaction test was used for significance testing of the differences between the estimates based 
on the RCT and RWD approach.27 A significance threshold of p < 0.10 was used to avoid type II error 
rate. 
Data availability 
The generated patient-level data used for the RCT approach is available as Supporting Information. 
The registry data that support the findings of the RWD approach in this study are upon request 
available from the NCR. 
Results 
RCT approach 
Eligible studies  
We identified 3,324 potentially eligible studies that provided survival data on DFS for Stage II colon 
cancer patients. Of these, five publications met the inclusion criteria. The five publications reported 
nine trials which were included in the current study.16,17,19,35,36 Four of the five included publications 
were RCTs and one was a meta-analysis of five RCTs. 
Study characteristics  
Characteristics of the nine included studies are presented in Table 1. The studies were published 
between 1999 and 2011. Five studies originated from European centers, two from North America and 
two included patients from multiple Western countries. Comparison of baseline characteristics was 
hampered, because three of the five publications did not report baseline characteristics for stage II 
colon cancer separately. The total sample size of stage II patients in the nine included studies was 6,076 
patients. 
Pooled treatment groups  
Included trials either compared fluoropyrimidine monotherapy to a control arm, that is, IMPACT, 
QUASAR and Schippinger et al. or fluoropyrimidine in combination with oxaliplatin to fluoropyrimidine 
monotherapy, that is, NSABP C07 and MOSAIC. To maintain the randomization of the trials, HRs were 
estimated in two separate pooled analyses. In the first analysis, we pooled trials that compared 
2
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fluoropyrimidine monotherapy to a control arm whereas, in the second analysis, we pooled trials that 
compared fluoropyrimidine in combination with oxaliplatin to fluoropyrimidine monotherapy. The 5-
year DFS of the pooled studies were in the same range (Table 2). Based on the interaction test, no 
significant differences were found in 5-year DFS between the pooled study arms (Appendix Table 2). 
Survival analyses 
The Kaplan Meier curves for DFS are shown by trial arm in Appendix Figure 1a for the fluoropyrimidine 
monotherapy group which was compared to the control group, in Appendix Figure 1b for the control 
group, in Appendix Figure 1c for the combination therapy group and in Appendix Figure 1d for the 
fluoropyrimidine monotherapy group which was compared to the combination therapy group. In the 
population for the first pooled analysis, there were 454 recurrences among the 2,244 patients in the 
control group after 5 years of follow-up. For the treatment group with fluoropyrimidine monotherapy, 
the number of recurrences was 399 in a population of 2,245 patients. A pooled Kaplan–Meier curve is 
shown in Figure 2a. In the population for the second pooled analysis, there were 175 recurrences 
among 788 patients in the fluoropyrimidine monotherapy group. In the group which received 
fluoropyrimidine in combination with oxaliplatin the number of recurrences was 166 in 799 patients. 
A pooled Kaplan-Meier curve is shown in Figure 2b. The HR for treatment effect in the first pooled 
analysis, fluoropyrimidine compared to no treatment, was 0.77 (95% CI 0.43;1.10) for DFS. In the 
second pooled analysis, in which fluoropyrimidine combined with oxaliplatin was compared to 
fluoropyrimidine monotherapy, a HR of 0.93 (95% CI 0.72;1.15) was found for DFS. Both treatment 
effects were estimated with a multilevel Cox model. HRs for the multilevel and non-multilevel Cox 
survival models are shown in Table 4. 
RWD approach 
Table 4 shows the treatment effect estimates based on the NCR cohort. The unadjusted naive Cox 
model estimated an HR of 1.65 (95% CI 1.13;2.42, p = 0.01) for DFS. 
Propensity score risk adjustments  
Adjuvant treatment propensity scores ranged from <0.01 to 0.84 in the control group and from 0.01 
to 0.89 in the treated group. Thus, the treatment group showed sufficient overlap with the control 
group. Means of the distribution of the confounders age, pT stage, evaluated lymph nodes, tumor site 
and differentiation grade were equal in the matched sample, after weighting, and in all propensity 
score strata. 
For matching, weighting and stratification, both univariate and multivariate survival models were 
fitted. Below, only HRs for DFS of the multivariate survival models are described as these are 
considered as most reliable. Results of the univariate models are shown in Appendix Table 3. For the 
matching method, two samples were defined: (i) a sample of 76 matched pairs based on a caliper score 
of 0 and (ii) a sample of 112 matched pairs based on a caliper score of 0.2 of the standard deviation of 
the logit propensity score (Table 3). Estimated multivariate HRs were 0.95 (95% CI 0.50;1.80) and 1.00 
(95% CI 0.58;1.70), respectively. For the weighting method, a HR of 0.88 (95% CI 0.24;3.21) was 
estimated in a multivariate survival model. A pooled HR of 1.05 (95% CI 0.04;2.06) was found for the 
stratification method (Table 4). It should be noted that all confidence intervals are wide and do not 
reach clinical relevance or statistical significance. 
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Figure 2. Kaplan Meier curves for the treatment and control groups for pooled population 1 (a) and 
the curves for fluoropyrimidine combined with oxaliplatin compared to fluoropyrimidine monotherapy 
in pooled population 2 (b). 
 
Comparison RCT and RDW approach 
In Table 4, the p values of the interaction tests are shown. No significant differences were found 
between the estimates based on the RCT and RDW approach, which is potentially due to the small 
sample size of treated patients in the RWD approach. Furthermore, the estimate derived from the RCT 
approach suggests a clinically relevant treatment effect, while the treatment effect found in the RWD 
approach was not clinically relevant. 
 
Discussion 
The primary aim of this study was to estimate adjuvant treatment effects for DFS in stage II colon 
cancer patients using pooled summary survival data from RCTs (RCT approach). Given the dilemma 
regarding the applicability of outcomes from RCTs to the real-world population, our secondary aim 
was to compare the RCT estimate to estimates based on a national oncology registry (RWD approach). 
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The RCT approach resulted in a HR of 0.77 (95% CI 0.43;1.10) for fluoropyrimidine monotherapy 
compared to no treatment. In addition, a HR of 0.93 (95% CI 0.72;1.15) was found for fluoropyrimidine 
in combination with oxaliplatin compared to fluoropyrimidine monotherapy. Although point estimates 
from the separate studies as well as our pooled estimate suggests a clinically relevant benefit (HR < 
0.80) in terms of DFS from adjuvant chemotherapy in stage II colon cancer, no statistical significance 
was reached. For the RWD approach, in which we compared patients treated with adjuvant 
chemotherapy (33.3% fluoropyrimidine monotherapy and 66.6% fluoropyrimidine therapy with 
oxaliplatin) to patients who did not receive treatment, none of the applied propensity score methods 
resulted in a clinically relevant or significant treatment effect. Finally, no significant differences were 
found between estimates based on the RCT and RWD approach. It should be noted that the sample 
size of the cohort used for the RWD estimates was small, resulting in large confidence intervals. This is 
also the likely explanation for insignificance of the interaction test on the difference between estimates 
based on the RCT and RWD approach. Overall, no significant treatment effect was found, neither in 
the RCT approach nor in the RWD approach. Nevertheless, the point estimate in the RCT approach 
suggests a clinically relevant benefit of adjuvant chemotherapy. To improve guidance in adjuvant 
treatment decisions in stage II colon cancer, larger sample sizes, the pooling of true patient-level data 
with covariate information and/or subgroup-specific analyses are required. 
The non-significant result for the comparison of fluoropyrimidine to control in the RCT approach is 
probably related to the following two aspects. First, we used a multilevel Cox proportional hazard 
model to estimate treatment effect. The variance in a multilevel model consists of two components; 
the variance around the treatment effect and the variance around the added random effect.37 As a 
result, the variance is increased compared to a non-multilevel approach. This is underlined by our 
results in which the multilevel estimate of 0.77 has a much wider confidence interval (95% CI 0.43;1.10, 
p = 0.13) than the non-multilevel estimate of 0.78 (0.68;0.89, p < 0.01). Second, we did not have the 
original patient-level data to our disposition. Therefore, we opted for using a curve fitting approach 
developed by Hoyle and Henley. This method precludes the inclusion of relevant covariates in the 
survival models, which may narrow down confidence intervals around the estimate for treatment 
effect. Moreover, it should be noted that statistical inference is increasingly questioned in the 
literature.38,39 That is, a p-value does not measure the size of an effect nor the importance of a result. 
Results should always be interpreted within their context; taking into account the sample size, the 
methods used to estimate the effect as precisely as possible, and relevance of a result in daily clinical 
practice.28 Taking these arguments into account, we would consider the treatment effect found in the 
RCT approach as clinically relevant.  
In the current study, DFS was used as outcome measure to estimate treatment effect. Although OS is 
acknowledged as the gold standard outcome in cancer trials,40 DFS can be considered as a surrogate 
endpoint for OS. This is underlined by Sargent et al.41 who showed that DFS and OS are highly 
correlated in colon cancer trials evaluating fluorouracil-based regimens in stage III colon cancer 
patients. Also, the majority of trials included in the current study reported similar results for DFS and 
OS in terms of clinical relevance and statistical significance. Only in Schippinger et al.,35 the results for 
DFS and OS were not consistent in terms of clinical relevance, which may be explained by the small 
sample size.  
Previously, Sargent et al.42 reported a relationship between treatment effect and microsatellite 
instability (MSI). In addition to improved prognosis, it was shown that patients with an MSI tumor have 
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a certain resistance to fluoropyrimidine based chemotherapy. It is possible that, in addition to MSI, 
more molecular characteristics can be identified that may influence the impact of treatment on DFS. 
Therefore, a stratified analysis would presumably have increased the ability to detect a stronger 
treatment effect in specific subgroups, such as patients with a MSS. Besides, data from other 
retrospective analyses strongly suggest pT4 as the strongest prognostic factor in stage II colon 
cancer.43,44 However, stratified analysis for both predictive and prognostic factors was hampered due 
to the absence of covariate information in the patient-level data for our RCT-based analysis. In the 
RWD approach, a stratified analysis was hampered due to the small sample size. 
The presented treatment effect estimate for fluoropyrimidine monotherapy compared to no 
treatment, is based on updating the IMPACT analysis with the trials of QUASAR and Schippinger et al. 
It should be noted that in the Sienna trial (included in the IMPACT meta-analysis) and the trial of 
Schippinger et al. a deviant treatment regimen of 12 or 13 months was prescribed instead of 6 months 
as in the other trials included in this study.19,35 We believe that this did not influence our results as the 
treatment effect for the Sienna trial and the trial of Schippinger et al. were in the same range as the 
other trials included in the current study (range 0.69–0.83). Furthermore, we estimated a treatment 
effect for fluoropyrimidine combined with oxaliplatin compared to fluoropyrimidine monotherapy. No 
significant differences were found in DFS for the addition of oxaliplatin. This finding is in contrast with 
the effect of adding oxaliplatin to adjuvant treatment in stage III colon cancer patients; both NSABP 
C07 and MOSAIC found a significant improvement in DFS for the addition of oxaliplatin in stage III colon 
cancer.17,36 Yothers et al. (2011) suggests that this difference found in effect between stage II and stage 
III patients can be explained by (i) the smaller sample size for stage II patients compared to stage III 
patients and (ii) the higher absolute survival probability for stage II patients. 
In the RWD approach, there was an imbalance between treated (n = 114) and untreated patients 
(1,833). The explanation for the imbalance is two-sided; first, the majority of the population is not 
high-risk and therefore not eligible for adjuvant chemotherapy according to guidelines. Second, only 
5% of all high-risk patients received chemotherapy in the dataset. From literature, we know that most 
guideline deviations are well-substantiated, for example, due to the poor clinical condition of the 
patient or a patients’ preference. Other possible explanations mentioned in the literature are 
unfamiliarity with the guideline and differences in expert opinions.45 Furthermore, data for DFS is often 
not collected by default in registry data. Therefore, only a small subset (n = 1,947) out of approximately 
10,000 Stage II cancer patients, was available to estimate the effect of treatment on recurrence. The 
small number of treated patients was a serious limitation in this analysis, causing large variance around 
the treatment effect estimates from the RWD approach compared to the RCT approach. These wide 
confidence intervals limit the power of the interaction test to detect a significant difference between 
the RCT and RWD approach, even though we used a lenient significance threshold of p < 0.10.  
In observational data such as national registry data, there is the potential for bias due to confounding 
by indication. In this study, we used appropriate, though complex methods to correct for this bias. 
These methods assume that there are no unmeasured confounders. In the NCR dataset, the most 
important clinical and pathological factors that determine treatment allocation were included (i.e. 
gender, age, pT stage, differentiation grade, lymph nodes evaluated and tumor site). Nevertheless, the 
patient-related factor performance status was not measured, while this variable is reported to affect 
treatment allocation.46 Furthermore, results of the RWD analysis were not entirely representative of 
the original sample. For example, in the matching analysis, many of the non-treated patients were 
2
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excluded due to the differences in sample size between the treated and non-treated group. Moreover, 
the estimates of the three methods used in the RWD analysis were not consistent in effect direction, 
which complicates the interpretation. In summary, results of our RWD analysis should be interpreted 
carefully, taking the limitations of the study design and the statistical methods into account. 
To summarize, the RCT data suggest a clinically relevant benefit of adjuvant chemotherapy in terms of 
DFS, although this benefit was not significant in our pooled analyses. To improve guidance in adjuvant 
treatment decisions in stage II colon cancer, future studies should focus on the pooling of true patient-
level data with covariate information and/or subgroup-specific analyses.  
30
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Appendix 1. Parametric estimates 
Rationale  
In our study all analyses were conducted both parametrically and semi-parametrically. Although non-
parametric or semi-parametric methods are more commonly used, parametric estimates have the 
advantage that they can serve as an input for cost-effectiveness analyses (CEAs). In a parametric 
survival model, it is assumed that the survival curve corresponds to a certain mathematical 
distribution. This is important because many CEAs analyze both effects and costs using a lifelong time 
horizon. Non-parametric or semi-parametric approaches generate output that is difficult to use for 
extrapolation, whereas this is straightforward when a fully parametrized mathematical function is 
obtained.  
Parametric analyses 
We estimated hazard ratios (HRs) by adding treatment as a covariate to the parametric survival model. 
Various parametric survival distributions i.e. Weibull, log-logistic, log-normal and Gompertz were 
fitted. Final choice of distribution for the parametric survival model was based on AIC and visual fit.1, 2 
All survival models were estimated using the survival and flexsurvreg package in Rstudio version 
3.4.2.3,4 Note that it was not possible to estimate e a mixed effect Gompertz model due to limitations 
in R. We therefore used a non-mixed effect Gompertz model.  
Appendix table 1 shows the results of the parametric analyses. The treatment effect estimates using a 
fully parametric approach were in line with the Cox estimates. 
Input for PATTERN model 
The parametric estimates derived from this study will be used as input for the Personalized Adjuvant 
TreaTment in EaRly stage coloN cancer (PATTERN) decision model. This model is developed to improve 
the selection of stage II colon cancer patients who benefit from adjuvant chemotherapy. PATTERN 
model predictions will provide more insight in the most cost-effective manner to allocate adjuvant 
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Appendix 2. Search method 
Search methods for identification of studies 
In 2007, a Cochrane review was conducted on adjuvant therapy in completely resected stage II colon 
cancer patients.5 The aim of this review was to determine the effect of treatment on disease-free 
survival (DFS) in patients with stage II colon cancer. This Cochrane review used the same inclusion 
criteria as used for the current study, with the exception of the requirement to present a Kaplan Meier 
curve stratified for stage II CC patients and duration of the chemotherapy. Therefore, we screened the 
included studies in this Cochrane review by Figueredo et al. (2008)5 for identification of relevant 
studies published before 2007. To complement this selection with more recent publications, the search 
strategy published in Figueredo et al. was used to identify studies published between January 2007 
and July 2018. We searched in accordance with Figueredo et al. in MEDLINE, EMBASE and the Cochrane 
library. Reference lists of relevant studies were also searched. There were no language restrictions.  
Search strategy Figueredo et al. (2008) 
1. Colonic Neoplasms/ [MeSH] 
2. Colorectal Neoplasms/ [MeSH] 
3. (colon OR colorectal OR colonic).ti.[title] 
4. (malignan$ OR Neoplas$ OR cancer OR carcinoma OR adenocarcinoma). 
5. 3 AND 4 
6. 1 OR 2 OR 5 
7. Chemotherapy, Adjuvant/ [MeSH] 
8. adjuv$.mp. 
9. 7 OR 8  
10. 6 AND 9 
11. (clinical AND trial).ab.ti. [abstract or title] 
12. Clinical Trials/ [MeSH] 
13. clinical trial.pt [publication type] 
14.random$.mp. 
15.Random Allocation/ [MeSH] 
16.therapeutic use$.mp. 
17. 11 OR 12 OR 13 OR 14 OR 15 OR 16 
18. 10 and 17  
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Appendix 3. Detailed description of confounding by indication methods 
Average treatment effect of the treated 
The secondary aim of this study was to compare the treatment effect obtained with the RCT approach 
to estimates based on real world data. The RWD treatment effect was estimated as the treatment 
effect for the treated; that is, both treated and untreated patients were included in the analysis, but 
the treatment effect was defined across patients having been assigned to adjuvant treatment in the 
observational data.  
This choice was mainly underpinned by the fact that there was a difference in age between the treated 
and non-treated population in the NCR cohort (Table 3). The age of the treated population in the NCR 
cohort was in line with the average age of the participants in the included trials, whereas the untreated 
population in the NCR cohort was considerably older (Table 2 and 3). It is known from the literature 
that younger patients are more likely to be eligible for adjuvant treatment in clinical practice.6 
Therefore, patients treated with adjuvant therapy in the observational cohort were expected to be 
more comparable to patients included in the RCTs than those patients that did not receive adjuvant 
treatment. 
Double robustness property 
For the methods used, i.e. matching, weighting and stratification, we additionally used covariate-based 
regression-adjustment. Weighted regression with covariate adjustment possesses the double-
robustness property which offers protection against model-misspecification.7 Performing covariate 
adjustment in matched or stratified samples can also lead to more precise estimates and is advised by 
some scholars.8, 9 Therefore, the multivariate models were considered as main analysis in the current 
study.  
Matching 
Propensity score matching allows for matching of treated and untreated patients who have similar 
propensity scores.10 Patients who did not receive adjuvant treatment were 1:1 matched based on the 
logit of the propensity score to patients who did receive adjuvant treatment. In line with Austin et al. 
(2011), we used a caliper width equal to 0.2 of the standard deviation of the logit of the propensity 
score 11 as well as a caliper width equal to 0. Once a propensity score matched sample was defined, a 
Cox model was fitted on the matched cohort to compare recurrence rates between those patients who 
did and those who did not receive adjuvant treatment. All variance estimations were done as described 
in the coxme packages in Rstudio.3, 4, 12 
Weighting 
Inverse propensity score weighting is a method in which treatment effects are estimated by weighting 
the individuals based on the propensity score. This corrects for the systematic differences between 
treated and untreated patients. To estimate the treatment effect for the treated, the propensity score 
weights were defined as w(x) = 1 for the treatment group and as w(x) = p(x)/(1-p(x)) for the control 
group, where w(x) is the weight for each individual and p(x) is the propensity score.13, 14 A weighted 
Cox model was fitted to compare recurrence rates between those patients who did and those who did 
not receive adjuvant treatment. In the weighted method, in addition to uncertainty surrounding the 
estimated HRs, there is uncertainty around the weights assigned to each individual as well.15 To 
2
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account for this additional uncertainty, the analysis was bootstrapped using 1000 resamples, where 
the weights were re-estimated upon each bootstrap draw.  
Stratification 
In the stratification method, the sample was stratified into five mutually exclusive subclasses based on 
the propensity score.9, 16 Propensity score bins were defined such that the number of treated patients 
in each stratum was equal to assure stability of variance estimates. Cox models were used to compare 
recurrence rates between those patients who did and those who did not receive adjuvant treatment 
in each stratum.17 The pooled HR was obtained by taking the sum of the weighted estimates in each 
stratum, where weights denoted the ratio of the treated patients in that stratum divided by the total 
treated patients. 
 
Appendix table 2. Interaction test to compare 5-year DFS in pooled study arms 
 IMPACT QUASAR Schippinger et al. 
Survival model 1 - Control    
 IMPACT NA   
 QUASAR 0.39 NA  
 Schippinger et al. 0.40 0.29 NA 
    
Survival model 1 - FU IMPACT QUASAR Schippinger et al. 
 IMPACT NA   
 QUASAR 0.36 NA  
 Schippinger et al.  0.30 0.18 NA 
    
Survival model 2 - FU MOSAIC NSABP C07  
 MOSAIC NA   
 NSABP C07 0.56 NA  
    
Survival model 2 FU + Oxaliplatin  MOSAIC NSABP C07  
 MOSAIC NA   
 NSABP C07 0.66 NA  
Abbreviations: NA=not applicable, FU=Fluorouracil. Survival model 1 refers to the analysis in which a treatment 
effect was estimated for a capecitabine or fluorouracil regimen versus no treatment. IMPACT, QUASAR and 
Schippinger et al. were included in this analysis. Survival model 2 refers to the analysis in which a treatment effect 
was estimated for capecitabine or fluorouracil regimen with oxilaplitin compared to capecitabine or fluorouracil 
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 Appendix Table 3. Estimated treatment effects without adding covariates to the Cox survival models 
in the RWD approach 
 Hazard ratio  
(95% CI) 
p-value p-value of comparison RWD 
to RCT 
 
RWD approach – observational data adjusted based on propensity scores 
 
 
PS matching – caliper 0     
 Univariate survival model 0.93 (0.49;1.75) 0.82 0.57 
PS matching – caliper 0.2*sd logit propensity   
 Univariate survival model 1.11 (0.65;1.88) 0.71 0.35 
PS inverse weighting    
 Univariate survival model  0.83 (0.23;2.96) 0.93 0.91 
    
PS stratification    
 Univariate survival model 1.45 (0.55;2.34) 0.72 0.24 
Abbreviations: NA = not applicable; RCT = randomized clinical trial; RWD = real world data; PS = propensity score; sd = 
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Abstract 
Patient’s quality of life should be included in clinical decision making regarding the administration of 
adjuvant chemotherapy (ACT) in stage II/III colon cancer (CC). Therefore, quality of life, summarized as 
health utility (HU), was evaluated for patients treated with and without ACT. Furthermore, the role of 
Chemotherapy Peripheral Induced Neuropathy (CIPN) on HU was evaluated. Patients diagnosed with 
stage II/III CC between 2011-2019 and participating in the Prospective Dutch ColoRectal Cancer cohort 
were included (n=914). HU scores were assessed with the EQ-5D-5L at baseline, 3, 6, 12, 18, and 24 
months. Patients treated with ACT received mainly CAPOX (57%) or Capecitabine monotherapy (40%) 
(average duration: 3.5 months). HU 3-18 months after diagnosis (potential ACT period + 12 months 
follow-up) was compared between patients treated with and without ACT using a mixed model 
adjusted for age, sex and education level. Subsequently, the CIPN sensory-, motor- and autonomy 
scales, measured using the EORTC QLQ-CIPN20, were independently included in the model to evaluate 
the impact of neuropathy. Using a mixed model, a significant difference of -0.039 (95% CI, -0.062;-
0.015) in HU was found between patients treated with and without ACT. Including the CIPN sensory-, 
motor- and autonomy scales decreased the difference with 0.019, 0.015 and 0.02 respectively. HU 3-
18 months after diagnosis is significantly lower in patients treated with ACT versus without ACT. This 
difference is on the boundary of clinical relevance and appears to be partly related to the sensory and 
motor neuropathy-related side effects of ACT.  
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Background 
Colon cancer is one of the most frequently occurring cancers in the Netherlands with approximately 
10,000 new cases and 3,750 deaths in 2018.1 Around 60% of newly diagnosed colon cancer patients 
are classified as stage II or III. The standard treatment for stage II and III colon cancer patients is surgical 
resection, followed by an additional treatment with adjuvant chemotherapy (ACT) for those with a 
high-risk of recurrence, i.e. stage II patients with pT4 and MSS and all stage III patients.2  
Currently, the standard ACT regimen for high-risk stage II and stage III patients in the Netherlands 
consists of three months oxaliplatin with capecitabine (CAPOX).3-5 However, the benefit in overall 
survival that has been demonstrated in prospective studies2 only concerns a subgroup of patients that 
cannot be identified upfront. As a result, the majority of patients do not derive any benefit from ACT, 
either because they are cured by surgery alone or experience a recurrence despite ACT. Treatment 
with CAPOX is associated with side effects such as fatigue, hand-foot syndrome, bone marrow 
suppression, nausea, diarrhoea and vomiting.6, 7 In addition, oxaliplatin causes neurotoxicity in 
approximately 30% of patients, which is acknowledged as the most severe and sometimes irreversible 
side effect of ACT.3, 6 Neurotoxicity means that the nerves are damaged, causing discomfort in patients’ 
daily life.8 For approximately 5% of the patients, the complaints are chronic.3, 8 Given the possible 
severity of side effects of ACT, patients should be well informed on their decision regarding the 
administration of ACT.  
To support decision making, policy makers often use economic evaluations, in which the value of a 
medical intervention is evaluated by carefully balancing the health impact of the intervention against 
the costs. In economic evaluations, health effects are expressed in Quality adjusted life years (QALYs), 
which is a measure of disease burden, including both the quality and quantity of life years lived. One 
QALY is equal to one year of life in perfect health. To calculate QALYs, life years lived are weighted with 
a health utility, ranging from 0 (dead) to 1 (perfect health). Thus, health utilities are important input 
for economic evaluations.9, 10 
However, literature data regarding the influence of ACT on health utility in stage II and III colon cancer 
is scarce, outdated and concerns mixed populations of patients with colon and rectal cancer.11-13 
Furthermore, there are indications that health utility changes over time during the different phases in 
a patient's course of disease, i.e. prior to, during and after ACT treatment.14, 15 The studies conducted 
so far are less suitable to evaluate health utility over time given their retrospective nature.11, 12 In 
addition, given that Chemotherapy Induced Peripheral Neuropathy (CIPN) is a common side effect of 
ACT with direct consequences for patients' daily life, the degree of CIPN may influence health utility 
among ACT treated patients.8 To our knowledge, no previous studies investigated in detail the impact 
of ACT on health utility over time in colon cancer and assessed the impact of CIPN on health utility.  
Given the limited knowledge in this field, our primary aim was to investigate the longitudinal impact 
of ACT on patients’ health utility in stage II and III colon cancer patients. As a secondary aim we 
evaluated the impact of CIPN on the association between ACT and health utility. We used data from 
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Methods 
Patient population and selection 
We used data from the PLCRC, which is a prospective multidisciplinary nationwide observational 
cohort study in the Netherlands.16 All colorectal cancer patients (stage I–IV) are eligible for inclusion. 
After patients have given their informed consent, longitudinal clinical data are registered and patient 
reported outcomes (PROMS) are collected. For the present study, 2,526 questionnaires of 914 
participants with an average age of 66 years and diagnosed with stage II or III colon cancer between 
2011-2019 were available.  
Patients received a questionnaire at baseline and at 3, 6, 12, 18 and 24 months follow-up. Patients 
were included at different time points after diagnosis (0-240 months). Only 45% of the patients was 
included directly after diagnosis. To avoid distortion of the results by patients who were included in 
the cohort extremely long after diagnosis, all questionnaires filled in more than 60 months after 
diagnosis were excluded (Figure 1). All remaining 2,313 questionnaires of 859 patients were linked to 
a specific time period; 1) prior to surgery, 2) after surgery and before start chemotherapy, 3) during 
chemotherapy, 4) first 12 months after chemotherapy and 5) more than 12 months after 
chemotherapy. For patients who did not receive ACT, the same time periods as in the ACT group were 
used. For this purpose, we defined the periods “after surgery and before chemotherapy” and “during 
chemotherapy” for the group without ACT based on mean time between surgery and the start of 
chemotherapy (1 month) and the mean duration of chemotherapy (3.5 months) in the group with ACT. 
Measurements for which the timing was missing, were excluded (Figure 1). 
Firstly, we described average health utility in the defined time periods for patients with and without 
ACT. In this analysis we included all measurements that were taken within 60 months after diagnosis 
(Subset 1). Secondly, we conducted mixed model analyses to compare health utility between patients 
treated with and without ACT during chemotherapy and the first 12 months thereafter, taking into 
account repeated measurements of patients and relevant covariates. To correct for differences in 
health utility at baseline in the mixed model, only patients were included for whom at least one 
baseline measurement (before the start of ACT) and one follow-up measurement was available (Subset 
2).17 A flowchart of the data is shown in Figure 1.  
Study Measures  
The available data regarding administration of ACT were based on the patients’ medical record. It 
should be noted that in 2018 the Dutch guideline recommended to limit the duration of oxaliplatin-
based ACT from 6 to 3 months for stage III patients. In 2019 this guideline adaption was made for high-
risk stage II patients.5 The majority of the patients (approximately 85%) were included in the cohort 
prior to this guideline adjustment and were therefore scheduled for a duration of 6 months of ACT.  
Chemotherapy induced peripheral neuropathy was measured using the European Organization for 
Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy Induced Peripheral 
Neuropathy 20 (EORTC QLQ-CIPN20).18 This questionnaire consists of 20 items evaluating sensory, 
motor and autonomic symptoms. The items were measured on a four point Likert scale ranging from 
1 (not at all) to 4 (very much). Subsequently, the individual items belonging to sensory, motoric and 
autonomic symptoms were summarized in an average score ranging from 0 to 100 for each domain 
separately.18 For an overview of the separate items belonging to the scales see Appendix 1. The internal 
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consistency of the scales was examined with Cronbach's alpha coefficients. In line with the literature, 
an internal consistency of 0.7 or higher was considered as adequate.18, 19 The Cronbach’s alpha was 
0.81, 0.84 and 0.51 respectively for the sensory-, motor-, and autonomy scale. Given the poor internal 
consistency of the two items included in the autonomy scale, we examined these two items 
individually.  
Health utility was assessed with the EQ-5D-5L, which consists of five questions evaluating the health 
dimensions mobility, self-care, usual activities, pain/discomfort, and anxiety/depression on a five point 
Likert scale ranging from 1 (no complaints) to 5 (extreme complaints).20 The patients’ scores on these 
health dimensions were transformed into a utility score using the Dutch tariff.21  
Descriptive patterns of health utility over time 
Using the patient population included in subset 1, we calculated average health utility with 95% 
confidence intervals for the abovementioned time periods separately for patients treated with and 
without ACT. When a patient had completed two or more questionnaires during one of the defined 
time periods, an average value for this patient was calculated before the average utility was estimated 
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Mixed model analyses 
Linear mixed models were used to study the difference in health utility during chemotherapy and the 
first 12 months thereafter between patients with and without ACT. Measurements in time periods 
“before surgery” and “after surgery and before chemotherapy” were considered as baseline 
measurements. In the rare case of two baseline measurements (n=2), the two baseline measurements 
were averaged. Measurements in the periods “during chemotherapy” and ”first 12 months after 
chemotherapy” are follow-up measurements. Because of absence of either a baseline measurement 
or at least one follow-up measurement, 1,246 measurements of 577 patients were excluded (Figure 
1). It should be noted that this large loss in number of measurements is mainly due to the fact that 
many of the excluded patients were included in PLCRC relatively long after primary diagnosis (more 
than one year after the start of ACT).  
Firstly, we developed a crude model, which included adjuvant treatment (yes/no), baseline health 
utility measurement and time between the start of the chemotherapy and the follow-up 
measurement. Secondly, the model was adjusted for age, sex and education level, based on previous 
literature.14 This adjusted model was used to estimate the total effect of chemotherapy (yes/no) on 
health utility. As a third step, we independently included the CIPN scores for the sensory-, motor- and 
autonomy scale in the adjusted model to evaluate the impact of neuropathy, i.e. the direct effects. 
Note that the two items belonging to the autonomy scale were included as separate items in the mixed 
model, given the poor internal consistency at scale level. Correlation between repeated measurements 
within one individual was taken into account by using a random intercept in all analyses. The indirect 
effects, i.e. the impact of the sensory-, motor- and autonomy neuropathy scales, were calculated by 
subtracting the direct effects from the total effect. 
Sensitivity analyses  
In the mixed models, we were not able to include disease stage as a confounder due to the strong 
correlation between ACT and stage (correlation 0.73).17, 22 Given the baseline difference in stage 
between the group with and without ACT, we conducted two sensitivity analyses to investigate the 
potential impact of stage on the association between ACT and health utility. First, we conducted a 
propensity score matching analysis to correct for potential confounding by indication. The propensity 
score was estimated in a logistic regression model with ACT as dependent variable. Using a backward 
selection procedure the independent variables age, sex, education level, baseline health utility and 
disease stage were evaluated as predictors for treatment. Age and stage were included in the final 
model. Based on the propensity score, 38 patients who received ACT were matched 1:1 to 38 patients 
who did not receive ACT using the R matching package.23 Subsequently, the mixed model analyses 
described above were repeated in the matched population.  
Second, we conducted a subgroup analysis in which we only included patients for which the baseline 
measurement was taken during the time period “after surgery and before chemotherapy”, thereby 
excluding patients with a baseline measurement that was taken during the time period “before 
surgery”. The rationale behind this is that before surgery, patients do not know the post-surgical 
disease stage and the potential need for ACT. However, after surgery the disease stage is known and 
as a result, stage III colon cancer patients may experience more mental stress than stage II colon cancer 
patients after surgery and before chemotherapy. We corrected for this potential difference in mental 
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stress by only selecting the patients with a baseline measurement in the time period “after surgery 
and before chemotherapy” and including the baseline health utility measurement in the model. 
Results 
Baseline characteristics 
In subset 1, 1,100 measurements of 405 colon cancer patients treated without ACT and 1,113 
measurements of 454 colon cancer patients treated with ACT were included (Table 1). Patients treated 
with ACT were younger during all defined time periods compared to patients treated without ACT. The 
majority of the patients were men in both treatment groups in all defined time periods. Furthermore, 
the majority of the patients treated without ACT had stage II disease and the majority of the patients 
treated with ACT had stage III disease (Table 1). Because only one out of the ten comparisons between 
stage II and III colon cancer patients was statistically significant, namely the comparison in the no 
adjuvant chemotherapy group for the time period more than 12 months after chemotherapy 
(Appendix Table 1), we decided to further analyse stage II and III colon cancer patients together. 
In subset 2, 585 measurements of 153 patients treated without ACT and 482 measurements of 129 
patients treated with ACT were included (Table 2). At baseline, the median age was lower in the ACT 
group (difference: 5 years). The majority of the patients treated without ACT was stage II (82%). Among 
patients treated with ACT the percentage of stage II patients was only 9%. All other baseline 
characteristics were comparable between the ACT and no ACT group. ACT consisted mostly of 
capecitabine plus oxaliplatin (CAPOX, 57%) and capecitabine monotherapy (40%). The average 
treatment duration was 3.5 months. Note that the baseline characteristics of subset 1 and subset 2 
were in line with each other.  
Descriptive patterns of health utility over time 
In Figure 2 the health utility measurements for the different time periods for patients treated with and 
without ACT are summarized by means of boxplots. After surgery and before start of chemotherapy 
we found a difference in health utility of 0.04 between patients treated with ACT (average: 0.81) and 
those treated without (average: 0.85) (Figure 2b). We also observed a difference in average health 
utility between the group treated with ACT (average 0.83) and the group treated without ACT (average 
0.86) in the periods “during chemotherapy” and “first year after chemotherapy” (Figure 2c and 2d). 
For the time period “more than 12 months after chemotherapy” we found a small difference of 0.01 
between the group treated with ACT (average 0.83) and for the group treated without ACT (average 
0.84) (Figure 2e). For the time period “before surgery” average health utilities were comparable in 
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Linear mixed model analyses 
Table 3 provides the crude and adjusted parameter estimates of the linear mixed model in which we 
investigated the association between ACT and health utility during chemotherapy and the first 12 
months thereafter. Note that the residuals in the mixed models were normally distributed after 
including the health utility baseline measurement. A significant difference of -0.039 (95% CI, -0.062;-
0.015) in health utility was found for the group treated with ACT compared to the group treated 
without ACT in a mixed model adjusted for age, sex and education level (total effect). Subsequently, 
we independently included the CIPN sensory-, motor- and autonomy scale to evaluate the impact of 
neuropathy in the association between ACT and health utility, i.e. the direct effects. The neuropathy 
scores for the sensory- motor- and autonomy scale were considerably higher in the group treated with 
ACT compared to the group treated without ACT during follow-up (Table 2). Including the sensory CIPN 
scale resulted in a coefficient for ACT of -0.020 (95% CI: -0.044;0.003), which indicated an indirect 
effect of 0.019. Furthermore, the association between ACT and health utility over time was no longer 
significant (p=0.09). The addition of the motor and autonomy scale resulted in coefficients for ACT of 
-0.024 (95% CI: -0.046;-0.002) and -0.037 (95% CI: -0.060;-0.014), indicating indirect effects of 0.015 
and 0.02, respectively (Table 3). A complete overview of all parameters of the mixed models is given 
in Appendix Table 2.  
Sensitivity analyses 
Results for both sensitivity analyses are reported in Appendix Table 3 and Appendix Table 4. In the 
analysis in which we corrected for potential confounding by indication using matching, we found a 
difference of -0.036 (-0.085;0.012) in health utility for the group with ACT compared to the group 
without ACT in a model corrected for age, sex and education level. Including the CIPN sensory, motor 
and autonomy scale resulted in effects of -0.031(-0.075;0.013), -0.031 (-0.074;0.013) and -0.045 (-
0.089;-0.001). In the second sensitivity analysis in which we only included patients with a baseline 
measurement after surgery and before chemotherapy, we found an effect of -0.058 (-0.090;-0.027) in 
the adjusted model. After including the CIPN sensory, motor and autonomy scale the effect decreased 
to -0.036 (-0.067;-0.006), -0.044 (-0.072;-0.016) and -0.057 (-0.086;-0.028). The results of both 
sensitivity analyses were roughly in line with the findings in the main analyses. The slightly different 
findings for the impact of neuropathy in the matching analysis may be caused by the smaller sample 
size.  
Discussion 
The primary aim of this study was to estimate the impact of ACT on health utility over time in stage II 
and III colon cancer patients. Subsequently, we evaluated whether the impact of ACT on health utility 
could be (partly) explained by its major side effect, peripheral neuropathy. We found a small but 
statistically significantly lower health utility of -0.039 (95% CI, -0.062;-0.015) in patients who received 
ACT compared to patients without ACT in a mixed model adjusted for age, gender and education level. 
The difference in health utility seems to be partly related to the sensory and motor neuropathy-related 
side effects of adjuvant chemotherapy, given the decreases in ACT effect to -0.020 (95% CI: -
0.044;0.003) and -0.024 (95% CI: -0.046;-0.002), respectively. Overall, the differences in health utility 
between patients with and without ACT are small, indicating that the effect of ACT on health utility 
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There are only limited published data regarding the impact of ACT on stage II and III colon cancer 
patients’ health utility. In the study of Ness et al. a mean difference of 0.04 in average health utility 
was reported between stage III patients who were treated with ACT and stage I/II patients who did not 
receive ACT, which is in line with our results.11 However, the absolute values for health utility for both 
groups treated with and without ACT in the study by Ness et al. are slightly (≈10%) lower compared to 
the values we found in the current study. There are a number of reasons that may explain the 
differences in absolute values. Firstly, Ness et al. included rectal cancer patients as well, while our 
study was limited to colon cancer patients. Secondly, the data that we used in the current study were 
derived from a prospective cohort and contained repeated measurements, while Ness et al. used a 
retrospective study design. Thirdly, the study of Ness et al. was conducted in 1999, and since that time 
diagnostic procedures have changed leading to stage migration.24 That is, a patient that was classified 
as stage II in the study of Ness et al. would probably be classified as stage III in our study. Also other 
studies showed that the administration of ACT may decrease quality of life during the treatment period 
and in the months following chemotherapy.2, 14 A detailed comparison of the findings of these studies 
is hampered by the fact that these studies focused on specific domains of quality of life, such as self-
care, anxiety, mobility and pain, while our study focused on overall heath utility.  
Several challenges should be taken into account in the interpretation of our results. In the PLCRC 
cohort, patients are included at different periods during their course of disease, resulting in patients 
without baseline or follow-up measurement(s). At least one baseline measurement and one follow-up 
measurement before 60 months after diagnosis per patient was required to include patients in the 
mixed model analyses.17 Although we were forced to exclude many measurements in the mixed model 
analyses due to this requirement, the results of the descriptive statistics (n=859) and the mixed model 
analyses (n=282) were in line with each other as are the baseline characteristics for both subsets. To 
illustrate, in the descriptive statistics we found a difference of 0.03 in health utility between patients 
with and without ACT during chemotherapy and the first 12 months thereafter while we found a 
difference of 0.04 using a mixed model. Thus, taking into account relevant covariates, resulted in a 
slightly larger difference.  
Although differences in health utility were statistically significant in the mixed models, the absolute 
difference is small, which raises the question of its clinical significance. A measure to express the 
clinical significance of quality of life measurements is the minimally important difference (MID). The 
MID is defined as the smallest difference in score which patients perceive as beneficial.25 In the field 
of oncology MID scores in a range of 0.03-0.10 were reported for the EQ-5D.26 Based on these MID 
scores, our results are on the boundary of clinical relevance. Therefore, our results indicate that the 
effect of ACT on health utility should not play a major role in the decision whether or not to assign ACT. 
Our mixed models were adjusted for the confounders age, sex and education level based on previous 
literature.14 Given the role of the patients’ clinical condition in the decision to prescribe adjuvant 
chemotherapy, it is likely that the performance status of the patient could also cause confounding in 
the investigated association. However, we were unable to include this covariate in the mixed model, 
which may have caused incomplete correction for confounding. Furthermore, we were not able to 
include stage in the mixed models due to the high correlation with chemotherapy prescription. To 
evaluate the potential impact of stage, we conducted two sensitivity analyses; a propensity score 
matching analysis and an analysis in which we only included patients for which the baseline 
measurement was taken during the time period “after surgery and before chemotherapy”. In both 
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sensitivity analyses, the effect estimated in the model adjusted for age, sex and education level was 
comparable to the effect in the main analysis, which indicates a minor impact of stage on health utility. 
During the collection of the PLCRC data, the Dutch guidelines for the duration of oxaliplatin-based ACT 
in stage II and stage III colon cancer patients were adjusted from 6 months to 3 months. Only a small 
subset of our population was intentionally treated for 3 months (approximately 15%), therefore we 
were unable to correct for treatment duration in the analyses. However, the SCOT trial, which 
compared 6 versus 3 months of ACT in stage II and III colon cancer patients, showed that the health 
utility during ACT and the first months thereafter was significantly higher in patients who received 3 
months ACT (health utility 0.86) compared to 6 months ACT (health utility 0.81).15 In the current study, 
we found an average health utility of 0.83 for the group with ACT during and directly after 
chemotherapy, which is in line with average findings of the SCOT trial. Interestingly, despite the fact 
that planned treatment duration was 6 months for the majority of patients, the average actual 
treatment duration was 3.5 months. The main reason for this shorter treatment duration presumably 
was a premature discontinuation due to side effects.  
In the current study patients were mainly treated with CAPOX (57%) and capecitabine monotherapy 
(40%). FOLFOX is rarely prescribed in the Netherlands (2% in the current study). Literature shows that 
the degree to which neuropathy side effects occur may differ between CAPOX and FOLFOX. To 
illustrate, the incidence of neuropathy was significantly lower for patients treated with CAPOX than 
for FOLFOX in the ACHIEVE trial from the start of the chemotherapy until 3 years thereafter.27 In 
contrast, the SCOT trial found similar incidences of neuropathy in the CAPOX and FOLFOX group.28 
Although the findings are contradictory, generalizing the results of the current study to countries 
where FOLFOX is the most commonly prescribed treatment, such as France, Italy, Canada and the 
United States, should be done with caution.  
To our knowledge, this is the first study that evaluated the impact of peripheral neuropathy on the 
association between ACT and health utility. Our results show that the sensory and motoric neuropathy-
related side effects influence the association between ACT and health utility. When interpreting the 
results, it is important to consider that patients without ACT also scored higher than zero on the EORTC 
QLQ-CIPN20 questionnaire, although the scores were significantly lower compared to the group that 
received ACT. The score > 0 in the group without ACT is caused by questions in the EORTC QLQ-CIPN20 
that are not specifically related to neuropathy complaints, such as “Did you have cramps in your 
hands?” and “Did you have difficulty hearing?”. These complaints also occur in elderly people without 
neuropathy-related side effects. As a result, the role of neuropathy in the association between ACT 
and health utility may be underestimated in the current study. This raises the question whether the 
EORTC QLQ-CIPN20 is the optimal questionnaire to measure CIPN as it might be difficult to distinguish 
between patients with and without neuropathy complaints induced by chemotherapy.  
The results of this study may serve as input for future cost-effectiveness analyses. Prescribing adjuvant 
treatment in stage II and III colon cancer patients is a changing landscape and is referred to in the 
literature as a medical dilemma.29 Particularly in such complex treatment decisions, cost-effectiveness 
studies are needed to support medical decision-making.  
In conclusion, a statistically significant but small decrease in health utility of -0.039 during 
chemotherapy and the first 12 months thereafter was observed between stage II/III colon cancer 
patients treated with ACT compared to those without ACT. Given the small difference in health utility 
between patients with and without ACT, the impact on health utility should not play a major role in 
3
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the treatment decision. The sensory and motor neuropathy-related side effects of chemotherapy 
explained part of the association between chemotherapy and health utility. 
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Age, median (IQR) 
 
67 (61-74) 70 (61-75) 65 (59-71) 













Disease stage, number (%) 
  II 











Treatment regimen, number (%) 
  Capecitabine monotherapy 
  CAPOX 
  FOLFOX 

















Average treatment duration in 
months, mean (sd) 
 
NA NA 3.5 (1.4) 
Education level, number (%) 
  low 
  moderate 
  high 

















Neuropathy baseline measure, 
median (IQR)1 
  Sensory 
  Motoric 















measurements, median (IQR)1 
  Sensory 
  Motoric 
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Table 3: Estimates for the mixed model regression parameters for the association between 
chemotherapy and health utility.  
 
 Estimate1 95% CI P-value 
Crude model2 -0.039 -0.062;-0.015 <0.01 
Adjusted model 1 -0.039 -0.062;-0.015 <0.01 
Adjusted model 2 -0.020 -0.044;0.003 0.09 
Adjusted model 3 -0.024 -0.046;-0.002 0.03 
Adjusted model 4 -0.037 -0.060;-0.014 <0.01 
1 The difference in health utility over time for patients treated with 
adjuvant treatment compared to no adjuvant treatment 2 Crude mixed 
model which includes treatment, baseline measurement and time from 
start chemotherapy to follow-up measurement. Model 1: Additionally 
corrected for age, gender and education level. Model 2: Additionally 
corrected for age, gender, education level and the sensory neuropathy 
scale. Model 3: Additionally corrected for age, gender, education level and 
the motor neuropathy scale. Model 4: Additionally corrected for age, 
gender, education level and the items of the autonomy neuropathy scale. 
Note that no summary score was calculated for the autonomy scale, due 
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Appendix 1. EORTC QLQ – CIPN20 questionnaire.  
Sensory scale 
Did you have tingling fingers or hands? 
Did you have tingling toes or feet? 
Did you have numbness in your fingers or hands? 
Did you have numbness in your toes or feet? 
Did you have shooting or burning pain in your fingers or hands? 
Did you have shooting or burning pain in your toes or feet? 
 9.    Did you have problems standing or walking because of difficulty feeling the 
ground under your feet? 
10.   Did you have difficulty distinguishing between hot and cold water? 
18.   Did you have difficulty hearing? 
Motor scale 
Did you have cramps in your hands? 
Did you have cramps in your feet? 
11.   Did you have a problem holding a pen, which made writing difficult? 
12.   Did you have difficulty manipulating small objects with your fingers (for 
example, fastening small buttons)? 
13.   Did you have difficulty opening a jar or bottle because of weakness in your 
hands? 
14.   Did you have difficulty walking because your feet dropped downwards? 
15.   Did you have difficulty climbing stairs or getting up out of a chair because of 
weakness in your legs? 
19.   Only for those who driving cars,  did you have difficulty using the pedals?1 
Autonomy scale 
16. Were you dizzy when standing up from a sitting or lying position? 
17. Did you have blurred vision? 
20.  Only for males, did you have difficulty getting or maintaining an erection?1 
1 Note that this item was not taken into account in the analyses, because it only 
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CHAPTER 4




Aim: To develop a decision model for the population-level evaluation of strategies to improve the 
selection of stage II colon cancer (CC) patients who benefit from adjuvant chemotherapy. 
Methods: A Markov cohort model with a one-month cycle length and a lifelong time horizon was 
developed. Five health states were included; diagnosis, 90-day mortality, death other causes, 
recurrence and CC death. Data from the Netherlands Cancer Registry were used to parameterize the 
model. Transition probabilities were estimated using parametric survival models including relevant 
clinical and pathological covariates. Subsequently, biomarker status was implemented using external 
data. Treatment effect was incorporated using pooled trial data. Model development, data sources 
used, parameter estimation, and internal and external validation are described in detail. To illustrate 
the use of the model, three example strategies were evaluated in which allocation of treatment was 
based on (A) 100% adherence to the Dutch guidelines, (B) observed adherence to guideline 
recommendations and (C) a biomarker-driven strategy. 
Results: Overall, the model showed good internal and external validity. Age, tumor growth, tumor 
sidedness, evaluated lymph nodes, and biomarker status were included as covariates. For the example 
strategies, the model predicted 83, 87 and 77 CC deaths after 5 years in a cohort of 1000 patients for 
strategies A, B and C, respectively. 
Conclusion: This model can be used to evaluate strategies for the allocation of adjuvant chemotherapy 
in stage II CC patients. In future studies, the model will be used to estimate population-level long-term 
health gain and cost-effectiveness of biomarker-based selection strategies. 
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Background 
With around 10,500 new cases and 4000 deaths in 2016, colon cancer is a major disease in the 
Netherlands leading to a substantial burden for patients, health care and society.1 Over 25% of newly 
diagnosed colon cancer patients have stage II disease and it is likely that this will increase due to the 
recently initiated population based colorectal cancer screening program.2, 3 
In stage II colon cancer, surgical resection is the curative treatment option of choice, followed by 
adjuvant therapy in a subgroup of patients. The benefit of adjuvant chemotherapy after surgical 
resection remains a matter of debate. Adjuvant chemotherapy is often recommended for stage II 
patients with a high risk of recurrence. However, there is no consensus on which factors predict the 
benefit from adjuvant chemotherapy. The correct identification of prognostic and predictive 
parameters is essential to optimize survival without inducing the harms of overtreatment in patients 
who will not benefit.  
Until 2014, high-risk stage II patients were identified using clinical and pathological factors, i.e., pT4 
stage (i.e., tumor growth), < 10 lymph nodes evaluated, perforation, vascular invasion, perineural 
invasion, and a high degree of differentiation.4–6 In response to new findings, the Dutch guidelines 
were updated in 2014 with microsatellite stability (MSS) status in addition to the high-risk features 
mentioned above. In 2018, the Dutch association for medical oncology (NVMO) indicated that only pT4 
and MSS status should be considered in the decision to allocate adjuvant chemotherapy in stage II 
colon cancer patients.7–10 However, adherence to these guideline recommendations is low. In addition 
to substantiated deviations from the guideline recommendations, possible explanations for low 
adherence are unfamiliarity with this guideline, differences in expert opinions, and the clinical 
condition of the patient.11 Presumably, increased compliance due to more awareness of the guideline 
recommendations could lead to health gains. 
Additional molecular markers may enable improved patient selection for adjuvant chemotherapy as a 
number of specific aberrations, such as BRAF and KRAS mutations, are associated with prognosis.12–18 
To illustrate, MSI positive stage II and III patients with double wild-type cancers had a 5-year cancer-
specific survival of 93% (95% CI 84–100%); while, patients with cancers harboring mutations in either 
BRAF or KRAS had a 5-year cancer-specific survival of 76% (95% CI 67–85%) [15]. The potential value 
of using these subtypes to inform adjuvant chemotherapy selection in colon cancer patients is 
acknowledged by several studies.12, 14 
Despite these developments in the field of colon cancer, the cost-effectiveness of different (biomarker-
based) strategies for selecting high-risk stage II colon cancer patients has not been assessed so far. To 
address this issue, we developed the Personalized Adjuvant TreaTment in EaRly stage coloN cancer 
(PATTERN) model to synthesize evidence on different aspects of the decision problem, such as disease-
free survival, overall survival, biomarker status, treatment effect, health utilities, and costs, from 
different sources in one coherent framework. This model can be used to evaluate the population-level 
cost-effectiveness of biomarker-based selection strategies for high-risk stage II colon cancer patients. 
Model structure, model assumptions, data sources, quantification and internal and external validation 
of model predictions are presented in this paper. As an example of the application of the model, the 
NVMO guideline and a hypothetical biomarker-driven strategy are compared with observed adherence 
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Methods  
Description of the Markov cohort model 
The Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN) model is a deterministic 
Markov cohort model that simulates the disease progression of stage II colon cancer patients from the 
moment of diagnosis until death. A flowchart of the model is shown in Figure 1. A Markov model 
describes a sequence of possible events in which the probability of a subsequent event depends solely 
on the state currently attained. This means that the time spent in a health state or the specific health 
states that are visited has no effect on the probability of a future transition. This is commonly referred 
to as the no-memory property. To be able to take time-dependent hazards into account, such as the 
hazards for the transition from recurrence to death, we incorporated tunnel states in the Markov 
model.19 We opted for a cohort approach instead of a micro-simulation approach to increase the 
computational speed, such that the probabilistic sensitivity analysis is possible for future cost-
effectiveness analyses. This choice for this approach seems counter intuitive for a relatively complex 
decision model, but it was possible by replicating the cohort model for each possible subgroup (defined 




Figure 1. Structure of the Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN) 
model 
 
We used a 1-month cycle length in the model. The model consists of 5 clinical states: diagnosis, 90-day 
mortality (90DM), recurrence, death due to other causes than colon cancer (DOC) and death of colon 
cancer (DCC). All patients start in the state ‘diagnosis’, and are treated surgically after pathological 
diagnosis. Furthermore, this state contains the option for patients to undergo or not undergo adjuvant 
chemotherapy. From diagnosis, patients may die within 90 days after resection due to complications 
after surgery or poor clinical condition (DIAG-90DM), they may die from DOC (DIAG-DOC) or they may 
develop a recurrence (DIAGREC). After transitioning to ‘recurrence’, patients are again at risk of DOC 
(REC-DOC) and DCC (REC-DCC). In the model, probabilities for the transitions DIAG-90DM, DIAGDOC 
and DIAG-REC were considered as competing events. 
78
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Data used for parameter estimation  
Model quantification was based on data from the NCR. Recurrence follow-up data are not collected by 
default in the NCR. Therefore, we used a selection of 2271 patients from the nationwide registry for 
which this information was collected. The dataset consists of patients diagnosed with stage II colon 
cancer between 2002 and 2008. Patient and tumor characteristics, time to recurrence and time to 
death were collected. To estimate transition parameters using this dataset, we defined two partly 
overlapping subpopulations; (1) patients who underwent surgery and did not receive adjuvant 
chemotherapy, with or without a recurrence in the follow-up (n = 2152) and (2) patients who 
underwent surgery and developed a recurrence, with or without prior adjuvant chemotherapy (n = 
317) (Figure 2). 
Biomarker data were not collected in the NCR; therefore, we used data of three external cohorts to 
include biomarker status. The following three cohorts were used; (1) a cohort from the MicroArray and 
proteomics Technologies to analyse Colorectal cancer and Hepatic metastases (MATCH) study20, (2) a 
cohort obtained through the Baylor Scott and White Research Institute and Charles A Sammons Cancer 
Center (Texas cohort)21 and (3) a cohort obtained through Instituto Biodonostia, Universidad del País 
Vasco, Centro de Investigación Biomédica en Red de Enfermedades Hepaticas y Digestivas (DONOSTIA 
cohort). These cohorts consisted of 105, 133 and 96 stage II colon cancer patients, respectively, and 
provided data on patient and tumor characteristics as well as biomarker status for MSS, BRAF (MATCH 
only) and KRAS (MATCH only). 
 
 
Figure 2. Flowchart of the 2002-2008 Netherlands Cancer Registry (NCR) data. 
 
Parametrization of the model  
For DIAG-90DM, we estimated a time-independent transition probability using the whole NCR 
population (n = 2271), based on the assumption that all observed deaths within 90 days are due to 
4
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surgical complications or comorbidities.22, 23 For all other transitions, the model was parametrized by 
parametric survival models including relevant covariates. The prognostic value of the following 
covariates was tested in our survival models: pT stage, tumor sidedness, differentiation grade, number 
of evaluated lymph nodes and age. The covariates were selected based on clinical relevance and data 
availability. 
Transitions DIAG-DOC and DIAG-REC were estimated in subpopulation 1, in which patients with 
adjuvant chemotherapy were excluded. Because we aimed to include the impact of treatment on 
recurrence in the model on the basis of high-level evidence from randomized trials, we used the 
untreated patients from the NCR to estimate these two transitions in the absence of treatment.24 
Transitions REC-DOC and REC-DCC were estimated in subpopulation 2, in which only patients were 
included who developed a recurrence. We assumed that the administration of adjuvant chemotherapy 
after surgery does not influence mortality in adjuvant chemotherapy were not excluded in 
subpopulation 2. 
To estimate the parametric survival models, we tested for each transition four commonly used 
parametric survival distributions in health economic modeling (Weibull, Log normal, Log logistic and 
Gompertz).25 The choice for a distribution was based on the lowest Akaike’s information criterion (AIC) 
in combination with strict visual inspection in a model without covariates.25, 26 After selecting the best 
fitting distribution, the prognostic value of the abovementioned covariates was assessed using a 
forward selection procedure. The added covariate was tested for significance using the Wald statistic, 
considering a two-sided p value of < 0.157 as statistically significant. Subsequently, the variable 
selection was extensively discussed with clinical experts, to ensure a conceptually valid inclusion of 
covariates. As a final check, the four parametric model distributions were again compared based on 
the lowest AIC in the models including the relevant covariates, which were selected in the previous 
step. This final check was conducted to confirm that the distribution selected in step 1 was still the 
best fitting distribution after covariate inclusion. It should be noted that the best fitting distribution 
did not change after covariate inclusion for any of the transitions. 
In the dataset used for model parametrization, only overall survival was reported. That is, no 
distinction was made between DOC and DCC. Making this distinction is necessary to estimate the 
impact of improved selection strategies for adjuvant chemotherapy administration on the number of 
deaths due to colon cancer. To quantify the transition REC-DEATH (REC-DOC + REC-DCC), we selected 
the patients who developed a recurrence (subpopulation 2). This subpopulation was used to estimate 
a survival model with time to death as the outcome. Subsequently, we differentiated between DOC 
and DCC by assuming that the probability of DOC is equal for patients with and without a recurrence. 
That is, we assumed the transition REC-DOC to be equal to the transition DIAG-DOC in which DOC was 
estimated in the population without recurrence. The remaining deaths were considered due to DCC. 
All survival models were estimated using the flexsurvreg package in Rstudio version 3.4.2.27 
 
Addition of biomarker status  
Literature shows that MSS, BRAF and KRAS mutation status are associated with prognosis in stage II 
colon cancer patients and that these factors may enable improved patient selection for adjuvant 
chemotherapy.12–18 Therefore, we distinguished three biomarker subgroups in the model; (1) 
microsatellite instable tumors (MSI), independent of BRAF and KRAS status, (2) microsatellite stable 
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tumors (MSS) without a mutation for BRAF or KRAS (MSSdwt), and (3) MSS in combination with a 
mutation in BRAF and/or KRAS (MSSmut). 
To incorporate biomarker status in the transition DIAG-REC in the PATTERN model, the survival model 
reflecting time to recurrence since diagnosis was adjusted by including a hazard ratio (HR) for each 
biomarker subgroup. It should be noted that we assumed the same effect of biomarker status in all 
subgroups included in the PATTERN model. The HR for the MSI subgroup was estimated using the 
MATCH, Texas and Donostia cohorts. The HRs for the MSSdwt and MSSmut subgroups were estimated 
using the MATCH cohort only, as in the Texas and Donostia cohorts, KRAS and BRAF mutation status 
was unknown. The HRs for the MSSdwt and MSSmut subgroups were estimated relative to the MSI 
subgroup. The HRs for the biomarker subgroups were both estimated in a Gompertz parametric 
survival model and were applied directly to the overall hazard predicted by the Gompertz parametric 
survival model for the transition DIAG-REC, in which the clinical features were included. 
 
Addition of treatment effect  
The selection strategy determines which patients receive adjuvant chemotherapy after diagnosis. The 
incorporated treatment effect was not based on the NCR data due to confounding by indication in the 
dataset. We implemented a treatment effect for adjuvant chemotherapy based on a meta-analysis of 
9 Randomized Clinical Trials (RCTs) evaluating the effectiveness of adjuvant therapy in stage II colon 
cancer patients, published between 1999 and 2011. An extensive description of the used procedure is 
given elsewhere.24 In short, we systematically searched relevant trials which reported summary 
disease-free survival data. Second, we generated patient-level data from the reported summary of 
survival data in the included trials using the method described by Hoyle and Henly.28 Patient-level data 
of 4489 patients (events: 853) were generated from seven trials which compared fluoropyrimidine 
monotherapy to no adjuvant treatment (population 1). Furthermore, patient-level data of 1587 
patients (events: 341) were generated from two trials which compared FOLFOX to fluoropyrimidine 
monotherapy (population 2). In the first population, a HR for fluoropyrimidine monotherapy compared 
to no adjuvant treatment of 0.78 (0.68; 0.89) was estimated in a Gompertz parametric survival model. 
In the second population, a HR for FOLFOX compared to fluoropyrimidine of 0.94 (0.76;1.16) was 
estimated in a Gompertz model. To calculate a HR for FOLFOX compared to no adjuvant chemotherapy, 
we multiplied the HRs estimated in population 1 and 2, which resulted in a HR of 0.73. We 
implemented treatment effect in the PATTERN model by adjusting the transition DIAGREC. As data on 
treatment heterogeneity are lacking, potential differences in treatment effect between subgroups 
were not taken into account. 
Competing risk correction  
For transitions DIAG-90DM, DIAG-DOC and DIAG-REC, parametric survival modelling allowed for the 
estimation of the cause-specific hazard rates, which means that competing events were treated as 
censored for the event of interest. Because 90DM, DOC and recurrence are mutually exclusive events 
in the Markov cohort model, a competing risk correction was required. This correction was conducted 
according to the cumulative incidence competing risk (CICR) method29, 30, which has previously been 
applied in a health economic model.31 
In essence, the corrected cumulative risk by time t is an estimate of the risk of failure from a specific 
cause, acknowledging that the absolute risk of the event is lowered by the presence of other competing 
4
81
Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)
149602 Jongeneel BNW.indd   81 04-06-2021   13:48
 
risks. The corrected instantaneous risk at time t to experience each one of the transitions DIAG-90DM, 
DIAG-DOC and DIAG-REC is calculated by multiplying the hazard to experience each specific event at 
time t multiplied by the cumulative chance to be free of any of the three events at t − 1. The competing 
risk correction was carried out in discrete time steps of one month, corresponding to the 1-monthly 
cycles used in the Markov model. Note that for transitions REC-DOC and REC-DCC, a competing risk 
correction was not necessary, because these transitions were estimated jointly in the same survival 
model due to limitations in the data. 
Internal validity of the PATTERN model  
First, we evaluated the internal validity of the final parametric survival models by visual inspection. 
That is, we compared the predicted recurrence and survival rates with their 95% confidence intervals 
to the NCR data. Second, the model performance was evaluated with the Greenwood–D’Agostino–
Nam test for model calibration, which is a modification of the Hosmer–Lemeshow statistic.32 The test 
for model calibration was assessed by dividing the cohort into deciles based on the predicted risk at 
36 months. Subsequently, predicted and observed risks were compared. Third, the discriminatory 
capacity of the parametric survival models was assessed using the Uno modification of the Harrel’s c-
statistic, which is suitable for censored survival data.33, 34 Finally, to show that the model simulations 
correspond well with the NCR data used for model development, we compared the model estimates 
for recurrence and overall survival rate with data estimates and the corresponding 95% confidence 
interval at 12, 24, 36, 48 and 60 months. This approach was conducted for the overall population, and 
for subgroups for age (< 70 and > 70), pT stage (pT3 and pT4), number of lymph nodes examined (< 10 
and ≥ 10) and tumor sidedness (left and right). 
External validation of the PATTERN model  
To evaluate the external validity of the PATTERN model, model predictions for recurrence and overall 
survival rate were compared to the observed data of the NCR 2015 cohort, which was not used for 
model development. The NCR 2015 dataset consists of 1214 stage II colon cancer patients who did not 
receive adjuvant treatment for whom 3-year follow-up data were available for recurrence and overall 
survival (Appendix Table 1). Patient subgroups in the model were weighed in accordance with the 
subgroup distribution in the 2015 cohort. The model-predicted number of recurrences and deaths was 
compared to the 2015 data at 12, 24 and 36 months for the overall population and subgroups for age 
(≤ 70 and > 70), pT stage (pT3 and pT4), number of lymph nodes examined (≤ 10 and > 10) and tumor 
sidedness (left and right). If the model predictions did not fit within the 95% confidence interval of the 
data for all 3 evaluated time points for a specific subgroup, the PATTERN model was updated by 
adjusting the regression coefficients for that subgroup. 
In addition, the implemented treatment effect in the PATTERN model, which was based on external 
RCT data, was validated in a separate analysis. First, survival curves for recurrence and overall survival 
were constructed for the subset of patients from the 2002–2008 NCR dataset (n = 129) and the 2015 
NCR dataset (n = 115) who received adjuvant treatment (Table 1 and Appendix Table 1). Second, we 
set up the PATTERN model to simulate a scenario in which patients receive adjuvant chemotherapy. 
Note that we weighed the subgroups in the model such that it reflected the subgroup distribution in 
the systemically treated population of cohort 2002–2008 and 2015. Finally, we visually assessed the 
agreement between the model predictions for recurrence and overall survival with the data estimates 
at 12, 24, 36, 48 and 60 months for cohorts 2002–2008 and at 12, 24 and 36 months for cohort 2015. 
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Model‑based predictions for three selection strategies  
We illustrated the application of our model by evaluating the health gain of the following selection 
strategies: (A) 100% adherence to the 2018 NVMO guideline, (B) observed adherence to NVMO 
guideline recommendations and (C) a biomarker-driven strategy. To explicitly demonstrate the impact 
of treatment on recurrence-free survival and colon cancer survival within 5 years, an additional 
strategy was evaluated: (D) none of the patients receive adjuvant chemotherapy. 
In the 2018 NVMO guideline strategy, adjuvant chemotherapy is only considered in stage II colon 
cancer patients with pT4 tumors that are MSS. In the observed adherence to the NVMO guideline 
strategy, adherence was based on treatment allocation according to the most recent NCR data; that is 
21% of the patients with a pT4 tumor and MSS receive chemotherapy and 4% of patients who do not 
meet these high-risk requirements. In the hypothetical biomarker-driven strategy, we assumed that 




Characteristics of the patient population  
In Table 1, the baseline characteristics for the NCR cohort are shown for the whole population (n = 
2271), subpopulation 1 (n = 2152) and subpopulation 2 (n = 317). In the whole NCR cohort, the majority 
of patients was aged > 70 (59.6%), had a pT3 stage tumor (88.4%), less than 10 lymph nodes examined 
(52.8%) and a right-sided tumor (55.1%). 344 recurrences and 751 deaths were observed. Follow-up 
duration of the patients was at least 36 months, with a maximum of 179 months. The median follow-
up duration was 53 months. There were no missing values in the follow-up measurements and age. 
Only 5.5% of the patients had missing values in one of the clinical features (pT stage, evaluated lymph 
nodes and tumor sidedness). These missing values were not related to the follow-up measurements. 
Baseline characteristics for the MATCH cohort, Texas cohort and DONOSTIA cohort are shown in Table 
2. In the MATCH cohort the average age was 69.9 years. The majority of the patients had a MSSdwt 
biomarker status (37.1%), followed by MSSmut (34.3%) and MSI (26.7%). In the Texas cohort, the 
average age was 69.9 years as well. The majority of patients had MSS status (51.9%), MSI status was 
present in 6.8% of the cases, for the remaining 41.4%, MMR status was unknown. In the DONOSTIA 
cohort, the average age was 69.1 and the majority of patients had MSS status (76.0%). For the three 
cohorts, 53 recurrences were observed within 5 years of follow-up. The median follow-up duration of 
the patients was 73 months, with a minimum of 2 months and a maximum of 290 months. There were 
no missing values in the follow-up measurements for all three cohorts.  
Estimates for transitions in the model with clinical and pathological features only 
Transitions DIAG‑90DM, DIAG‑DOC, DIAG‑REC  
For the transition DIAG-90DM, we assumed a constant transition probability for the first three cycles. 
For the transition DIAG-DOC, a Gompertz distribution was fitted to estimate time to DOC (Table 3). 
Age was included as covariate in the survival model. For the transition DIAG-REC, we used a Gompertz 
distribution to estimate time to recurrence. The included covariates for the transition DIAG-REC are 
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the number of evaluated lymph nodes, pT stage and tumor sidedness (Table 3). Patients with a missing 
value in one of the covariates were excluded from the analysis (5.5%). 
Transitions REC‑DOC and REC‑DCC  
For transitions REC-DOC and REC-DCC, we first used a Log logistic distribution to estimate time to death 
after a recurrence. Age was included as covariate in the survival model (Table 3). We subsequently 
differentiated between DOC and DCC, as described above. Tunnel states were used to correctly 
incorporate the time-dependent HR for transitions REC- DOC and REC-DCC in the model. 
Subgroups included in the PATTERN model 
The transition probabilities are dependent on prognostic factors, the hazards to transit vary between 
patients based on their clinical and pathological factors. For that reason, 72 subgroups are 
distinguished in the practical implementation of the cohort model based on; age (50–95) in nine 5-year 
categories, number of lymph nodes evaluated (< 10 and ≥ 10), pT stage (pT3 and pT4) and tumor 
sidedness (left and right). 
Internal validity of the model with clinical and pathological features only  
In Appendix Figs. 1–3, the ability of the simulation model to reproduce the data is shown for the 
transitions DIAG-DOC, DIAG-REC and REC-DEATH (REC to DOC + DCC) separately. For the transition 
DIAG-DOC, the predicted number of deaths fits well to the observed death rate (Appendix Figure 1). 
For the transition DIAGREC, the predicted number of recurrences is less close to the data. Especially, 
the predictions for the subgroups with a pT4 profile, for which the sample size was small, deviate from 
the observed data. However, all Kaplan–Meier curves lie within the 95% confidence interval of the 
parametric survival model (Appendix Figure 2). Transitions REC-DOC and REC-DCC were estimated in 
one survival model. In contrast to the survival model used for the transition DIAG-DOC, age was added 
as a continuous covariate in this survival analysis because the small sample sizes of the subgroups for 
age hampered inclusion of age as a categorical variable. For the sum of the transitions REC-DOC and 
REC-DCC, mortality predictions fit in general well with the death rate in the dataset. In age categories 
85–89 and 90–95, the model deviates from the data, probably due to the small sample size in these 
subgroups (Appendix Figure 3). 
Results of the Greenwood–D’Agostino–Nam test for model calibration are shown in Appendix Figure 
4. For all three transitions, DIAG-DOC, DIAG-REC and REC-DEATH, sufficient model calibration was 
shown (p values of 0.93, 0.16 and 0.29, respectively). In addition, C-statistics were 0.74 (0.71–0.78), 
0.63 (0.58–0.68) and 0.64 (0.61–0.68) for the transitions DIAG-DOC, DIAG-REC and REC-DEATH, 
respectively, (Table 3), which indicate sufficient to good model discrimination.35 Finally, the model 
predictions corresponded reasonably well with the NCR data used for model development; 73% (66 
out of 90) of the number of time points for which, in this validation exercise, predictions were obtained 
in the general population and in the subgroup populations, were within the 95% CI of the data 
(Appendix Table 2).  
Addition of biomarker status 
The model including clinical and pathological factors was extended using three biomarker categories, 
i.e., MSI, MSSdwt and MSSmut. We used a Gompertz distribution to estimate HRs for the 3 subgroups 
with which we could correct the transition DIAG-REC. HRs of 0.25 (0.08; 0.80), 0.88 (0.36; 2.17) and 
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1.53 (0.56; 4.15) were estimated for the MSI, MSSdwt and MSSmut subgroups, respectively. 
Parameters are shown in Table 3 and the ability of the simulation model to reproduce the data is shown 
in Appendix Figure 5.  
Addition of treatment effect 
We implemented treatment effect in the decision model by adjusting the transition DIAG-REC; the 
shape parameter of the Gompertz distribution was multiplied with the previously estimated HR of 
0.73.24 
External validation of the PATTERN model  
The results of the external validation of the PATTERN model are shown in Appendix Table 2. 72% (13 
out of 18), 64% (23 out of 36) and 56% (30 out of 54) of the model predictions, in the general population 
and in the subgroup populations, fitted within the 95% CI of the 2015 NCR data at months 12, 24 and 
36, respectively. In general, the model predictions fitted reasonably well with the 2015 data, except 
for the pT4 subgroup. In this subgroup, at none of the time points, the model-predicted recurrence 
rates fitted within the 95% confidence interval. Based on these findings and after discussion with 
clinical experts, the PATTERN model was updated to 2015 for the pT4 subgroup. The transition from 
recurrence to diagnosis is the only transition in the PATTERN model in which pT stage was included as 
covariate. We re-estimated the transition DIAG-REC in the NCR 2015 data and compared the betas for 
pT stage to the estimates in the 2002–2008 NCR data. The beta in the 2015 NCR data was 1.47, which 
is a factor 1.36 higher compared to the 2002–2008 NCR data. The transition from diagnosis to 
recurrence in the PATTERN model was, therefore, adjusted by multiplying the original beta for pT stage 
in the PATTERN model by the factor 1.36. After the model update, the external validation was repeated 
and showed that 83%, 81% and 70% of the model predictions fitted within the 95% CI of the data at 
months 12, 24 and 36, respectively. Especially, the fit for the pT4 subgroup improved (Appendix Table 
2). 
Validation of the treatment effect that was implemented in the PATTERN model based on external RCT 
data, showed that overall 94% of the model predictions for recurrence and overall survival fitted within 
the 95% confidence interval of the data (Appendix Table 4).  
Model‑based predictions for the selection strategies 
For the selection strategy in which none (strategy D) of the patients received adjuvant chemotherapy, 
the model predicted 126 recurrences and 89 deaths due to colon cancer after 5 years in a cohort of 
1000 patients.  
For the observed adherence to guideline recommendations strategy, the model predicted 123 
recurrences after 5 years in a cohort of 1000 patients. For deaths due to colon cancer, this figure was 
87. In case of 100% adherence to the 2018 NVMO guideline recommendations, the model predicted 
119 recurrences and 83 deaths due to colon cancer in a 5-year time horizon. This is a decrease of 3.3% 
in the number of recurrences and a decrease of 4.6% in DCC compared to the observed adherence to 
guideline recommendations strategy. For the hypothetical biomarker-driven strategy, 110 recurrences 
and 77 deaths due colon cancer were predicted after 5 years. Compared to observed adherence to 
guideline recommendations, this is a decrease of 10.6% in the number of recurrences and a decrease 
of 11.5% in DCC. Model predictions are shown in Figure 3. 
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Figure 3. Model predictions for recurrence-free survival (a) and deaths due to colon cancer (b). 
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Discussion  
In this study, a Markov cohort model was developed for the future population-level evaluation of 
different strategies to improve the selection of stage II colon cancer patients for adjuvant 
chemotherapy. The decision model describes the influence of pT stage, number of lymph nodes 
evaluated, tumor sidedness, MSS status, BRAF mutation status, and KRAS mutation status on relevant 
outcomes, such as the recurrence rate and disease-specific survival. Sufficiently adequate internal and 
external validity of the model was demonstrated. To illustrate the application of the model, we 
evaluated the potential health gain that can be achieved with 100% adherence to the 2018 NVMO 
guideline recommendations for adjuvant chemotherapy compared to observed adherence to these 
recommendations. A hypothetical biomarker selection strategy was evaluated as well. Full adherence 
to the NVMO guideline and the biomarker strategy resulted in a 4.6% and 11.5% decrease, 
respectively, in colon cancer mortality compared to observed adherence to NVMO recommendations. 
A Markov decision model for the evaluation of adjuvant chemotherapy in stage II colon cancer was 
developed earlier by Avayci et al.36 These authors used the model to assess the cost-effectiveness of 
adjuvant treatment compared to no adjuvant treatment. This study concluded that fluorouracil 
monotherapy was cost-effective; whereas, fluorouracil in combination with oxaliplatin was considered 
as not cost-effective compared to no treatment. However, this model does not distinguish between 
different patient groups with a different prognosis, and is therefore not able to evaluate different 
selection strategies for adjuvant treatment. To our knowledge, the PATTERN model is the first model 
that can compare different strategies for selecting high-risk stage II colon cancer patients for adjuvant 
therapy. In addition, the PATTERN model is able to perform evaluations for both adjuvant treatment 
with fluoropyrimidine monotherapy and fluoropyrimidine combined with oxaliplatin.  
To develop the PATTERN model, we assumed that all deaths during the first 90 days after diagnosis in 
the NCR dataset were caused by complications of surgery or poor clinical condition of the patient. The 
estimated probabilities of 0.029, 0.051 and 0.12 for age categories < 65, 65–74 and > 74, respectively, 
were in line with previously reported probabilities (0.022, 0.045 and 0.12, respectively).23 Furthermore, 
we assumed that the probability to die from DOC was slightly different in the NCR population 
compared to the general population, due to a different selection of individuals. To illustrate, the factors 
that increase the risk of developing colon cancer are also risk factors for developing other chronic 
diseases, such as cardiovascular diseases.37 Therefore, we used the NCR data to estimate the 
transitions to DOC instead of life tables from the Central Bureau for Statistics Netherlands (CBS). As a 
check, we compared our estimates to the CBS, which showed that the probabilities to die from DOC as 
estimated in our data were higher for ages lower than 65 and were in line for ages 65–85. After age 
85, the probability to die due to other causes was lower in our dataset compared to the CBS. A reason 
for the difference in probability to die from DOC in the population aged < 65 could be the different 
selection of individuals compared to the general population. The difference in patients aged > 85 might 
be explained due to the fact that not all people aged above the 85 are eligible for the initial surgery 
due to reduced clinical condition. As we only included patients with initial surgery in our analysis, we 
probably had a selection of patients aged above 85 with a better clinical condition compared to the 
general population. In addition, we also assumed that patients can only die from colon cancer after 
having a recurrence. That is, patients in our model cannot directly transit from diagnosis to DCC. As 
there may be some underreporting of the number of recurrences in the NCR data, it is possible that 
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the probability to die from colon cancer was also underestimated in the decision model, which could 
result in an underestimation of the impact of adjuvant treatment. 
In our dataset, 3-year and 5-year disease-free survival (DFS) without adjuvant treatment was 0.89 and 
0.86, respectively. These probabilities were higher compared to those found in the literature. For 
example, in the QUASAR trial, probabilities of 0.81 and 0.76 were found for 3-year and 5-year DFS, 
respectively.38 There are several reasons that may explain this difference. First, the populations are 
not completely comparable at baseline. The percentage of patients with a pT4 stage in QUASAR was 
17.4% compared to 9.6% in our data. It should be noted that direct comparison of baseline 
characteristics is hampered due to the fact that the QUASAR trial population also included stage III 
patients (8%) and patients with rectal cancer (29%). Second, the patient inclusion of the QUASAR trial 
took place in 1994–2003, compared to diagnosis years 2002–2008 in the dataset used in the current 
study. Literature shows that quality of diagnosis has improved over the last decades.39 Therefore, it is 
possible that stage III patients were classified as stage II patients in QUASAR, which has worsened the 
overall DFS for stage II patients in the QUASAR trial. Finally, we cannot exclude the possibility that 
recurrences may have been missed in the Netherlands cancer registry (NCR). Overall, the PATTERN 
model was quantified based on Dutch DFS and OS rates. As a consequence, our model predictions are 
only generalizable to countries with similar survival rates.  
In the survival model that was used to calculate the transition probabilities for diagnosis to recurrence, 
the following factors were found to be prognostic: pT stage, tumor sidedness and number of evaluated 
lymph nodes. Degree of differentiation, despite previously included in the guidelines, was not a 
prognostic factor in our dataset. This finding is in line with Snaebjornsson et al.40 reporting that there 
is no support to take poor differentiation as a high-risk factor in stage II colon cancer patients into 
account when deciding on the administration of adjuvant chemotherapy. Despite the fact that tumor 
sidedness is not included in the guidelines as a prognostic factor for recurrence, this factor is 
nevertheless included in our survival model because of its strong prognostic effect in favor of the right-
sided tumors. This is in line with a population-based SEER analysis of 33,323 stage II colon cancer 
patients which demonstrated that both 5 year OS and DFS were superior in right-sided compared to 
left-sided colon cancers (HR 0.85, 95% CI 0.81; 0.89 and HR 0.75, 95% CI 0.70; 0.80, respectively).41 It 
should be noted that this is contradictory to the majority of studies regarding the prognostic value of 
primary tumor location, which indicated that patients with a right-sided tumor have in general a worse 
prognosis compared to left-sided tumors.42, 43 Overall, the majority of the prognostic factors found in 
our data were in line with the literature.44 
The external validation, for which the 2015 NCR data were used, showed overall good agreement 
between the model predictions and the external data, except for the pT4 subgroup. The model 
underestimated the number of recurrences in this subgroup. The difference in recurrence rate in 
cohort 2002–2008 and cohort 2015 could potentially be explained by the increased awareness of the 
poorer prognosis of pT4 stage II patients compared to pT3 stage II patients, which was especially 
triggered by the published findings of the MOSAIC trial in 2004.4 It could be that as a result of these 
findings, pT4 patients are currently better monitored after diagnosis, leading to earlier detection of 
recurrences and, thus, higher recurrence rates. After discussion with clinical experts in the field, we 
decided to update the beta for pT stage, to inform the PATTERN model with the most recent 
information available.  
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Because there is currently a lack of knowledge in the field regarding the most (cost-)effective manner 
to assign treatment in stage II colon cancer patients, it is important to combine all the knowledge we 
have acquired over the past decade in a decision model to enable evaluation of selection strategies. It 
is expected that the number of patients with stage II colon cancer will increase due to the introduction 
of the Dutch CRC screening program, thereby increasing the importance of treating these patients 
optimally. The PATTERN model can address this issue, as has been demonstrated in our simulation of 
3 hypothetical strategies for 100% adherence to the 2018 NVMO guidelines, observed adherence to 
guideline recommendations and a biomarker-driven strategy. 
To adequately interpret the results of these simulations, a number of issues require attention. First, 
treatment heterogeneity was not included in the PATTERN model. In a previous study, a predictive 
effect was found for patients with a microsatellite instable (MSI) tumor. In addition to having a 
favorable prognosis, it was shown that these patients have a certain resistance to fluorouracil-based 
chemotherapy.17 The predictive treatment effect for the MSI subgroup was not taken into account in 
the PATTERN model, because this patient subgroup is not eligible for adjuvant treatment in the current 
guideline because of its favourable prognosis. For the BRAF and KRAS biomarkers and the other 
included prognostic features in the model, no predictive effect for adjuvant chemotherapy has yet 
been demonstrated in stage II colon cancer patients. It should be noted that the PATTERN model was 
built in a flexible manner, e.g., treatment heterogeneity can be implemented when the required data 
become available. Second, it was assumed that the distribution of biomarker status was independent 
of clinical and pathological factors. There is no clear evidence in favour or against this assumption. 
Third, due to limitations in the data, no distinction was made in the MSI group for the presence or 
absence of a mutation in BRAF and/or KRAS. In addition, we did not correct for heterogeneity between 
the cohorts used for biomarker analysis. 
Moreover, it should be noted that we did not aim to conduct a full cost-effectiveness analysis to 
determine the optimal selection strategy for patients with stage II colon cancer. Instead, we solely 
evaluated the impact on health gain of a limited number of example strategies on recurrence and 
death to illustrate the application of the model. In this example analysis, we did not include adverse 
effects of adjuvant chemotherapy on quality of life and costs. In order to evaluate selection strategies 
from a health economic perspective, the PATTERN model will be further informed with cost data and 
quality adjusted life years (QALYs) data.  
To conclude, we presented the development of the Personalized Adjuvant TreaTment in EaRly stage 
coloN cancer (PATTERN) model which is, to our knowledge, the first model that allows a population-
level comparison of different personalized strategies for selecting high-risk stage II colon cancer 
patients for adjuvant chemotherapy. The model includes clinical and pathological features as well as 
biomarker status for MSS, BRAF and KRAS. This model will be used to evaluate the effectiveness and 
cost-effectiveness of existing and biomarker-based selection strategies to improve treatment 
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Table 1. Patient characteristics NCR cohort 2002-2008. 
Variable Whole populationa 
(n=2,271) 








70.7 (10.9) 71.5 (10.7) 70.2 (9.4) 61.3 (10.6) 
Gender     
 Male 1,078 (47.5) 1,020 (47.4) 145 (45.7) 62 (48.1) 
 Female 
 
1,193 (52.5) 1,132 (52.6) 172 (54.3) 67 (51.9) 
pT stage     













    
 <10 1,198 (52.8) 1,123 (52.2) 194 (61.2) 81 (62.8) 
 ≥10 946 (41.7) 906 (42.1) 104 (32.8) 44 (34.1) 
 Unknown 127 (5.5) 123 (5.7) 19 (6.0) 4 (3.1) 
 
 Tumor sidedness 
    













    
 High 145 (6.4) 138 (6.4) 19 (6.0) 10 (7.8) 
 Middle 1,574 (69.3) 1,504 (69.9) 228 (71.9) 76 (58.9) 
 Poor 346 (15.2) 314 (14.6) 45 (14.2) 34 (26.4) 
 Unknown 
 
205 (9.1) 196 (9.1) 25 (7.9) 9 (7.0) 
Chemotherapy 129 (5.7) NA 25 (7.9) 129 (100.0) 
     
Data are presented as means (±SD) or numbers (%). NA = not applicable. a This population was used to estimate a time 
independent hazard ratio for the transition DIAG-90DM. b Patients who underwent surgery and did not receive 
adjuvant chemotherapy. This population was used to estimate the transitions DIAG-DOC and DIAG-REC. c Patients who 
underwent surgery and developed a recurrence, independent of adjuvant chemotherapy. This population was used to 
estimate the transition REC-DEATH. d Note that this subpopulation of adjuvant treated patients was only used for 
external validation of the PATTERN model and not for model parametrization.  
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Table 2. Patient characteristics of the MATCH cohort, Texas cohort en Donostia cohort.  





















Gender     
 Male 153 (45.8) 51 (48.6) 72 (54.1) 30 (31.3) 
 Female 
 







 Wild type 
 Mutation 
 Unknown  
 
KRAS status 




























































































Data are presented as means (±SD) or numbers (%). NA = not applicable. Abbreviations: MSI = Microsatellite instability 
independent of status for BRAF and KRAS; MSSdwt = Microsatellite stability without a mutation for BRAF or KRAS; 
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Appendix Table 1. Patient characteristics of the 2015 NCR cohort, which was used for the external 
validation of the PATTERN model.  








72.0 (9.5) 62.6 (7.8) 
Gender   
 Male 627 (51.6) 63 (54.8) 
 Female 
 
587 (48.4) 52 (45.2) 
pT stage   








Evaluated lymph nodes 
  
 <10 53 (4.4) 8 (7.0) 
 ≥10 1,161 (95.6) 107 (93.0) 
 
 Tumor site 
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Appendix Table 2. Results of the internal validation (NCR cohort 2002-2008) and external validation 
(NCR cohort 2015). The results of the external validation are reported for both before and after the 
model update.  
  Recurrence Overall survival 
   Data estimate Model prediction  Data estimate  Model prediction 
  Point 
estimate 















2002-2008 n=2,211  n=2,206 
12 months 0.95 0.94-0.96 0.95 NA 0.88 0.86-0.89 0.90 NA 
24 months 0.90 0.89-0.92 0.91 NA 0.81 0.80-0.83 0.84 NA 
36 months  0.87 0.85-0.89 0.89 NA 0.76 0.75-0.78 0.79 NA 
48 months 0.85 0.83-0.86 0.87 NA 0.72 0.70-0.74 0.73 NA 
60 months 0.83 0.82-0.85 0.85 NA 0.67 0.65-0.69 0.68 NA 
2015 n=1,214 n=1,214 
12 months 0.96 0.94-0.97 0.96 0.96 0.92 0.91-0.93 0.90 0.90 
24 months 0.90 0.89-0.92 0.93 0.92 0.88 0.86-0.89 0.84 0.85 
36 months 0.87 0.84-0.89 0.91 0.90 0.83 0.82-0.84 0.79 0.79 
pT3 population 
2002-2008 n=1,979 n=1,974  
12 months 0.97 0.95-0.97 0.96 NA 0.90 0.89-0.92 0.90 NA 
24 months 0.92 0.90-0.93 0.93 NA 0.85 0.83-0.86 0.85 NA 
36 months  0.89 0.87-0.90 0.90 NA 0.80 0.78-0.81 0.80 NA 
48 months 0.86 0.84-0.88 0.88 NA 0.75 0.73-0.77 0.74 NA 
60 months 0.85 0.83-0.87 0.87 NA 0.71 0.69-0.73 0.69 NA 
2015 n=1,089 n=1,089 
12 months 0.97 0.96-0.98 0.97 0.97 0.95 0.94-0.97 0.91 0.91 
24 months 0.93 0.91-0.94 0.94 0.94 0.91 0.89-0.93 0.86 0.86 
36 months 0.90 0.87-0.91 0.93 0.93 0.88 0.86-0.89 0.81 0.81 
pT4 population 
2002-2008 n=179 n=179 
12 months 0.84 0.78-0.89 0.89 NA 0.79 0.73-0.85 0.89 NA 
24 months 0.74 0.67-0.81 0.81 NA 0.65 0.58-0.72 0.80 NA 
36 months  0.70 0.62-0.77 0.75 NA 0.61 0.53-0.68 0.72 NA 
48 months 0.67 0.59-0.75 0.71 NA 0.52 0.45-0.60 0.65 NA 
60 months 0.64 0.56-0.72 0.68 NA 0.48 0.41-0.56 0.59 NA 
2015 n=124 n=124 
12 months 0.81 0.73-0.89 0.91 0.87 0.85 0.80-0.92 0.86 0.85 
24 months 0.67 0.58-0.77 0.85 0.77 0.74 0.67-0.89 0.77 0.74 
36 months 0.61 0.51-0.71 0.80 0.71 0.68 0.57-0.80 0.69 0.64 
                                                             Aged <70 
2002-2008 n=894 n=891 
12 months 0.95 0.93-0.96 0.95 NA 0.95 0.93-0.96 0.96 NA 
24 months 0.90 0.88-0.92 0.91 NA 0.91 0.89-0.93 0.93 NA 
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36 months  0.87 0.85-0.89 0.88 NA 0.87 0.85-0.89 0.90 NA 
48 months 0.85 0.82-0.87 0.85 NA 0.84 0.81-0.86 0.87 NA 
60 months 0.84 0.81-0.86 0.84 NA 0.80 0.78-0.83 0.83 NA 
2015 n=517 n=517 
12 months 0.96 0.94-0.98 0.96 0.96 0.97 0.95-0.98 0.96 0.96 
24 months 0.91 0.89-0.94 0.93 0.93 0.95 0.92-0.98 0.93 0.93 
36 months 0.88 0.85-0.91 0.91 0.90 0.92 0.89-0.95 0.90 0.90 
Aged ≥70 
2002-2008 n=1,317 n=1,315 
12 months 0.96 0.95-0.97 0.95 NA 0.83 0.81-0.85 0.86 NA 
24 months 0.90 0.89-0.92 0.92 NA 0.75 0.72-0.77 0.79 NA 
36 months  0.87 0.85-0.89 0.89 NA 0.69 0.66-0.71 0.72 NA 
48 months 0.84 0.82-0.87 0.87 NA 0.64 0.61-0.66 0.65 NA 
60 months 0.83 0.81-0.85 0.86 NA 0.58 0.56-0.61 0.58 NA 
2015 n=697 n=697 
12 months 0.95 0.93-0.97 0.96 0.96 0.89 0.87-0.91 0.86 0.87 
24 months 0.89 0.87-0.92 0.94 0.93 0.82 0.79-0.85 0.79 0.79 
36 months 0.85 0.82-0.88 0.90 0.90 0.79 0.75-0.82 0.72 0.71 
<10 lymph nodes evaluated 
2002-2008 n=1,151 n=1,148 
12 months 0.94 0.93-0.95 0.94 NA 0.84 0.82-0.86 0.89 NA 
24 months 0.88 0.86-0.90 0.90 NA 0.77 0.74-0.79 0.83 NA 
36 months  0.83 0.81-0.85 0.86 NA 0.70 0.67-0.73 0.77 NA 
48 months 0.80 0.77-0.82 0.84 NA 0.65 0.62-0.68 0.71 NA 
60 months 0.79 0.77-0.83 0.82 NA 0.60 0.57-0.63 0.66 NA 
2015 n=53 n=53 
12 months 0.91 0.83-0.99 0.93 0.92 0.81 0.71-0.92 0.88 0.88 
24 months 0.75 0.62-0.88 0.88 0.86 0.77 0.66-0.89 0.81 0.80 
36 months 0.72 0.59-0.86 0.84 0.82 0.67 0.56-0.78 0.74 0.73 
≥ 10 lymph nodes evaluated 
2002-2008 n=937 n=935 
12 months 0.97 0.96-0.98 0.97 NA 0.92 0.90-0.94 0.91 NA 
24 months 0.93 0.92-0.95 0.94 NA 0.87 0.85-0.89 0.86 NA 
36 months  0.92 0.90-0.93 0.92 NA 0.84 0.81-0.86 0.81 NA 
48 months 0.90 0.88-0.92 0.90 NA 0.79 0.77-0.82 0.76 NA 
60 months 0.88 0.86-0.90 0.89 NA 0.76 0.73-0.78 0.72 NA 
2015 n=1,161 n=1,161 
12 months 0.96 0.95-0.97 0.97 0.96 0.94 0.93-0.96 0.90 0.90 
24 months 0.91 0.89-0.93 0.94 0.93 0.90 0.89-0.93 0.85 0.85 
36 months 0.87 0.85-0.89 0.92 0.91 0.86 0.84-0.88 0.80 0.80 
Right sided tumor 
2002-2008 n=1,222 n=1,218 
12 months 0.96 0.94-0.97 0.96 NA 0.88 0.86-0.89 0.90 NA 
24 months 0.92 0.90-0.93 0.93 NA 0.83 0.80-0.85 0.84 NA 
36 months  0.89 0.87-0.91 0.91 NA 0.78 0.75-0.80 0.79 NA 
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48 months 0.88 0.86-0.90 0.89 NA 0.74 0.72-0.77 0.74 NA 
60 months 0.87 0.85-0.89 0.88 NA 0.70 0.68-0.73 0.69 NA 
2015 n=714 n=714 
12 months 0.96 0.95-0.98 0.97 0.97 0.92 0.88-0.94 0.89 0.89 
24 months 0.92 0.90-0.94 0.95 0.94 0.87 0.83-0.90 0.84 0.84 
36 months 0.88 0.86-0.91 0.93 0.93 0.82 0.79-0.85 0.79 0.80 
Left sided tumor 
2002-2008 n=957 n=956 
12 months 0.95 0.94-0.96 0.94 NA 0.88 0.86-0.90 0.90 NA 
24 months 0.88 0.86-0.91 0.89 NA 0.80 0.78-0.83 0.84 NA 
36 months  0.84 0.81-0.87 0.85 NA 0.75 0.72-0.77 0.78 NA 
48 months 0.80 0.77-0.83 0.82 NA 0.69 0.66-0.72 0.72 NA 
60 months 0.79 0.76-0.82 0.80 NA 0.64 0.61-0.67 0.67 NA 
2015 n=481 n=481 
12 months 0.95 0.92-0.97 0.95 0.95 0.94 0.92-0.95 0.91 0.91 
24 months 0.88 0.85-0.91 0.91 0.91 0.89 0.86-0.92 0.86 0.86 
36 months 0.84 0.80-0.88 0.88 0.88 0.85 0.82-0.88 0.80 0.80 
Abbreviations: CI = confidence interval, NA = not applicable. a Based on the results of the external validation 
on the NCR 2015 data, a model update was needed. The external validation on the NCR 2015 data was 
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Appendix Table 3. Parameter estimates for the transition from diagnosis to recurrence for cohort 
2002-2008 and cohort 2015.  
 NCR cohort 2002-2008 NCR cohort 2015 
 Estimate 95% confidence interval Estimate 95% confidence interval 
  Lower Upper  Lower Upper 
Shape -0.016 -0.021 0.010 -0.005 -0.017 0.007 
Rate 0.004 0.003 0.005 0.006 0.003 0.012 
pT stage (pT4 vs pT3) 1.081* 0.779 1.383 1.468* 1.098 1.838 
Lymph nodes evaluated (>10 vs ≤10) -0.519 -0.762 -0.276 -0.823 -1.395 -0.251 
Tumor side (Left vs Right) 0.505 0.272 0.737 0.269 -0.054 0.591 
Abbreviations: NCR = Netherlands Cancer Registry. *Note that the parameters in bold were used to determine the factor 
of 1.36, which was used to update the PATTERN model. 
 
 
Appendix Table 4. Results of the validation of treatment effect in the PATTERN model, which was 
implemented based on external Randomized Clinical Trial data. Model predictions under treatment 
with adjuvant chemotherapy for populations with characteristics conform the 2002-2008 NCR cohort 
and the 2015 NCR cohort, respectively, were compared to the observed survival curves of adjuvantly 
treated patients in these cohorts. 
  Recurrence Overall survival 
  Data estimate Model prediction Data estimate Model prediction 
  Point 
estimate 















2002-2008 n=129 n=129 
12 months 0.95 0.89-1.00 0.95 NA 0.96 0.93-0.99 0.95 NA 
24 months 0.83 0.74-0.91 0.91 NA 0.88 0.83-0.94 0.91 NA 
36 months  0.78 0.68-0.87 0.88 NA 0.84 0.77-0.90 0.88 NA 
48 months 0.77 0.67-0.86 0.85 NA 0.78 0.71-0.85 0.84 NA 
60 months 0.73 0.63-0.84 0.83 NA 0.76 0.68-0.83 0.80 NA 
2015 n=115 n=115 
12 months 0.97 0.93-1.00 0.95 0.94 0.95 0.92-0.99 0.95 0.94 
24 months 0.88 0.81-0.94 0.91 0.89 0.90 0.84-0.96 0.91 0.91 
36 months 0.86 0.79-0.92 0.88 0.85 0.87 0.81-0.94 0.88 0.87 
Abbreviations: CI = confidence interval. a Based on the results of the external validation reported in Table 2, a model 
update was necessary. Therefore, validation of the implemented treatment effect in the PATTERN model was conducted 
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Appendix Figure 2. Parametric survival models for parametrization of the transition from diagnosis to 
recurrence. Each subpanel shows the data and the corresponding predicted recurrence rate in each 
subgroup including the lower and upper bound of the 95% confidence interval of the prediction. Note 
the different scaling for each subgroup on the y axis. Abbreviations: <10 = less than 10 lymph nodes 
evaluated; ≥ 10 = 10 or more lymph nodes evaluated; R = right sided tumor; L = left sided tumor.
104
4      Chapter 4
149602 Jongeneel BNW.indd   104 04-06-2021   13:48
   
 












































































































































































Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)































Appendix Figure 4. Calibration plot for the parametric survival models for the transitions from 
diagnosis to death other causes (a), diagnosis tot recurrence (b) and recurrence to death (c). 
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Appendix Figure 5. Parametric survival models for the biomarker subgroups Microsatellite instability 
(MSI), Microsatellite stability without a mutation in BRAF and/or KRAS (MSSdwt) and Microsatellite 
stable in combination with a mutation in BRAF and/or KRAS (MSSmut). Each subpanel shows the data 
and the corresponding predicted recurrence-free survival in each biomarker group including the lower 
and upper bound of the 95% confidence interval of the prediction. 
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Abstract 
Background: Our aim was to evaluate the cost-effectiveness of 3 months adjuvant chemotherapy 
versus 6 months in high-risk (T4 stage + Microsatellite stable) stage II colon cancer (CC) patients. 
Methods: Using the validated PATTERN Markov cohort model, which simulates the disease 
progression of stage II CC patients from diagnosis to death, we first evaluated a reference strategy in 
which high-risk patients were treated with chemotherapy for 6 months. In the second strategy, 
treatment duration was shortened to 3 months. Both strategies were evaluated for CAPOX and 
FOLFOX. Based on trial data, we assumed that shortened treatment duration compared with a 6-
month regimen was equally effective for CAPOX and less effective for FOLFOX. Adverse events were 
highest in the 6-month strategy. Analyses were conducted from a societal perspective using a lifelong 
time horizon. Outcomes were number of CC deaths per 1,000 patients and total discounted costs and 
quality adjusted life-years (QALYs) per patient (pp). Incremental Net monetary benefit (iNMB) was 
calculated using a willingness-to-pay value of 50,000 €/QALY.  
Results: For CAPOX, the 6-month strategy resulted in 316 CC deaths per 1,000 patients, 6.71 QALYs pp 
and total costs of €41,257 pp. The 3-month strategy resulted in an equal number of CC deaths, but 
higher QALYs (6.80 pp) and lower costs (€37,645 pp), leading to a iNMB of €8,454 per person for 3 
months versus 6 months. For FOLFOX, the 6-month strategy resulted in 316 CC deaths per 1,000 
patients, 6.71 QALYs pp and total costs of €47,135 pp. The 3-month strategy resulted in more CC deaths 
(393), lower QALYs (6.19 pp) and lower costs (€44,389 pp). A iNMB of -€23,189 was found for 3 months 
versus 6 months. 
Conclusion: Our findings indicate that 3 months adjuvant chemotherapy should be considered as 
standard of care in high-risk stage II CC patients for CAPOX, but not for FOLFOX.   
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Introduction  
Colon cancer is a major disease in The Netherlands. With around 10,000 new cases and 3750 deaths 
in 2017, it leads to a significant burden for patients, healthcare and society.1 To illustrate, the total 
healthcare costs for colon cancer patients in the Netherlands are estimated at 597 million euros in 
2017.2 This is 0.7% of the total Dutch healthcare expenditure, and 10.2% of all expenditure on cancer 
care in that year. Around a quarter of the newly diagnosed colon cancer patients are classified as stage 
II. 
The initial treatment for stage II colon cancer patients is surgical resection. Without further adjuvant 
treatment and depending on the tumor invasiveness, around 20% of these patients will develop a 
recurrence in the next 5 years.3 Therefore, stage II patients who are considered at high risk of 
developing a recurrence are eligible for adjuvant chemotherapy. In The Netherlands, only a T4 stage 
in combination with a microsatellite stable (MSS) tumor is considered as a selection criterion for 
adjuvant chemotherapy in stage II colon cancer.4 Using this criterion, 8.5% of the total stage II 
population in The Netherlands is eligible for adjuvant chemotherapy. However, clinicians may of 
course deviate from this recommendation. To illustrate, data of the Netherlands Cancer Registry (NCR) 
showed that only 21% of the stage II population with an indication for adjuvant chemotherapy actually 
received adjuvant chemotherapy in The Netherlands between 2015 and 2017.5 In addition, 4% percent 
of the patients without indication for adjuvant chemotherapy were treated with adjuvant 
chemotherapy.  
Until recently, the standard adjuvant chemotherapy treatment regimen for high-risk stage II patients 
in The Netherlands was 6 months oxaliplatin with a fluoropyrimidine.6–9 Although this treatment 
lowers the risk of recurrence,3 approximately 60% of the treated patients suffer from peripheral 
neuropathy as a result of the adjuvant chemotherapy, and for some patients, the side effects are 
chronic.10 Neuropathy-related complaints can have a major impact on a patient’s quality of life.11 
Previous studies showed that the degree of neuropathy is correlated with the duration of treatment; 
the percentage of patients who suffer from peripheral neuropathy halves when the treatment duration 
is shortened to 3 months.10,12 This raises the question whether the duration of the treatment can be 
shortened without reducing the effectiveness. 
So far, two trials, both part of the International Duration Evaluation of Adjuvant Therapy (IDEA) 
collaboration,10,12 compared a 3-month to a 6-month adjuvant treatment duration in high-risk stage II 
colorectal cancer patients. In the SCOT trial, the authors reported a hazard ratio (HR) for recurrence of 
0.99 [95% confidence interval (CI): 0.75–1.31] for a 3-month oxaliplatin-based treatment regimen 
compared with 6 months of treatment in high-risk stage II colorectal cancer. This suggests that a 3-
month treatment duration is non-inferior to a 6-month treatment duration.10 In contrast, the TOSCA 
trial found a significant HR of 1.42 (95% CI: 1.06–1.90) for recurrence of disease when comparing 3 
versus 6 months of treatment in stage II colon cancer. The most likely explanation for these conflicting 
findings is the higher number of patients treated with FOLFOX (fluorouracil, leucovorin and oxaliplatin) 
in the TOSCA trial (64%) compared with the SCOT trial (32%). This is supported by a pooled analysis of 
the stage II patients included in the IDEA trials.13,14 The results strongly suggest that 3 months of CAPOX 
(capecitabine plus oxaliplatin) is non-inferior to 6 months of CAPOX, whereas 3 months of FOLFOX is 
inferior to 6 months of FOLFOX.13,14 
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Based on the findings from the IDEA collaboration, opinions are shifting regarding the optimal duration 
of oxaliplatin-based adjuvant chemotherapy. Recently presented data showed that approximately 27% 
of the European clinicians prescribe 3 months of chemotherapy to high-risk stage II and III patients.15 
Furthermore, in The Netherlands the recommended treatment duration for high-risk stage II patients 
is recently revised from 6 to 3 months of oxaliplatin-based chemotherapy.4 To carefully balance the 
benefits and potential harms of shortening the treatment duration, we evaluated the cost 
effectiveness of a 3-month adjuvant chemotherapy regimen compared with a 6-month regimen for 
CAPOX and FOLFOX separately in high-risk stage II colon cancer patients using the ‘Personalized 
Adjuvant TreaTment in EaRly stage coloN cancer’ (PATTERN) model.16 
Methods 
PATTERN model 
The PATTERN model has been comprehensively described elsewhere.16 A flowchart of the model is 
shown in Figure 1 and model parameters are shown in Appendix Table A1. In short, the PATTERN model 
is a Markov cohort model with a lifelong time horizon and a 1-month cycle length. The model consists 
of five health states: diagnosis; 90-day mortality; death by other causes; recurrence; and death of colon 
cancer. Patient-level data from the NCR (n = 2271) and three external cohorts (n = 258) were used for 
model quantification.17,18 The PATTERN model was extensively validated both internally and externally. 
For the transition from diagnosis to 90-day mortality, we assumed that all observed deaths within 90 
days after diagnosis were due to surgical complications. For all other transitions in the model, 
parametric survival models, including relevant covariates, were used for parametrization. Note that 
only patients without adjuvant chemotherapy treatment were included for fitting the survival models. 
In addition, we included an HR for treatment effect of 0.73 for fluoropyrimidine monotherapy 
combined with oxaliplatin, compared with no adjuvant treatment, based on pooled trial data 




Figure 1. Flowchart of the Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN) 
model. 
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In the model, 216 subgroups were distinguished based on number of lymph nodes evaluated (<10 and 
≥10), T stage (T3 and T4), tumor site (left and right), age (50–95 in nine 5-year categories), and 
biomarker status (microsatellite instability, MSS without a mutation in BRAF and KRAS and MSS 
combined with a mutation in BRAF and/or KRAS). The subgroups were weighted such that the 
distribution of clinical and pathological features reflects Dutch patients with colon cancer stage II. In 
line with the Dutch guideline recommendations, we only simulated high-risk patients (T4+MSS) in the 
current study.4 
Strategies 
The base-case analysis was conducted for CAPOX and FOLFOX separately. In the reference strategy, 
high-risk patients received 6 months of oxaliplatin-based chemotherapy. Patients were classified as 
high risk according to the current Dutch guidelines (T4+MSS status).4 In the 6-month strategy, an HR 
for recurrence compared with no treatment of 0.73 was assumed for both CAPOX and FOLFOX, based 
on pooled trial data.19 Subsequently, a strategy was simulated in which high-risk patients receive 3 
months of adjuvant chemotherapy. In the 3-month strategy, the above-mentioned HR for treatment 
effect in the 6-month strategy was multiplied with an HR for treatment effect for a 3-month during 
treatment regimen compared with a 6-month during treatment regimen, based on the pooled analysis 
for high-risk stage II colon cancer patients in the IDEA trials.13,14 These HRs for 3 versus 6 months of 
adjuvant chemotherapy were 1.0 (0.88; 1.17) for CAPOX (estimated in a population of 2019 high-risk 
stage II patients) and 1.4 (1.19; 1.70) for FOLFOX (estimated in a population of 1254 high-risk stage II 
patients). Note that the T4 stage, poor differentiation, invasion, inadequate nodal harvest, obstruction 
and perforation were specified as high-risk features in the IDEA trials.10,12,13 
Costs  
In Table 1, an overview of resource use, costs, and utilities is presented. Costs were determined from 
a societal perspective and included costs for initial surgery, drugs, adverse events, absenteeism from 
work, patient travel to hospital, surveillance, and recurrence of disease.4,6,7,20–28 Costs of chemotherapy 
were calculated separately for CAPOX and FOLFOX. We assumed in the 6-month strategy that the 
FOLFOX regimen consisted of 12 cycles of 2 weeks, while the CAPOX regimen consisted of 8 cycles of 
3 weeks.4 In the 3-month strategy, the number of cycles was halved for both CAPOX and FOLFOX. Per 
treatment schedule, we calculated the amount of medication needed for a patient with an average 
body surface of 1.7 m2. The adverse event rates were based on the TOSCA trial and were highest in 
the 6-month strategy.26 Per adverse event category, costs were based on follow-up care. For 
neutropenia, this was defined as a visit to the outpatient clinic for febrile neutropenia, as a hospital 
stay of 5 days, and for diarrhea, as oral rehydration medication.20,22 Surveillance was based on the 
Dutch guideline recommendations4 and consisted of consultations every half-year during the first 3 
years after surgery, and yearly thereafter until 5 years after surgery. Each consultation is combined 
with an ultrasound scan of the liver, as well as a carcinoembryonic antigen (CEA) determination. In 
addition, patients undergo colonoscopy every 3 years, with the first colonoscopy 1 year after surgery.4 
Health-related quality of life  
To inform the model, we used utility estimates derived from the SCOT trial which reported the utilities 
for both a 3-month treatment regimen and 6-month treatment regimen.10,29 We calculated the average 
health utility in different time periods separately for the 3-month and 6-month strategy. We defined 
the following periods: before surgery; after surgery; before start of chemotherapy; during 
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chemotherapy; first year after chemotherapy; 2–5 years after chemotherapy; and more than 5 years 
after chemotherapy (Table 1). As the health utility for patients who developed a recurrence was not 
reported in the SCOT trial, the utility for this health state was derived from other literature.30–32 Once 
a patient in the model developed a recurrence, the health utility was reduced to 0.45 for 60 months. 
At 60 months after recurrence, the patient was considered to be a cancer survivor and the value 0.90 
was assigned, in line with the reported health utility in the SCOT trial for more than 5 years after 
chemotherapy. A full overview of health utilities is shown in Table 1. 
Outcome  
Model outcomes consisted of the number of recurrences and deaths due to colon cancer per 1000 
treated patients, life-years per patient (pp), quality-adjusted life-years (QALYs) pp, and total lifetime 
costs pp. Dutch discount rates of 4% and 1.5% were used for costs and health effects, respectively.22 
The incremental net monetary benefit (NMB) of the 3-month strategy was calculated relative to the 6-
month strategy as follows: [(incremental benefit × willingness to pay)− incremental cost], using a 
willingness-to-pay value of €50,000 per QALY. A positive incremental NMB indicates that the 3-month 
strategy is cost-effective compared with the 6-month strategy. A negative incremental NMB indicates 
that the 3-month strategy is not cost-effective compared with the 6-month strategy. Furthermore, the 
incremental cost-effectiveness ratio (ICER) was calculated as the ratio between the difference in costs 
and the difference in QALYs between the 3-month and 6-month strategies. A strategy is considered as 
cost-effective when the ICER does not exceed the threshold value of €50,000 per QALY.33 
Sensitivity analyses  
In the base-case analysis, we assumed in the 3-month strategy an HR for treatment effect for 3 months 
compared with 6 months’ chemotherapy of 1.0 (0.88; 1.17) for CAPOX, and 1.4 (1.19; 1.70) for FOLFOX. 
However, there is uncertainty around these treatment effects.13,19 To investigate the impact of this 
uncertainty on the base-case results, we performed a threshold analysis separately for CAPOX and 
FOLFOX. In this analysis, the HR for treatment effect for 3 months compared with 6 months 
chemotherapy for CAPOX was increased from 1.0 to 1.17 in accordance with the upper limit of the 
corresponding CI in the pooled IDEA analysis.13 For 3 months of FOLFOX, the HR decreased from 1.4 to 
1.19, which is the lower limit of the CI for FOLFOX in the pooled IDEA analysis.13 Note that we only 
varied the treatment effect for the 3-month strategies in the direction in which changes could occur 
with regard to the conclusion of the cost-effectiveness of the 3-month strategy compared with the 6-
month strategy. 
Furthermore, in a one-way sensitivity analysis, we investigated the impact of the uncertainty around 
the utility estimates derived from the SCOT trial. In this sensitivity analysis, we changed the health 
utilities according to the upper and lower limit of the CI reported in the SCOT trial (Table 1).29  
Finally, a probabilistic sensitivity analysis was conducted to investigate the joint impact of parameter 
uncertainty. All parameters in the PATTERN model were varied simultaneously according to the most 
appropriate distribution. The Monte Carlo simulation, which was conducted separately for CAPOX and 
FOLFOX, consisted of 1000 iterations for both the 3-month strategy and the 6-month strategy. To 
graphically illustrate the uncertainty surrounding the base-case model predictions, incremental costs 
and effects were plotted on a cost-effectiveness plane. In addition, cost-effectiveness acceptability 
curves (CEACs) were constructed for CAPOX and FOLFOX separately. 
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In the 6-month strategy, the model predicted 369 recurrences and 316 colon cancer deaths for both 
CAPOX and FOLFOX in the lifetime of 1000 high-risk stage II colon cancer patients. For CAPOX, these 
figures for the 3-month strategy were equal to the 6-month strategy. For FOLFOX, the model predicted 
457 recurrences and 393 colon cancer deaths in the 3-month strategy in a cohort of 1000 patients, 
which corresponds to an increase of 19.3% and 19.6% compared with the 6-month strategy, 
respectively (Table 2). For both CAPOX and FOLFOX, the predicted QALYs in the 6-month strategy were 
6.71 pp. For CAPOX, the predicted QALYs increased to 6.80 pp in the 3-month strategy, while for 
FOLFOX the QALYs decreased to 6.19 pp.  
Cost-effectiveness  
For CAPOX, the predicted costs pp were €41,257 for the 6-month strategy and €37,645 for the 3-month 
strategy. This cost difference of €3612 was due to saving resources related to the adjuvant 
chemotherapy. The incremental NMB for the 3-month strategy relative to the 6-month strategy was 
€8454, considering a willingness to pay of €50,000/QALY. The 3-month strategy was more effective 
and less costly compared with the 6-month strategy, leading to a negative ICER of -€37,308/QALY. This 
indicates that the 3-month strategy is cost saving compared with the 6-month strategy. For FOLFOX, 
the predicted costs were €47,135 for the 6-month strategy and €44,389 for the 3-month strategy. An 
incremental NMB of -€23,189 was found for the 3-month strategy compared with the 6-month 
strategy, indicating that the 3-month strategy is not cost-effective compared with the 6-month 
strategy.  
Sensitivity analyses  
Results of the threshold analysis, in which treatment effect for the 3-month strategy was varied 
separately for CAPOX and FOLFOX, are shown in Figure 2. Note that the HR for recurrence for the 6-
month strategy compared with no treatment remained the same as in the base-case analysis, namely 
0.73. For CAPOX, the 3-month strategy is no longer delivering more QALYs than the 6-month strategy 
when the HR for a 3-month strategy compared with a 6-month strategy is higher than 1.06. 
Furthermore, the 3-month strategy is no longer cost-effective compared with the 6-month strategy 
when the HR for a 3-month strategy compared with a 6-month strategy is higher than 1.09 [Figure 
2(a)]. For FOLFOX, the 3-month strategy was not more effective nor cost-effective compared with the 
6-month strategy when we assumed an HR for a 3-month strategy compared with a 6-month strategy 
in a range of 1.19–1.4 [Figure 2(b)]. Results of the one-way sensitivity analysis, in which we changed 
the utility estimates according to the upper and lower limit of the confidence intervals derived from 
the SCOT trial, are reported in Table 3. The results of this sensitivity analysis were comparable with the 
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Figure 2. Results of the threshold analysis for CAPOX (a) in which the HR for treatment effect for 3 
versus 6 months of adjuvant chemotherapy was increased from 1 to 1.17, and FOLFOX (b) in which the 
HR for treatment effect for 3 versus 6 months of adjuvant chemotherapy decreased from 1.4 to 1.19. 
The figure is shown in comparison to the 6-months strategy, so the origin of the curve represents the 
situation for 6-months. The solid line through the origin corresponds to an ICER of €50,000/QALY. 
Therefore, every result below that line is considered as cost-effective and everything above this line is 
considered as not cost-effective.
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Probabilistic sensitivity analysis  
Figure 3 presents the results of the probabilistic sensitivity analysis. For CAPOX, the 3-month strategy 
is more effective and less costly compared with the 6-month strategy [Figure 3(a)]. The CEAC showed 
that the probability of having the highest NMB was 1.0 for the 3-month strategy and 0 for the 6-month 
strategy in a range of willingness- to-pay thresholds of €0–100,000 [Figure 3(b)]. For FOLFOX, the 3-
month strategy is less effective and less costly compared with the 6-month strategy [Figure 3(c)]. The 
CEAC showed that the probability of having the highest NMB was highest for the 3-month strategy up 
to a willingness-to-pay threshold of €10,000/QALY. For a willingness to pay above €10,000/QALY, the 
probability to have the highest NMB was higher for the 6-month strategy than for the 3-month 
strategy. At a willingness to pay of €50,000 €/QALY, the probability that the 6-month strategy results 




Figure 3. Results of the probabilistic sensitivity analysis presented in a cost-effectiveness plane and 
cost effectiveness acceptability curve, separately for CAPOX (a,b) and FOLFOX (c,d).
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Discussion 
This study evaluated the cost-effectiveness of a 3-month adjuvant chemotherapy regimen compared 
with a 6-month chemotherapy regimen consisting of either FOLFOX or CAPOX in high-risk stage II colon 
cancer patients using the PATTERN model.16 For both CAPOX and FOLFOX, the 3-month strategy was 
less costly compared with the 6-month strategy (cost difference €3612 and €2745 per person, 
respectively). The lower costs were mainly caused by cost savings related to adjuvant chemotherapy. 
For CAPOX, the QALY lived were highest in the 3-month strategy (0.1 QALY difference pp), resulting in 
an incremental NMB of €8454 at a willingness-to-pay threshold of €50,000/QALY. For FOLFOX, QALYs 
lived were lower in the 3-month strategy compared with the 6-month strategy (0.5 QALY difference 
pp), resulting in a negative incremental NMB of €23,189 at a willingness-to-pay threshold of 
€50,000/QALY. The robustness of the base-case results was underpinned by a probabilistic sensitivity 
analysis.  
The divergent results for CAPOX and FOLFOX were mainly due to the difference in the assumed HR for 
3 versus 6 months of adjuvant chemotherapy, which was based on a pooled analysis of the IDEA trials. 
For CAPOX, we assumed an HR of 1.0, which amounts to an equal treatment effect compared with no 
adjuvant treatment as in the 6-month strategy. For FOLFOX, we assumed an HR of 1.4, which is equal 
to no effect of adjuvant treatment at all. To investigate the influence of uncertainty around the pooled 
HRs from the IDEA collaboration on our base-case results, a threshold analysis was conducted 
separately for CAPOX and FOLFOX. For 3 months’ CAPOX, the results showed a decrease in QALYs 
compared with 6 months’ CAPOX when the HR for 3 versus 6 months of adjuvant chemotherapy 
changed from 1.00 to 1.06 or higher. Given the relatively small change in HR that would lead to a QALY 
loss instead of gain, it would be appropriate to reappraise the cost-effectiveness of a 3-month CAPOX 
regime when additional data on the comparison of a 3-month regimen with a 6-month regime 
becomes available. For FOLFOX, the 3-month strategy resulted in lower QALYs than the 6-month 
strategy, for the entire range of HRs that was assumed in the threshold analysis. These findings indicate 
that the 3-month regimen for FOLFOX should not be recommended in clinical practice, given current 
data. 
The uncertainty in the trial data that we used as input for our analyses should also be considered in 
daily clinical practice, as discussed in the work from Moretto et al.,14 especially because the non-
inferiority for a 3-month strategy compared with a 6-month strategy, for both FOLFOX and CAPOX, was 
not proven in a per-protocol analysis among stage III colon cancer patients.34 A per-protocol analysis 
is recommended to perform in non-inferiority trials because the usual intention-to-treat analysis may 
be biased by the inclusion of patients who did not follow the protocol sufficiently.35 Unfortunately, no 
per-protocol sub-analysis was conducted for stage II colon cancer patients. Nevertheless, given the 
conflicting results between the intention-to-treat and per-protocol analysis in stage III colon cancer 
patients, we should interpret the results of the current study carefully. As Moretti et al. propose, after 
the first 3 months of CAPOX, it would be appropriate to discuss treatment continuation per individual 
patient such that the patient’s preference, tolerance, and degree of neurotoxicity are taken into 
account.14 
To our knowledge, this is the first model-based study evaluating the cost-effectiveness of a 3-month 
during-treatment regimen compared with a 6-month during-treatment regimen in high-risk stage II 
colon cancer patients only. An evaluation of the cost-effectiveness of a 3-month strategy compared 
with a 6-month strategy in high-risk stage II and III colorectal cancer patients was conducted earlier for 
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the SCOT trial by Robles-Zurita et al.29 and Iveson et al.10,36 These studies concluded that a 3-month 
regimen with either FOLFOX or CAPOX was cost-effective compared with a 6-month regimen, and that 
a 3-month regimen should be considered as a new standard of care for both FOLFOX and CAPOX.29 
This conclusion is in line with the findings of our study for CAPOX, but in contrast to our findings for 
FOLFOX. These contrasting results for FOLFOX can be explained by the HR of 1.16 for the 3-month 
FOLFOX regimen compared with the 6-month FOLFOX regimen reported in the SCOT trial. As 
mentioned above, we assumed an HR for 3 months compared with 6 months’ adjuvant chemotherapy 
of 1.4 in the current study, based on pooled data of the IDEA collaboration.13 Nevertheless, in the 
FOLFOX subgroup analysis of the SCOT trial, authors found 0.1 lower QALYs pp in the 3-month strategy 
compared with the 6-month strategy, which is in line with the findings of our study. However, in the 
SCOT trial, the cost savings for the 3-month FOLFOX regimen compared with the 6-month FOLFOX 
regimen were such that a higher NMB was found for the 3-month regimen compared with the 6-month 
regimen. A second explanation for the different directions of the results for FOLFOX could be a 
difference in study population. To illustrate, only 18.1% of the patients included in the SCOT trial were 
classified as stage II. Further comparison of the study populations was hampered, because separate 
baseline characteristics for stage II patients were not presented for the SCOT trial.10,29 
In the current study, we included an HR for treatment effect for the 6-month strategy of 0.73 for 
FOLFOX compared with no adjuvant chemotherapy, based on pooled trial data.19 Due to a lack of 
available trial data, no separate HR was reported in this study for CAPOX compared with no adjuvant 
treatment. Therefore, we assumed in the current study that the HR for treatment effect is similar for 
CAPOX and FOLFOX for the 6-month regimen, which is justified, based on literature in stage III colon 
cancer.37–39 To illustrate, the X-ACT trial showed that capecitabine is non-inferior to fluorouracil. 
Subsequently, the NO169968 trial showed that the benefit of adding CAPOX is similar to the addition 
of FOLFOX. 
The results of our economic evaluation support the adjustment in the Dutch guidelines in which the 
duration for a CAPOX regimen is shortened from 6 months to 3 months for high-risk stage II colon 
cancer patients (MSS+T4). However, guideline adherence in clinical practice may be suboptimal, as has 
been shown in The Netherlands in both stage II and III colon cancer.40 Possible explanations for this 
suboptimal adherence are differences in expert opinions and unawareness of the guidelines. Based on 
these findings, extra support for guideline implementation and monitoring in clinical practice should 
be considered. Furthermore, in The Netherlands, approximately 95% of stage II colon cancer patients 
who receive adjuvant treatment receive CAPOX, leading to a relatively high benefit for society if the 
treatment duration of CAPOX is shortened. However, internationally, FOLFOX is prescribed in the 
majority of cases. To illustrate, in the IDEA studies, FOLFOX was prescribed to 90% of the patients in 
France, 65% of patients in Italy and 42% to the patients in Greece.34 Our results do not support a 
duration of 3 months for FOLFOX, as this leads to more recurrences and fewer QALYs. 
In line with the IDEA collaboration, our study focused on comparing a 6-month treatment duration 
with a 3-month treatment duration rather than comparing FOLFOX and CAPOX.10,12,13 However, the 
results reported in the current study strongly suggest that 3 months of CAPOX is cost-effective 
compared with both 3 and 6 months of FOLFOX, given the higher QALYs and lower costs. The 
associated incremental NMBs are −37,521 and −14,332 for 3 months CAPOX compared with 3 and 6 
months FOLFOX, respectively, using a threshold value of €50,000/QALY. 
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In conclusion, this is the first model-based study that evaluated the cost-effectiveness of a 3-month 
adjuvant chemotherapy regimen compared with a 6-month chemotherapy regimen, separately for 
CAPOX and FOLFOX, in high-risk stage II colon cancer. Our findings indicate that a 3-month regimen is 
the most favorable treatment duration for CAPOX, given the higher QALYs and lower costs compared 
with 6 months. Nevertheless, given the uncertainty in the data we used as input for our analyses, the 
decision to continue the treatment after the first 3 months should be considered per individual based 
on the patient’s attitude, tolerance, and degree of neurotoxicity. For FOLFOX, our findings showed that 
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Table 1: Overview of resource use, unit costs and utilities. All costs were standardized to 2018 Euros, 











    
Initial surgery €12,987a €12,987a  24 
Biomarker tissue test €372 €372  29 
Treatment cost per full regimen     
 CAPOX 
 % quitting before end regimen 
€11,843 €5,982  4,20,22 
7 
 FOLFOX 
 % quitting before end regimen 
€19,563 €10,284  4,20,22 
7 
Adverse event cost per case     
 Grade 3/4 neutropenia €95 €95 0.249/0.193
b 
20,21,22,26 
 Febrile neutropenia €3,309 €3,309 0.027/0.014
b 
20,21,22,26 
 Grade 3/4 diarrhea €50 €50 0.064/0.051
b 
20,21,22,26 
Absenteeism costs per cycle c 













Travel costs per cycle €8 €8  22 
Surveillance costs per patientd     
 Colonoscopy €850   4,23 
 Colonoscopy with complications €1,430  0.028 23 
 Ultrasound scan €83   22 
 CEA determination €8   24 
Relapse costs €41,868   25 
 
 







 Before surgery (month 1) 
 After surgery/before chemotherapy (month 2 to 3) 
 During chemotherapy (month 4 to 6) 
 During/after chemotherapy (month 7 to 9) 
 First year after chemotherapy (month 10 to 18) 
 Year 2-5 after chemotherapy (month 19 to 60) 






















 Recurrence month 1 to 60 after recurrence 0.45 (NA) 0.45 (NA)  30,31,32 
 
a DBC tariffs from 24 hospitals in the Netherlands were averaged  
b Proportions apply across the entire 3-month or 6-month treatment regimen 
c To calculate the absenteeism costs we assumed that; 1) the male to female ratio was 0.47/0.5318, 2) number of hours 
worked per week was 40 and 38 for men and 28 and 25 for women in the age groups <55 and 55-65, respectively,39 and 3) 
patients do not work during chemotherapy. The absenteeism costs were calculated according to the friction cost approach. 
d Surveillance costs were calculated according to the Dutch guideline for colon cancer surveillance  
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Abstract  
Background: We aimed to evaluate the cost-effectiveness of risk-based strategies to improve the 
selection of surgically treated stage II colon cancer (CC) patients for adjuvant chemotherapy. 
Methods: Using the ‘Personalized Adjuvant TreaTment in EaRly stage coloN cancer’ (PATTERN) model, 
we evaluated five selection strategies; 1) no chemotherapy, 2) Dutch guideline recommendations 
assuming observed adherence, 3) Dutch guideline recommendations assuming perfect adherence, 4) 
biomarker mutation OR pT4 stage strategy in which patients with MSS status combined with a pT4 
stage or a mutation in BRAF and/or KRAS receive chemotherapy assuming perfect adherence and 5) 
biomarker mutation AND pT4 stage strategy in which patients with MSS status combined with a pT4 
stage tumor and a BRAF and/or KRAS mutation receive chemotherapy assuming perfect adherence. 
Outcomes were number of CC deaths per 1,000 patients and total discounted costs and quality-
adjusted life-years (QALYs) per patient (pp). Analyses were conducted from a societal perspective. The 
robustness of model predictions was assessed in sensitivity analyses. 
Results: The reference strategy, i.e. no adjuvant chemotherapy, resulted in 139 CC deaths in a cohort 
of 1,000 patients, 8.077 QALYs pp and total costs of €22,032 pp. Strategies 2 to 5 were more effective 
(range 8.094-8.217 QALYs pp and range 118-136 CC deaths per 1,000 patients) and more costly (range 
€22,404-25,102 pp). Given a threshold of €50,000/QALY, the optimal use of resources would be to 
treat patients with either the full adherence strategy and biomarker mutation OR pT4 stage strategy. 
Conclusion: Selection of stage II CC patients for chemotherapy can be improved by either including 
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Background 
After surgical resection, patients with stage II colon cancer have around 15% chance of developing 
recurrence of disease.1, 2 The chance of developing a recurrence may be reduced by treating stage II 
patients with adjuvant chemotherapy after initial surgery. Several trials indicated small, but absolute 
benefits of adjuvant chemotherapy in these patients for both disease-free survival (DFS) and overall 
survival (OS). For example, the QUASAR trial indicated an absolute improvement in OS of 3.6% (95% 
CI, 1.0% to 6.0%) for fluorouracil monotherapy compared to observation.3 Our recent meta-analysis of 
9 RCTs estimated a statistically non-significant treatment effect in terms of DFS of 0.77 (95% CI, 
0.43;1.10) for fluorouracil monotherapy compared to observation and 0.93 (95% CI, 0.72;1.15) for 
FOLFOX compared to fluorouracil monotherapy.4 It should be noted that most of the included trials in 
the meta-analysis were not powered to estimate treatment effectiveness in the stage II colon cancer 
population. 
To prevent the harms of overtreatment, only stage II patients at high risk of recurrence should be 
treated with chemotherapy. To better understand which stage II colon cancer patients are likely to 
benefit from chemotherapy, several studies were performed that identified prognostic high-risk 
characteristics that can be used for decision making in daily clinical practice. The American Society of 
Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) published guidelines 
describing these high-risk characteristics. Both guidelines agreed on the following clinical and 
pathological high-risk factors: pT4, poor differentiation, tumor perforation, lymphovascular invasion, 
perineural invasion, and number of lymph nodes evaluated (<13 in the ASCO guideline and <12 in the 
ESMO guideline).5, 6 In the Netherlands, patients with a pT4 status combined with a Microsatellite 
Stable (MSS) status are eligible for adjuvant chemotherapy in stage II colon cancer.7  
In addition to the clinical and pathological high-risk features included in the international guidelines, 
interest in the prognostic value of biomarkers is currently increasing. Examples of relevant biomarkers 
in stage II colon cancer are Microsatellite Instability (MSI), BRAF and KRAS status. The scientific 
literature describes longer DFS and OS for stage II patients with a MSI status compared to patients with 
a MSS status.8, 9 Furthermore, various studies showed worse DFS for patients with a mutation in BRAF 
and/or KRAS compared to patients with double wild type.10 To illustrate, Hutchins et al. found that 
patients with a BRAF mutation and a MSS status had a 1.42 (95% CI, 0.80 to 2.54) times higher risk of 
recurrence than patients without a BRAF mutation and MSS status. For patients with a KRAS mutation, 
the risk of recurrence was 1.32 (95% CI, 1.04 to 1.67) higher than for patients without a KRAS 
mutation.11 
Although the literature is promising regarding the prognostic value of biomarkers in addition to or 
instead of clinical and pathological factors, the evidence to incorporate these in daily clinical decision-
making is limited. Thus, there is a knowledge gap as to which stage II patients do benefit from adjuvant 
chemotherapy. The cost-effectiveness of different (molecular-based) strategies for selecting stage II 
colon cancer patients for adjuvant treatment has not been assessed so far. Therefore, we aimed to 
evaluate molecular-based selection strategies for adjuvant chemotherapy in stage II colon cancer 
patients in terms of effectiveness and cost-effectiveness. For these analyses, we used the Personalized 
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The PATTERN model has been extensively described elsewhere.12 A flowchart of the model is shown in 
Figure 1 and model parameters are shown in Appendix 1. In brief, the PATTERN model is a Markov 
cohort model with a lifelong time horizon and an one-month cycle length. Five health states are 
included; diagnosis, recurrence, 90-day mortality, death of other causes, and death of colon cancer. 
Data from the Netherlands Cancer Registry (NCR) were used for model quantification.13 The NCR 
database consisted of 2,271 stage II colon cancer patients with an median age of 73 (interquartile 
range: 64-79), diagnosed between 2002-2008 (Appendix Table 1). It was assumed that transition 
probabilities from diagnosis to 90-day mortality were due to surgical complications. Other transitions 
in the model were parametrized using parametric survival models including relevant clinical and 
pathological covariates. The parametric survival models only included patients without adjuvant 
chemotherapy. Subsequently, biomarker status was included in the model based on three external 
cohorts.14 In addition, we included a HR for treatment effect of 0.73 for fluoropyrimidine monotherapy 
combined with oxaliplatin and a HR of 0.78 for fluoropyrimidine monotherapy, both based on trial 
data.4 The PATTERN model was internally validated. Furthermore, the model was externally validated 
and updated if necessary using the 2015 NCR data.12 
In the PATTERN model, 216 subgroups are distinguished based on age (50-95 in nine 5-year categories), 
number of lymph nodes evaluated (<10 and ≥10, as registered in NCR), pT stage (pT3 and pT4), tumor 
site (left and right), and biomarker status (MSI, MSS without a mutation in BRAF and KRAS and MSS 
combined with a mutation in BRAF and/or KRAS). The subgroups in the PATTERN model can be used 
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Strategies 
Five selection strategies were evaluated;  
1) None of the patients receive adjuvant chemotherapy; 
2) Current adherence to the Dutch guidelines; 
3) Full adherence to the Dutch guidelines; 
4) MSS combined with a pT4 stage OR biomarker mutation (BRAF and/or KRAS) assuming full 
adherence; 
5) MSS combined with a pT4 stage AND biomarker mutation (BRAF and/or KRAS) assuming full 
adherence. 
In the current adherence strategy (strategy 2), adjuvant chemotherapy administration was based on 
adherence to the Dutch guideline as observed in daily clinical practice, based on NCR data collected in 
2015-2017. In the Dutch guideline, only patients with a pT4 MSS tumor are considered at high risk for 
recurrence of disease.7 In the current adherence strategy, 21% of the high-risk patients and 3.5% of 
the low-risk patients is treated with adjuvant chemotherapy. In the full adherence strategy (strategy 
3), adherence to the Dutch guideline was set at 100%. That is, all patients with a pT4 MSS tumor are 
treated with adjuvant chemotherapy, and no treatment is given to patients with other characteristics. 
In the biomarker mutation OR pT4 stage strategy (strategy 4), all patients with a MSS tumor combined 
with a pT4 stage OR a biomarker mutation (BRAF and/or KRAS) receive adjuvant chemotherapy, and 
no treatment otherwise. In the biomarker mutation AND pT4 stage strategy (strategy 5), only patients 
with an MSS tumor in combination with a mutation in BRAF and/or KRAS AND a pT4 stage receive 
adjuvant chemotherapy. 
Costs  
Table 1 shows an overview of costs and utilities. Costs were calculated from a societal perspective and 
included costs for initial surgery, the biomarker tissue test, medication, adverse events, absenteeism 
from work, patient’s travel to the hospital, surveillance and recurrence of disease.7, 15-23 Costs of 
chemotherapy and adverse events were calculated separately for Capecitabine monotherapy, CAPOX 
and FOLFOX. We assumed a treatment duration of three months for CAPOX, consisting of 4 cycles of 3 
weeks.7 For FOLFOX and capecitabine monotherapy we assumed a duration of 6 months.24, 25 The 
FOLFOX regimen consisted of 12 cycles of 2 weeks and the capecitabine monotherapy regimen 
consisted of 8 cycles of 3 weeks. The adverse event rates were based on the MOSAIC trial.18 For each 
adverse event category, the costs were calculated based on follow-up care. Follow-up care was defined 
as a visit to the outpatient clinic for neutropenia, a hospital stay of 5 days for febrile neutropenia and 
as oral rehydration medication for diarrhea.15, 19  
In the base-case analysis, we assumed that all patients that receive adjuvant chemotherapy were 
treated for 3 months with CAPOX in accordance with the Dutch guideline.7 Surveillance was also based 
on the recommendations in the Dutch guideline and consisted of consultations every half-year during 
the first 3 years after surgery and yearly thereafter until 5 years after surgery.7 Each consultation is 
combined with a carcino-embryonaal antigen (CEA) determination and an ultrasound scan of the liver 
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Health-related quality of life 
We estimated utilities using prospective data obtained within the Prospective Dutch ColoRectal Cancer 
cohort (PLCRC).26 For the present study, 859 participants with an average age of 66 years and 
diagnosed with stage II or III colon cancer between 2011-2019 were selected (Appendix Table 3). 
Because there were no significant differences in health-related quality of life (HRQoL) between stage 
II and III patients, both stages were analysed together. HRQoL was assessed with the EQ-5D-5L, which 
consists of five questions evaluating the health dimensions mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression.27 The patients’ scores on these health dimensions were 
transformed into a utility score using the Dutch tariff.28 
To inform the model, average health utilities were calculated in six time periods separately for treated 
and untreated patients. The following time periods were defined; before surgery, after surgery and 
before start chemotherapy, during chemotherapy, first 12 months after chemotherapy and more than 
12 months after chemotherapy. A full overview of estimated utilities, baseline characteristics of the 
PLCRC cohort per time period and more details on the estimations on the utilities are shown in Table 
1 and Appendix 2. 
Outcome 
Model outcomes for each strategy included the number of recurrences and deaths due to colon cancer 
in the lifetime of 1,000 patients, life-years, quality-adjusted life-years (QALYs), total lifetime costs per 
patient and the net monetary benefit (NMB). Costs and effects were discounted annually with 4% and 
1.5%, respectively.19 The NMB was calculated as (total effect x threshold) – total cost. In addition, we 
conducted an incremental cost-effectiveness analysis. First, strategies were ordered from lowest to 
highest costs. Incremental cost-effectiveness ratios (ICERs), which is the difference in costs divided by 
the difference in QALYs, were calculated between consecutive non-dominated strategies. A strategy 
was considered as dominated when there was an alternative strategy or combination of strategies that 
was more effective at equal or lower costs. In agreement with the recommendations of the National 
Healthcare Institute, a strategy was considered as cost-effective when the ICER does not exceed the 
threshold value of €50,000 per QALY.29  
Sensitivity analyses  
To assess the impact of uncertainty in our model parameters on the results of the cost-effectiveness 
analysis, 8 one-way sensitivity analyses were conducted. First, we studied the impact of an imperfect 
adherence rate, i.e. 50%, for the selection strategies 3 (Dutch guidelines), 4 (biomarker mutation OR 
pT4 stage), and 5 (biomarker mutation AND pT4 stage) as literature and NCR data showed that 
guidelines are not always followed in daily clinical practice.13, 30 In a second sensitivity analysis, we 
studied the impact of prescribing Capecitabine monotherapy to 30% of the treated patients and CAPOX 
to 70% of the treated patients, as observed in the NCR dataset.13 In this sensitivity analysis, treatment 
effect, drug costs and adverse event rates were adjusted. In a third sensitivity analysis, we studied the 
impact of a treatment with FOLFOX. The IDEA trials showed that a 3 month treatment regimen with 
FOLFOX is inferior to a 6 month treatment regimen with FOLFOX.24, 25 Therefore, patients were treated 
with 6 months of FOLFOX in this sensitivity analyses. The same treatment effect was assumed as for 3 
months of CAPOX4, but drug costs and the period of disutility were adjusted. In the other sensitivity 
analyses, we decreased and increased the treatment effect with 10%, we decreased the drug costs 
with 10%, we decreased the health utility during treatment and the 12 months thereafter for patients 
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who receive chemotherapy with 10%, we decreased the dropout rate to 0% and we repeated the 
analysis with international discounting rates (3% for costs and effects annually)31. 
Furthermore, a probabilistic sensitivity analysis (PSA) was performed using Monte Carlo simulation to 
investigate the joint impact of parameter uncertainty. The Monte Carlo simulations consisted of 1,000 
iterations for all evaluated strategies with a fixed set of parameters per iteration. To graphically 
illustrate the uncertainty surrounding the deterministic outcomes, incremental costs and effects 
compared to the reference strategy were plotted on a cost-effectiveness plane. In addition, a cost-
effectiveness acceptability curve was constructed, depicting the proportion of PSA samples in which 
each of the simulated strategies is cost-effective, that is, with the highest net monetary benefit, as a 
function of the willingness-to-pay threshold. More detailed information of the PSA is provided in 
Appendix 3.  
Finally, to assess the impact of varying the risk of recurrence in the biomarker subgroups on model 
predictions, two scenario analyses were conducted in which we changed the HRs to develop a 
recurrence in the biomarker subgroups, while maintaining the same overall risk of recurrence in the 
population. More detailed information on the scenario analyses is provided in Appendix 3.   
Results 
Effectiveness  
The model predicted 165 recurrences and 139 colon cancer deaths when none of the patients receives 
chemotherapy (Table 2). All other strategies in which (part of the) patients were treated with 
chemotherapy (range treated patients 4.8%-43.2%), were more effective compared to no 
chemotherapy. The most effective strategy was the biomarker mutation OR pT4 stage strategy; 
compared to the reference strategy the number of recurrences and colon cancer deaths decreased 
with 14.8% and 15.0%, respectively. Predicted QALYs were lowest in the no adjuvant chemotherapy 
strategy with 8.077 QALYs per patient. All other evaluated strategies predicted higher QALYs in the 
range of 8.094-8.217 per patient.  
Cost-effectiveness 
The predicted costs per patient were lowest in the reference strategy in which no chemotherapy is 
given (€22,032 per patient). The majority of the costs concern initial surgery and surveillance costs. 
The costs for the other strategies were higher in a range of €22,404-€25,102 per patient (Table 2). The 
cost difference compared to the reference strategy was mainly caused by the increasing proportion of 
patients treated with adjuvant chemotherapy, leading to increased treatment costs. The biomarker 
mutation OR pT4 strategy had the highest NMB at a willingness-to-pay threshold of 50,000 €/QALY 
(€385,754), suggesting that this strategy is the preferred strategy at this threshold.  
In the incremental cost-effectiveness analysis, the no adjuvant treatment strategy served as the first 
comparator, because this strategy led to the lowest discounted costs and QALYs (Table 2). The next 
best strategy was the full adherence strategy, which had higher total average costs (€22,697 pp) and 
effects (8.136 QALYs pp), leading to an ICER of €11,181/QALY. The current adherence strategy was 
dominated by the biomarker mutation AND pT4 stage strategy, given the lower effects and higher 
costs. The biomarker mutation AND pT4 stage strategy was subject to extended dominance by the full 
adherence strategy, which means that the costs and benefits of this strategy are inferior to a 
combination of the strategies based on no adjuvant treatment and full adherence. The strategy based 
6
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on biomarker mutation OR pT4 stage was more effective and more costly compared to full adherence, 
which led to an ICERs of €29,767/QALY. Thus, given the Dutch threshold of €50,000/QALY, optimal use 
of resources would be to treat patients with either the full adherence strategy and biomarker mutation 
OR pT4 stage strategy. A visual representation of the cost-effectiveness frontier is shown in Figure 2. 
Sensitivity analyses  
Results of the one-way sensitivity analyses are shown in Appendix Table 4. For the sensitivity analyses 
in which we varied adherence rate, treatment effect, drug costs, discount rates, health utility, dropout 
rate and the percentage of patients that were treated with CAPOX, we found similar results as in the 
base-case analysis. That is, ICERS were similar for all evaluated strategies.  
Deviating ICERs were found in the sensitivity analysis in which we treated patients with FOLFOX for six 
months, although the ordering of the strategies remained the same. The biomarker mutation OR pT4 
stage strategy was no longer considered as cost-effective (ICER: 76,038 €/QALY). This deviating result 
was caused by the higher costs for 6 months of FOLFOX compared to 3 months of CAPOX on the one 
hand and the lower QALYs due to the longer treatment duration on the other hand. 
Figure 2 and 3 present the results of the PSA. For all evaluated strategies, all points on the cost-
effectiveness plane are located in the north-east quadrant, where strategies are more effective but 
also more costly compared to no adjuvant chemotherapy. The cost-effectiveness acceptability curve 
shows that up to a willingness-to-pay threshold of 11,000 €/QALY, the proportion of PSA samples in 
which the no adjuvant chemotherapy strategy has the highest NMB is larger than for any other strategy 
(Figure 3). Subsequently, the full adherence strategy dominates up to a willingness-to-pay threshold 
of 29,000 €/QALY. From a willingness-to-pay of 29,000 €/QALY onwards, the biomarker mutation OR 
pT4 strategy has the highest NMB in the largest proportion of PSA samples compared to all other 
strategies. The results of the PSA were also used to determine the 95% credibility intervals around the 
base-case results, which are shown in Appendix Table 5. 
Results for the scenario analyses, in which we varied the HRs determining the risk of recurrence in the 
biomarker subgroups, are shown in Table 3. In both scenarios, results were comparable to the base-
case results.   
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Discussion 
This study evaluated the effectiveness and cost-effectiveness of risk-based strategies to improve the 
selection of stage II colon cancer patients for adjuvant chemotherapy. We evaluated the following 5 
strategies 1) no adjuvant chemotherapy, 2) Dutch guideline recommendations assuming observed 
adherence, 3) Dutch guideline recommendations assuming perfect adherence, 4) a biomarker 
mutation OR pT4 strategy in which patients with MSS status combined with a pT4 stage or a BRAF 
and/or KRAS mutation receive treatment and 5) a biomarker mutation AND pT4 stage strategy in which 
patients with MSS status combined with a BRAF and/or KRAS mutation and a pT4 stage receive 
adjuvant treatment. The no adjuvant chemotherapy strategy was considered as the reference strategy. 
All strategies were more effective than no adjuvant chemotherapy in terms of QALYs pp (range 8.094-
8.217) and CC deaths per 1,000 patients (range 118.30-140.38), but also more costly (range €22,404-
25,102 pp). Considering a threshold value of €50,000/QALY, optimal use of resources would be to treat 
patients with either the full adherence strategy and biomarker mutation OR pT4 stage strategy. 
To our knowledge, the PATTERN model is the first decision model that can evaluate the effectiveness 
and cost-effectiveness of different (molecular-based) selection strategies for adjuvant chemotherapy 
in stage II colon cancer patients. An earlier model-based study by Avayci et al.17 showed that 
fluoropyrimidine in combination with oxaliplatin was not cost-effective compared to no adjuvant 
chemotherapy in stage II colon cancer. However, the evaluation of Avayci et al. did not distinguish 
between different patient groups, and was therefore not able to evaluate different selection strategies 
for adjuvant chemotherapy.  
Assigning chemotherapy in a personalized manner is a hotly debated topic in oncology. Molecular-
based selection strategies for adjuvant chemotherapy are already evaluated for other types of cancer, 
but not for early stage colon cancer. To illustrate, the results of Roth et al.32 and Jahn et al.33 suggest 
that assigning adjuvant chemotherapy based on molecular features may be a cost-effective alternative 
to standard guideline recommendations for early stage lung cancer and early stage breast cancer, 
respectively. It should be noted that these studies evaluated molecular-based selection strategies 
using a multiple-gene assay including 14 or 21 genes, while in the current study only MSS, BRAF and 
KRAS status were considered for treatment allocation in the biomarker strategies. Nevertheless, our 
results are in line with the findings of these studies since the biomarker mutation OR pT4 stage strategy 
was found to be cost-effective.  
Based on pooled trial data, we included a HR for treatment effect of 0.73 for fluoropyrimidine 
combined with oxaliplatin.4 Although the sample size was large in this pooled analysis, results were 
not statistically significant. To investigate the uncertainty around treatment effect we conducted a 
one-way sensitivity analysis, in which we decreased and increased treatment effect with 10%. This 
analysis showed that changes in treatment effect had no influence on the model outcomes.  
When interpreting the results of our model predictions, it should be noted that we did not take 
potential predictive treatment effects into account. That is, we used the same treatment effect in all 
subgroups when treating patients with the same treatment regimen. A previous study demonstrated 
a predictive effect for stage II and III colon cancer patients with a microsatellite instable (MSI) tumor. 
This study showed that these patients have a resistance to fluoropyrimidine monotherapy.34 It should 
be noted that in our model-based evaluation, none of the MSI patients were selected for adjuvant 
chemotherapy in both the base-case analysis and the sensitivity analyses. For the BRAF and KRAS 
6
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biomarkers, no predictive treatment effect has yet been found in stage II colon cancer patients. Thus, 
cost-effectiveness of the biomarker mutation OR pT4 stage strategy in the base-case analysis was 
solely based on the poorer prognosis of patients with a mutation in BRAF and/or KRAS. Model 
predictions need to be updated as soon as sufficient evidence for any differences in treatment effect 
in the biomarker subgroups becomes available.  
The health utilities used as input for the current study were derived from patient level data from the 
PLCRC cohort. It should be noted that the difference in health utility between patients with and 
without adjuvant chemotherapy during chemotherapy and the first 12 months thereafter was with 
0.03 relatively small, indicating that adjuvant chemotherapy has only a small impact on quality of life. 
As a result, the strategy in which the highest percentage of the cohort is treated is likely to lead to the 
highest number of quality-adjusted life years. To evaluate the impact of a higher burden of adjuvant 
chemotherapy on model predictions, we performed a sensitivity analysis in which we increased the 
difference in health utility between patients with and without adjuvant chemotherapy from 0.03 to 
0.08. Although the ICERs for the full adherence strategy and the mutation OR pT4 strategy increased 
in this sensitivity analysis, these strategies remained the optimal use of resources assuming a threshold 
value of €50,000/QALY. In addition, these strategies resulted in the highest QALYs compared to the 
other evaluated strategies.  
In line with the Dutch guideline recommendations7, treatment consisted of CAPOX in the base-case 
analysis. Literature and data show that not all patients are treated with oxaliplatin-based 
chemotherapy in clinical practice, which is primarily due to the clinical condition of the patients.30 
Therefore, we conducted a sensitivity analysis in which 70% of the patients were treated with CAPOX 
and 30% with Capecitabine monotherapy based on the NCR dataset used for model quantification. 
This analysis showed similar results compared to the base-case analysis. In addition, from NCR data we 
know that a small proportion of the patients switch from CAPOX to fluoropyrimidine monotherapy 
during the regimen. We were not able to evaluate the impact of any treatment modifications as there 
are no estimates for the effectiveness of such combined treatment regimens. Moreover, since the 
difference in treatment effectiveness between both regimens is relatively small (0.73 versus 0.78), the 
impact of treatment modifications on model predictions will be limited. 
In addition, it should be noted that in the Netherlands, the recommended treatment duration for stage 
II colon cancer patients is recently revised from 6 months to 3 months for CAPOX. However, FOLFOX is 
a regularly prescribed regimen in other European countries, for which the recommended duration is 
still 6 months. Therefore, we conducted a sensitivity analysis in which patients were treated with 
FOLFOX for 6 months. The biomarker mutation OR pT4 stage strategy was no longer considered as 
cost-effective in this sensitivity analysis with an ICER of 76,038 €/QALY, due to the higher costs and 
lower QALYs. Our results indicate that including biomarkers in the decision-making process is not 
beneficial in a setting where 6 months of FOLFOX is the most prescribed treatment.  
Furthermore, the guidelines for selection of stage II colon cancer patients for adjuvant chemotherapy 
are not strictly followed in daily clinical practice.30 Dutch national registry data show adherence rates 
of 21% for high risk patients and 3.5% for low-risk patients as simulated in the current adherence 
strategy. The current adherence strategy was dominated by extended dominance in the incremental 
base-case analysis by the full adherence strategy, which resulted in an ICER of 11,181 €/QALY. 
However, even a 50% adherence to the Dutch guidelines is already cost-effective (ICER 12,195 €/QALY) 
as shown in our one-way sensitivity analysis. 
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In the current study we had biomarker data available for only a limited number of patients, which 
resulted in broad confidence intervals. As a result, we did not vary the biomarker parameters in the 
probabilistic sensitivity analysis. As an alternative, we conducted two scenario analyses in which we 
varied the HRs to develop a recurrence in the biomarker subgroups, while the overall risk of recurrence 
in the population was kept identical. The results of these two scenario analyses were in line with the 
base-case results. However, the uncertainty surrounding the HRs for developing a recurrence 
dependent on biomarker status could be considered a limitation of the study and an area where 
additional data would be useful to improve model-based predictions. 
In conclusion, this is the first model-based study that evaluated risk-based selection strategies for 
adjuvant chemotherapy in stage II colon cancer. All of the evaluated strategies in which (part of the) 
patients were treated with adjuvant chemotherapy were more effective and more costly compared to 
no adjuvant chemotherapy. Given a threshold of €50,000/QALY, optimal use of resources would be to 
treat patients with either the full adherence strategy and biomarker mutation OR pT4 stage strategy. 
These findings indicate that selection of stage II colon patients for chemotherapy can be improved by 
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Table 1: Overview of resource use, unit costs and utilities. All costs were standardized to 2018 Euros, 
using the consumer price index.37 
 Value Proportion  Reference 
Resource use and costs     
Initial surgery €12,987a   21 






   
35 
Treatment cost per full regimen     
 CAPOX 
 % quitting before end of regimen 
€5,982  
0.25b 
 7, 15, 19 
16 
 FOLFOX 
 % quitting before end of regimen 
€10,284  
0.25b 
 7, 15, 19 
16 
 CAP 
 % quitting before end of regimen 
€989  
0.13b 
 7, 15, 19 
16 
Adverse event cost per case     
 Grade 3/4 neutropenia 
 With oxaliplatin 




 15, 17-19 
 Febrile neutropenia 
 With oxaliplatin 




 15, 17-19 
 Grade 3/4 diarrhea 
 With oxaliplatin 




 15, 17-19 
Absenteeism costs per cyclee  





  19 
Travel costs per cycle €8   19 
Surveillance costs     
 Colonoscopy €850   7,20 
 Colonoscopy with complications €1,430 0.028  20 
 Ultrasound scan €83   7,19 
 CEA determination €8   7,21 
Relapse costs €41,868   22 





Utilities    
Diagnosis month 1, before surgery 
Diagnosis month 2-3, after surgery/before chemotherapy 
Diagnosis month 4-6, during chemotherapy 
Diagnosis month 7-18, 1 year after end chemotherapy 
















Recurrence month 1-60 after recurrence 0.45 0.45 37-39 
a The DBC tariffs of 24 Dutch hospitals were averaged. 
b We assumed that these patients dropped out halfway through the chemotherapy regimen. That is, for 25%/13% of the 
treated patients only the treatment costs of for the first half of the regimen were included in the evaluation. 
c The values calculated for the treatment regimen without oxaliplatin were used for the sensitivity analysis in which part of 
the patients were treated without addition of oxaliplatin.  
d Proportions apply across the entire 3-month treatment regimen.  
e To calculate the absenteeism costs we assumed that; 1) the female to male ratio was 0.53/0.4712, 2) number of hours 
worked per week was 28 and 25 for women and 40 and 38 for men in the age groups <55 and 55-65, respectively,40 and 3) 
patients do not work during chemotherapy.  
Abbreviations: CAP = capecitabine monotherapy, FOLFOX = regimen that includes the drugs leucovorin, fluoropyrimidine 
and oxaliplatin, CAPOX = regimen that includes the drugs capecitabine and oxaliplatin. 
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Appendix 1. PATTERN model 
The PATTERN model is a Markov cohort model based on data of the Netherlands Cancer Registry (NCR) 
as described in Appendix Table 1.1 Note that the clinical and pathological subgroups in the PATTERN 
model are weighted such that the distribution of features is comparable to that of the NCR database. 
The distribution of molecular features is based on the QUASAR trial.2 That is, 16% of the population 
was classified as MSI, 47% as MSS without a mutation in BRAF and/or KRAS and 37% as MSS in 
combination with a mutation in BRAF and/or KRAS. 
The PATTERN model was extensively validated, both internally and externally. In the external 
validation, we compared the model predictions for recurrence rate and overall survival rate to the 
observed data of the 2015 NCR cohort, which was not used for model development. In general, the fit 
of the model predictions to the 2015 NCR data was satisfactory, except for the pT4 subgroup. 
Therefore, we updated the hazard ratio for the pT4 subgroup in the PATTERN model based on the 2015 
data (Appendix Table 2). The procedure is described in detail somewhere else.3  
Appendix Table 2 shows the parameter estimates specifying transitions in the PATTERN model.  
150
6      Chapter 6
149602 Jongeneel BNW.indd   150 04-06-2021   13:48
 
Appendix Table 1. Patient characteristics of the Netherlands Cancer Registry (NCR) cohort, which 












pT stage  






Evaluated lymph nodes 
 
 <10 1,198 (52.8) 
 ≥10 946 (41.7) 
 Unknown 127 (5.5) 
 
 Tumor site 
 






Degree of differentiation 
 
 High 145 (6.4) 
 Middle 1,574 (69.3) 




Treated with chemotherapy 119 (5.2) 
  
Data are presented as median (interquartile range) or numbers (%).
6
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Appendix 2. Health-related quality of life 
To inform the model, we calculated the average health utility in different time periods separately for 
patients treated with and without adjuvant chemotherapy. We defined the following periods; before 
surgery, after surgery and before start chemotherapy, during chemotherapy, first 12 months after 
chemotherapy and more than 12 months after chemotherapy. 
When a patient had completed two or more questionnaires during one of these periods, an average 
value for this patient was calculated before an average utility was estimated in the population. For the 
untreated group, the same time points in terms of months were used as in the treated group to define 
the "during chemotherapy" period. As recurrences were not reported in the PLCRC cohort, the utility 
for this health state was derived from the literature. Once a patient in the model transit to the health 
state recurrence, the health utility was reduced to 0.45 for a duration of 60 months. After these 60 
months the patient was considered as cancer survivor and the reference value of 0.83 was assigned.4-
6   
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Appendix 3. Sensitivity analyses 
One-way sensitivity analyses  
Appendix Table 4 shows the results of the one-way sensitivity analyses.  
Probabilistic sensitivity analysis  
All parameters in the PATTERN model were varied based on the most appropriate distribution, except 
for the parameters specifying the risk of recurrence in the biomarker subgroups. Due to the 
considerable uncertainty surrounding the biomarker parameters, it was not possible to vary these 
parameters in the probabilistic sensitivity analysis without seriously altering the average risk of 
recurrence in the population. 
Scenario analyses  
To assess the impact of varying the risk of recurrence in the biomarker subgroups on model 
predictions, two scenario analyses were conducted. In the base-case analysis, we used HRs derived 
from observational data of 0.25, 0.88 and 1.53 for patients with an MSI tumor, an MSS tumor without 
a mutation in BRAF and/or KRAS (MSSdwt) and MSS combined with a mutation in BRAF and/or KRAS 
(MSSmut), respectively, compared to the general population. In the first scenario analysis, we assumed 
that the risk of developing a recurrence for patients with a MSI or MSSdwt status was 10% lower than 
estimated in the data, i.e. 0.23 and 0.79 respectively. To maintain the same average risk of recurrence 
in the overall population as in the base-case analysis, the HR for patients with a MSSmut status was 
increased to 1.65. In the second scenario analysis, we assumed that the risk of developing a recurrence 
was 10% higher for patients with an MSI or MSSdwt status, i.e. 0.28 and 0.97 respectively. To maintain 
the same average risk of recurrence in the overall population as in the base-case analysis, the HR for 
patients with a MSSmut status was set at 1.41. 
6
155
Cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6      Chapter 6











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy














































































































































































































































































































































































































































































































































































































































































































6      Chapter 6
149602 Jongeneel BNW.indd   158 04-06-2021   13:48
 
References  
1. van Gestel YR, de Hingh IH, van Herk-Sukel MP, 
et al. Patterns of metachronous metastases after 
curative treatment of colorectal cancer. Cancer 
epidemiology 2014; 38: 448-454. 
2. Hutchins G, Southward K, Handley K, et al. Value 
of mismatch repair, KRAS, and BRAF mutations in 
predicting recurrence and benefits from 
chemotherapy in colorectal cancer. J Clin Oncol 
2011; 29: 1261-1270. 2011/03/09. DOI: 
10.1200/jco.2010.30.1366. 
3. Jongeneel G, Greuter M, van Erning F, et al. 
Modeling Personalized Adjuvant TreaTment in 
EaRly stage coloN cancer (PATTERN). The European 
Journal of Health Economics 2020. 
4. van den Brink M, van den Hout WB, Stiggelbout 
AM, et al. Cost-utility analysis of preoperative 
radiotherapy in patients with rectal cancer 
undergoing total mesorectal excision: a study of 
the Dutch Colorectal Cancer Group. Journal of 
clinical oncology 2004; 22: 244-253. 
5. Ness RM, Holmes AM, Klein R, et al. Utility 
valuations for outcome states of colorectal cancer. 
The American journal of gastroenterology 1999; 
94: 1650-1657. 
6. Attard C, Maroun J, Alloul K, et al. Cost-
effectiveness of oxaliplatin in the adjuvant 
treatment of colon cancer in Canada. Current 





Cost-effectiveness of risk-based selection strategies for adjuvant chemotherapy










Early cost-effectiveness analysis of risk-based selection strategies for 
adjuvant treatment in stage II colon cancer: the potential of molecular 
features 
 
Gabriëlle Jongeneel, Marjolein J.E. Greuter, Natalia Kunst, Felice N. van Erning, Miriam 
Koopman, Jan P. Medema, Louis Vermeulen, , Jan N.M. Ijzermans Geraldine R. Vink,  

















Accepted by Cancer Epidemiology, Biomarkers & Prevention 
Early cost-effective ess 
analysis of risk-based 
selection strategies for 
adjuvant treatment in stage 
II colon cancer: the potential 
of molecular features
Gabrielle Jongeneel, Marjolein J.E. Greuter, Natalia Kunst, 
Felice N. van Erning, Miriam Koopman, Jan P. Medema,  
Louis Vermeulen, , Jan N.M. Ijzermans Geraldine R. Vink,  
Cornelis J.A. Punt, Veerle M.H. Coupé
Accepted by Cancer Epidemiology, Biomarkers & Prevention
CHAPTER 7
149602 Jongeneel BNW.indd   161 04-06-2021   13:48
 
Abstract 
Background: To explore the potential value of Consensus Molecular Subtypes (CMS) in stage II colon 
cancer (CC) treatment selection, we carried out an early cost-effectiveness assessment of a CMS-based 
strategy for adjuvant chemotherapy.  
Methods: We used a Markov cohort model to evaluate three selection strategies: 1) the Dutch 
guideline strategy (MSS+pT4), 2) the mutation-based strategy (MSS plus a BRAF and/or KRAS mutation 
OR MSS plus pT4), and 3) the CMS-based strategy (CMS4 OR pT4). Outcomes were number of CC deaths 
per 1,000 patients, total discounted costs per patient (pp) and quality-adjusted life-years (QALYs) pp. 
The analyses were conducted from a Dutch societal perspective. The robustness of model predictions 
was assessed in sensitivity analyses. To evaluate the value of future research, we performed a value of 
information (VOI) analysis.  
Results: The Dutch guideline strategy resulted in 8.10 QALYs pp and total costs of €23,660 pp. The 
CMS-based and mutation-based strategies were more effective and more costly, with 8.12 and 8.13 
QALYs pp and €24,643 and €24,542 pp, respectively. Assuming a threshold of €50,000/QALY, the 
mutation-based strategy was considered as the optimal strategy in an incremental analysis. However, 
the VOI analysis showed substantial decision uncertainty driven by the molecular markers (expected 
value of partial perfect information: €18M). 
Conclusion: Based on current evidence, our analyses suggest that the mutation-based selection 
strategy would be best use of resources. However, the extensive decision uncertainty for the molecular 
markers does not allow to select an optimal strategy at present. 
Impact: Future research is needed to eliminate decision uncertainty driven by molecular markers.  
162
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Background 
After curative surgery, stage II colon cancer (CC) patients have a 15-20% risk to develop a recurrence.1-
3 This risk may be reduced by treatment with adjuvant chemotherapy. However, to prevent 
unnecessary exposure to potentially toxic treatment in patients who have already been cured by 
surgery alone, only stage II patients with a high risk of recurrence should be eligible for chemotherapy. 
The Dutch guidelines currently recommend to prescribe adjuvant chemotherapy only for stage II 
patients with microsatellite stable (MSS) pT4 tumours.4 However, insight into the molecular 
heterogeneity of tumours is increasing.5-7 Additional molecular markers, with an impact on either 
prognosis or response to adjuvant treatment, could potentially improve the currently used high-risk 
classification of stage II CC patients.5,8  
In a recent model-based cost-effectiveness study, we showed that adding BRAF and/or KRAS mutation 
status as a selection criterion for adjuvant chemotherapy in stage II CC can potentially improve 
patients’ survival.9 In addition to BRAF and KRAS mutation status, the prognostic value of a large 
number of other molecular markers in the stage II CC population has been demonstrated.5,8 To take 
the interconnectivity between these markers into account, the consensus molecular subtypes (CMS) 
for colorectal cancer were introduced.7 The CMS classification distinguishes four subtypes of specific 
molecular markers; CMS1 (MSI immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 
(mesenchymal).7 A pooled analysis of 1,785 stage I-IV colorectal cancer patients showed that patients 
with a CMS4 classification have a worse prognosis in terms of disease-free survival compared to 
patients with CMS1 (hazard ratio (HR): 1.77, 95% CI: 1.34-2.34), CMS2 (HR: 1.70, 95% CI: 1.39-2.06) 
and CMS3 (HR: 1.74, 95% CI: 1.29-2.33). Given the prognostic character, the CMS classification was 
discussed by several studies as a promising feature to inform adjuvant treatment decisions in stage II 
CC.7,10,11 However, limited survival data for CMS is available in the stage II population, since the 
classification system is only introduced in 2015.  
In this study, we aimed to explore the potential value of using the prognostic information of CMS in 
stage II CC treatment selection and to provide insight into the value of additional prospective research 
for the Dutch stage II CC population by means of an early cost-effectiveness assessment. Using the 
Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN) model12, we compared 
health effects and costs of three selection strategies to allocate chemotherapy in the stage II CC 
population: 1) the current Dutch guideline strategy, 2) a mutation-based selection strategy, and 3) a 
CMS-based strategy. We performed a number of sensitivity analyses to examine the robustness of the 
results. Furthermore, we evaluated decision uncertainty in our cost-effectiveness assessment using a 
value of information (VOI) analysis. 
Methods 
PATTERN model 
The PATTERN model has been comprehensively described elsewhere.12 The flowchart of the model is 
shown in Supplementary Figure A1 and the model parameters are reported in Supplementary Table 
A1. In short, the PATTERN model is a Markov cohort model with five health states: diagnosis, 
recurrence, 90-day mortality, death of other causes and death due to CC. We used the Netherlands 
Cancer Registry (NCR) data for model parametrization (n=2,271).13 Only patients without adjuvant 
treatment were selected for model quantification. As an additional step, a HR for treatment effect was 
included in the transition from diagnosis to recurrence, based on pooled trial data (Supplementary 
7
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Table A1).14 The PATTERN model distinguishes 72 clinical and/or pathological subgroups for pT stage, 
tumor sidedness, number of evaluated lymph nodes and age, which were weighted such that the 
distribution of clinical and pathological features reflects the Dutch stage II CC population 
(Supplementary A). The PATTERN model was extensively validated, both internally and externally.12 
Inclusion of mutation status in the PATTERN model 
Data of three cohorts (n=334) were used to distinguish between three biomarker subgroups in the 
PATTERN model: (1) microsatellite instable tumors (MSI), independent of BRAF and KRAS mutation 
status, (2) MSS tumors without a mutation for BRAF or KRAS (MSSdwt), and (3) MSS in combination 
with a mutation in BRAF and/or KRAS (MSSmut).15,16 The prognostic impact of biomarker status was 
incorporated in the model by means of a HR affecting the transition from diagnosis to recurrence. 
These HRs were estimated to be 0.25, 0.88 and 1.53 for the MSI, MSSdwt and MSSmut subgroups 
compared to the general stage II CC population, respectively (Supplementary Table A1).12 A detailed 
description of how we estimated and incorporated these HRs in the PATTERN model is described 
elsewhere.12  
Inclusion of CMS in the PATTERN model 
To include estimates for the prognostic impact of CMS subgroups in the PATTERN model, we used 
patient-level data of 428 stage II colorectal cancer patients that were included in the pooled analysis 
of Guinney et al. (2015), which focused on the optimal classification of CMS.7,17-21 Baseline 
characteristics for included patients are shown in Supplementary Table A2. The average age was 67.1 
years. The majority of the patients had a CMS2 classification (45.6%), followed by CMS4 (23.1%), CMS1 
(18.2%) and CMS3 (13.1%). Eighty-four recurrences (19.6%) were observed within an average follow-
up time of 51 months (range 1-201 months). As the disease-free-survival in patients with CMS1, CMS2 
and CMS3 was comparable (Supplementary Figure A2), we distinguished 2 CMS subgroups in the 
PATTERN model: CMS1-3 and CMS4 (Supplementary A). To incorporate CMS classification in the 
PATTERN model, the time-to-event model reflecting the transition from diagnosis to recurrence was 
adjusted by including HRs of 0.80 and 1.70 for CMS1-3 and CMS4, respectively compared to the general 
stage II population (Supplementary Table A1).12 
Strategies 
Three strategies were evaluated. First, we evaluated a strategy that represented the current Dutch 
guideline recommendations. In this strategy, patients with a MSS status AND a pT4 stage receive 
adjuvant chemotherapy (Dutch guideline strategy). Second, a strategy was evaluated in which patients 
with a MSS status combined with a mutation in BRAF and/or KRAS OR a MSS status combined with a 
pT4 stage receive adjuvant chemotherapy (mutation strategy).22 In the third strategy, patients with a 
CMS4 classification OR a pT4 stage receive adjuvant chemotherapy (CMS strategy). Note that these 
strategies were solely based on the prognostic value of the MMR, BRAF, KRAS and CMS parameters. 
For all strategies we assumed adherence as observed in 2018-2019 NCR data. That is, 44% of the high-
risk patients aged <75 received chemotherapy and 11% of the high risk patients aged ≥ 75 received 
chemotherapy. In accordance with the Dutch guidelines, patients were treated with 3 months of 
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Costs 
We present an overview of resource use, costs and utilities in Table 1. Costs were determined from a 
societal perspective and included costs for initial surgery, mutation testing, gene expression profiling, 
drug costs, costs of managing adverse events, absenteeism from work, patient’s travel to the hospital, 
surveillance and treatment for recurrence of disease.4,23-31 Surveillance was based on the 
recommendations in the Dutch guideline4, i.e., a carcino-embryonal antigen (CEA) determination every 
6 months and an ultrasound scan or CT scan of the liver once a year during the first 5 years after 
surgery. In addition, patients undergo colonoscopy every 3 years, with the first colonoscopy one year 
after surgery.  
Health utilities 
Health utilities were estimated using data from the Prospective Dutch ColoRectal Cancer cohort 
(PLCRC).32 For the present study, we selected 859 participants who were diagnosed with stage II or III 
CC between 2011-2019 and completed the EQ-5D-5L.33,34 The patients’ scores on this quality-of-life 
questionnaire were summarized into a health utility score using the Dutch tariff.35 
To inform the PATTERN model, average health utilities were calculated for different time periods in 
the disease process, separately for patients with and without adjuvant chemotherapy.34 A full overview 
of the estimated utilities for each time period is provided in Table 1.  
Base-case analysis 
Model predictions were conducted from a societal perspective, using a lifelong time horizon. The 
outcomes included the number of recurrences and deaths due to CC per 1,000 patients, life years per 
patient (pp), quality-adjusted life years (QALYs) pp, total life-time costs pp and net monetary benefit 
(NMB) associated with each strategy. The NMB was calculated for each strategy as: total QALYs x 
willingness-to-pay threshold – total cost, using a threshold of €50,000/QALY. Dutch discount rates of 
1.5% and 4% were used for health effects and costs, respectively.27 We conducted an incremental cost-
effectiveness analysis in which the evaluated strategies were ordered from lowest to highest costs. 
Subsequently, Incremental Cost-Effectiveness Ratios (ICERs) were calculated between successive non-
dominated strategies. The strategy associated with the highest ICER below a willingness-to-pay 
threshold of €50,000 per QALY was considered the cost-effective strategy.36 
One-way sensitivity analyses 
To evaluate the impact of uncertainty on our model predictions, we conducted 2 one-way sensitivity 
analyses. First, we increased and decreased the risk to develop a recurrence with 10% in the CMS4 
group. Note that the risk of a recurrence in the CMS1-3 group increased/decreased as well to maintain 
the same average recurrence risk in the population. Second, we increased and decreased the risk to 
develop a recurrence with 10% in the MSSmut group. Note that the recurrence risk for the MSI and 
MSSdwt increased/decreased as well to maintain the same average recurrence risk in the population.  
Threshold analysis 
Because of rapid developments in the field of genetic testing, the price of a test to determine CMS may 
likely decrease in the coming years.31 Therefore, we conducted a threshold analysis in which we 
decreased the costs for determining CMS from €500 in the base-case analysis to €0 in steps of €100. 
Subsequently, we compared the NMBs for the CMS strategy to the NMB for the mutation strategy to 
7
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evaluate if the costs for CMS classification would influence the cost-effectiveness ordering of 
strategies.  
Scenario analysis 
In the base-case analysis, we focused completely on the prognostic value of the MMR, BRAF, KRAS and 
CMS parameters. However, some studies indicated that patients with a CMS4 classification may be 
resistant to adjuvant chemotherapy.37-39 To investigate the influence of this potential resistance on 
optimal treatment selection for stage II CC patients, we evaluated a scenario in which we assumed that 
treatment has no effect in patients with a CMS4 classification. Since prescribing adjuvant treatment to 
CMS4 patients would be useless without any benefit of the treatment, the CMS4 strategy was not 
included in this scenario analysis. Instead, we defined two strategies in which we used the CMS4 
classification as feature to exclude patients from adjuvant chemotherapy. The following four strategies 
were evaluated in this scenario analysis: 1) The Dutch guideline strategy, 2) The mutation strategy, 3) 
A strategy in which patients with MSS AND pT4 receive chemotherapy, unless a patient is classified as 
CMS4 (Dutch guideline strategy without CMS4) 4) A strategy in which patients with MSS status in 
combination with a mutation in BRAF and/or KRAS OR pT4 receive chemotherapy, unless the patient 
is classified as CMS4 (mutation strategy without CMS4).  
In line with the base-case analysis, a patients’ CMS status was not determined in strategy 1 and 2. That 
is, part of the patients which were selected for adjuvant chemotherapy in these strategies have a CMS4 
classification. We assumed no treatment effect for those patients with a CMS4 classification in the 
evaluation of strategies 1 and 2, that is the HR for treatment was set to 1 (Supplementary B). 
Subsequently, we adjusted the treatment effect for the other subgroups to 0.65, so that the weighted 
mean was in line with the treatment effect of 0.73, which was the estimate for the general stage II 
population.14 In strategy 3 and 4, the CMS status of the patient was determined, so that we were able 
to exclude patients with a CMS4 classification from adjuvant chemotherapy. Note that for patients that 
were selected for adjuvant chemotherapy in strategy 3 and 4, also the adjusted treatment effect of 
0.65 was applied.  
Probabilistic analysis 
To estimate the joint impact of uncertainty in all model parameters on model predictions for the three 
selection strategies evaluated in the base-case analysis, a probabilistic analysis with 1,000 iterations 
was conducted. The parameters in the PATTERN model were varied simultaneously according to their 
most appropriate distribution (Table 1 and Supplementary Table A1). More detailed information about 
the probabilistic analysis is given in Supplementary B. To visually illustrate the results of the 
probabilistic analysis, a cost-effectiveness acceptability curve (CEAC) was constructed for a range of 
willingness-to-pay thresholds (€0-€100,000) per QALY. A CEAC depicts the probability for each strategy 
to result in the highest NMB at a specific willingness-to-pay threshold. Furthermore, the results of the 
probabilistic analysis were depicted in cost-effectiveness planes.  
The expected value of (partial) perfect information  
A Value of information analysis (VOI) provides insight in the decision uncertainty in the evaluation 
based on currently available evidence. The Expected value of perfect information (EVPI) quantifies the 
value of eliminating uncertainty from all parameters included in the model, and reflects the maximum 
value that decision makers should be willing to pay for future research.40,41 The Expected value of 
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perfect parameter information (EVPPI) quantifies the value of reducing decision uncertainty by 
eliminating uncertainty from one parameter or a group of parameters.40 The EVPPI helps to identify 
drivers of decision uncertainty and to select the potential outcomes that should be targeted in future 
research. To inform policy makers on the value of future research focusing specifically on an 
assessment of the prognostic value of genetic features in the stage II CC population, we examined the 
EVPPI for 3 sets of parameters: 1) CMS parameters 2) MMR, BRAF and KRAS parameters, and 3) CMS, 
MMR, BRAF and KRAS parameters. As recommended by Rothery et al., we extrapolated our VOI results 
to a population level using an annual incidence of 3,225 newly diagnosed stage II CC patients in the 
Netherlands.1,40 Furthermore, we assumed a 10-year decision horizon in our VOI analyses. We 
estimated the EVPI and EVPPI using the Sheffield Accelerated Value of Information (SAVI) tool, which 
uses a non-parametric regression approach to estimate the EV(P)PI.42 
Results 
Effectiveness 
For the current Dutch guideline strategy, the model predicted 162 CC recurrences and 137 CC deaths 
per 1,000 patients (Table 2). The CMS strategy and mutation strategy were more effective compared 
to the Dutch guideline strategy with a decrease of 2.5% and 3.1% in the number of recurrences and 
2.2% and 2.9% in CC mortality, respectively. The Dutch guideline strategy resulted in the lowest 
predicted QALYs of 8.10 pp, followed by the CMS strategy with 8.12 QALYs pp, and the mutation 
strategy with the highest number of predicted QALYs of 8.13 pp. 
Cost-effectiveness 
The predicted costs were with €23,660 pp lowest in the current Dutch guideline strategy (Table 2). The 
costs associated with the CMS strategy and with the mutation strategy were higher with €24,643 and 
€24,542 pp, respectively. The main cost driver in all three strategies was the cost for the initial surgery 
(Supplementary Table B1). The highest NMB at a willingness-to-pay threshold of 50,000 €/QALY was 
found for the mutation strategy (€381,827), indicating that this strategy was the preferred strategy at 
this threshold. 
In the incremental cost-effectiveness analysis, the current Dutch guideline strategy served as the first 
comparator, due to the lowest predicted cost for this strategy (Table 2). The mutation strategy was 
associated with an ICER of 28,893 €/QALY, and represented a cost-effective strategy at a willingness-
to-pay threshold of €50,000/QALY (Figure 1). The CMS strategy was dominated by the mutation 
strategy as the mutation strategy predicted higher QALYs and lower costs compared to the CMS 
strategy.  
One-way sensitivity analyses  
Results of the one-way sensitivity analyses are shown in Supplementary Table B2. 
Increasing/decreasing the recurrence risk in the MSSmut group and decreasing the recurrence risk in 
the CMS4 group led to comparable ICERs and the same optimal strategy as in the base-case analysis.  
When the recurrence risk in the CMS4 group was increased, the CMS strategy was no longer dominated 
by the mutation strategy and resulted in an ICER of 24,123 €/QALY compared to the Dutch guideline 
strategy. The mutation strategy was subject to extended dominance by the CMS strategy. Thus, in this 
analysis the CMS strategy was the preferred choice. 
7
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Figure 1. Results of the base-case analysis presented in a cost-effectiveness plane. The cost-
effectiveness plane depicts the discounted quality-adjusted life-years (QALYs) and discounted costs 
(€) of each strategy. The black line represents the cost-effectiveness frontier.  
 
Threshold analysis 
Results of the threshold analysis in which we decreased the test costs for a CMS classification are 
shown in Supplementary Figure B1. The NMB for the CMS strategy was lower compared to the 
mutation strategy when the test costs were between €500 and €200. From test costs from €100 or 
lower, the NMB of the CMS strategy was higher compared to the mutation strategy, indicating that 
the CMS strategy was the optimal strategy when the test costs were €100 or lower.  
Scenario analysis 
Results of the scenario analysis are reported in Table 3. The Dutch guidelines strategy served as the 
first comparison in the incremental cost-effectiveness analysis, given the lowest costs pp (€ 23,656). 
The mutation strategy without CMS4 resulted in an ICER of 32,633 €/QALY compared to the Dutch 
guidelines strategy, which is considered as cost-effective assuming a willingness-to-pay threshold of 
50,000 €/QALY. Furthermore, the Dutch guideline strategy without CMS4 was subject to extended 
dominance and the mutation strategy was dominated by the mutation strategy without CMS4.  
Probabilistic sensitivity analysis 
The cost-effectiveness acceptability curve shows that the Dutch guideline strategy was most likely to 
give the highest NMB up to a willingness-to-pay threshold of 35,000 €/QALY (Figure 2). From a 
willingness-to-pay of 35,000 €/QALY onwards, the mutation strategy had the highest probability to 
result in the highest NMB. The cost-effectiveness planes for the CMS strategy and mutation strategy 
compared to the Dutch guideline strategy are shown in Supplementary Figure B2.  
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Expected value of (partial) perfect information  
Figure 3 shows the population EVPI and EVPPI for a range of willingness-to-pay thresholds between 
€0-€100,000 per QALY. Assuming a willingness-to-pay threshold of 50,000 €/QALY, the population EVPI 
was €19M, which is the expected value of eliminating all current decision uncertainty. Thus, this value 
represents the maximum value that decision makers should be willing to pay for future research to 
improve their decision-making on the use of CMS and gene mutation in stage II CC treatment selection. 
The prognostic parameters for MMR, BRAF, KRAS and CMS status were the main drivers of the 
identified decision uncertainty as the population EVPPI for these parameters (€18M) was close to the 
population EVPI (€19M). We further evaluated the EVPPI for the CMS parameters and gene mutation 
(MMR, BRAF, and KRAS) parameters separately to examine whether the decision uncertainty was 
driven by one or both of these parameter subsets. Assuming a willingness-to-pay threshold of 




Figure 3. Population EVPI and EVPPI for (a selection of) the parameters in the PATTERN model. The 
population EVPI reflects the expected value of eliminating uncertainty from all model parameters 
over a range of willingness-to-pay thresholds of €0-100,000/QALY. The population EVPPI reflects the 
expected value of eliminating uncertainty in the selected sets of prognostic parameters concerning 
the gene mutations (MMR, BRAF and KRAS) and CMS, which are used to allocate adjuvant 
chemotherapy. The population EVPPI was depicted for the 3 following sets of parameters: 1) the 
MMR, BRAF and KRAS parameters, 2) the CMS parameters, and 3) the MMR, BRAF, KRAS and CMS 
parameters. Abbreviations: EVPI = expected value of perfect information; EVPPI = expected value of 
partial parameter information, CMS = consensus molecular subtype, GM = Gene mutation. 
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Discussion 
In this early cost-effectiveness study, we compared the (cost-)effectiveness of 3 selection strategies to 
allocate chemotherapy in the stage II CC population: 1) the current Dutch guidelines, 2) a selection 
strategy in which patients with a MSS status combined with a mutation in BRAF and/or KRAS OR a MSS 
status combined with a pT4 received chemotherapy and 3) a selection strategy in which patients with 
CMS4 OR pT4 received chemotherapy. These strategies were completely focused on the prognostic 
value of the MMR, BRAF, KRAS and CMS parameters. The CMS strategy and the mutation strategy were 
both more effective and more costly compared to the current Dutch guideline strategy. In an 
incremental cost-effectiveness analysis, the mutation strategy was the optimal strategy at a 
willingness-to-pay threshold of €50,000/QALY with an ICER of €28,893/QALY compared to the current 
Dutch guidelines. In addition, we evaluated the population EVPI and EVPPI for the MMR, BRAF, KRAS 
and CMS parameters. Assuming a willingness-to-pay threshold of €50,000/QALY, the expected value 
of reducing decision uncertainty by conducting further research on the MMR, BRAF, KRAS and CMS 
parameters was €18M. 
Although the CMS strategy was dominatedby the mutation strategy in the base-case analysis, the 
differences between both strategies were very small. To illustrate, comparing both the CMS strategy 
and mutation strategy to the current Dutch guideline strategy led to ICERs of €40,747/QALY and 
€28,893/QALY, respectively. Thus, assuming a willingness-to-pay threshold of €50,000/QALY, both 
strategies would be considered cost-effective compared to the current Dutch guidelines. In addition, 
in the sensitivity analysis in which we increased the recurrence risk with 10% in the CMS4 group, the 
CMS strategy became the optimal strategy with an ICER of €24,123/QALY and the mutation strategy 
was no longer considered as cost-effective as this strategy was subject to extended dominance by the 
CMS strategy. The results of this sensitivity analysis show that the optimal treatment decision depends 
on the prognostic value of the MMR, BRAF, KRAS and CMS parameters, which were the biggest drivers 
of decision uncertainty in our VOI analysis. Given the weak underlying evidence, small differences in 
predicted QALYs and costs, and the high identified decision uncertainty, the optimal strategy cannot 
be determined based on the currently available evidence.  
When interpreting our results, it should be noted that the dataset available from the study of Guinney 
et al., which was used for parametrisation of the prognostic value of CMS, also included rectal cancer 
patients (approximately 15%). As the distribution of colon cancer and rectal cancer patients is almost 
equal across the CMS subtypes and the proportion of rectal cancer patients was low, we expect that 
this had only a minor influence on the estimated hazard ratios.7 Furthermore, it should be noted that 
in the current study the molecular-based strategies were compared to the current Dutch guideline, 
which recommends adjuvant chemotherapy in patients with a MSS or pT4tumor. The Dutch guideline 
deviates from other international guidelines such as the European Society for Medical Oncology 
(ESMO) and American Society for Clinical Oncology (ASCO), as these include, besides MSS and pT4, also 
other high-risk features, i.e. <12 lymphnodes evaluated, primary tumor perforation, poor tumor 
differentiation, extramural vascular invasion (ASCO only) and obstructive tumors (ASCO only) in the 
decision to select patients for adjuvant chemotherapy.43,44 We were not able to compare the 
molecular-based strategies to strategies based on the ESMO and ASCO guideline recommendations as 
the high-risk features included in ESMO and ASCO guidelines were not included in the PATTERN model. 
As the ESMO and ASCO guidelines include more clinical and pathological high-risk factors than the 
Dutch guidelines, the percentage of treated patients would have been higher in a  potential ESMO or 
7
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ASCO strategy compared to the Dutch guideline strategy. If these clinical and pathological factors 
partly correlate with the molecular markers, the added value of the molecular markers might be more 
limited for the ESMO and ASCO guideline. 
In addition, it should be kept in mind that we assumed in the base-case analysis an equal treatment 
effect of adjuvant chemotherapy in all subgroups in the PATTERN model. That is, patients were 
selected for adjuvant chemotherapy solely based on their expected prognosis. To our knowledge, 
there are currently no indications for heterogeneous treatment effects in the clinical, pathological and 
biomarker subgroups. However, there are cautious indications that CMS4 patients are less likely to 
benefit from adjuvant chemotherapy.37-39,45 We did not take into account this potential resistance in 
the base-case analysis. The rationale for this choice is that currently available evidence is weak. 
However, it is of great importance that more data will be collected in the near future on the predictive 
value of CMS. When sufficient data is available, model analyses should be updated. Alternatively, we 
conducted a scenario analysis in which we assumed that adjuvant chemotherapy has no effect in CMS4 
patients. The results of this scenario analysis showed that it would be beneficial to exclude CMS4 
patients from adjuvant chemotherapy in case of resistance, since it leads to higher QALYs (less toxicity 
from ineffective treatment) and lower costs. This emphasizes the importance of including the 
predictive value of molecular markers in the decision making process, in addition to the prognostic 
value of these markers.  
Conducting additional research which focuses on the MMR, BRAF, KRAS and CMS parameters has the 
potential to improve decision-making on the optimal use of CMS and gene mutation data in stage II CC 
treatment selection and to reduce current decision uncertainty. A suitable design for additional data 
collection is a prospective observational cohort study. More specifically, data could be obtained as part 
of PLCRC, an observational nationwide cohort study in the Netherlands.32 Given that the expected 
costs of an observational study are substantially lower than the EVPPI estimate identified in our study 
(€18M)46, further research would be valuable to reduce the current decision uncertainty and improve 
decision-making on the value of MMR, BRAF, KRAS and CMS for treatment selection.47 
Before the CMS classification system could be used in daily clinical practice to guide adjuvant 
treatment decisions in the stage II CC population, a number of challenges should be overcome. First, a 
more standardized procedure to determine a patients’ CMS classification is needed. Nowadays, 
different procedures are used between studies, which may lead to heterogeneous results.7,48 Thus, 
future research should focus on optimizing the CMS test procedure. Second, additional data collection 
is not only needed to reduce the uncertainty around the prognostic and potential predictive value of 
molecular markers, but also to gain more insight in the interconnectivity between the CMS 
classification system and clinical and pathological high-risk features, such as pT stage and number of 
evaluated lymphnodes. To illustrate, a recent cohort study of 30 stage II CC patients with a CMS4 
classification showed that the 5-year overall survival (OS) differs between low-risk patients (5-year OS: 
41.7%) and high-risk patients (pT4 or < 10 lymphnodes evaluated) (5-year OS: 68.0%), which suggests 
that clinical an pathological characteristics are related to tumor biology.49 The association between 
CMS and clinical and pathological features should be further investigated in a larger sample size to 
optimize the identification of high-risk stage II patients.  
In conclusion, this is the first study that evaluates the cost-effectiveness of a CMS-based selection 
strategy for adjuvant chemotherapy in the stage II CC population. Both the CMS-based and mutation-
based strategy were more effective and more costly compared to the current Dutch guideline. Given 
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a threshold of €50,000/QALY, the preferred option would be to treat patients according to their BRAF 
and KRAS mutation status in addition to their MMR status and pT4. However, there was substantial 
decision uncertainty concerning the choice of optimal selection strategy, with the MMR, BRAF, KRAS 
and CMS parameters as the main drivers of this decision uncertainty. Given this decision uncertainty, 
the choice for the optimal strategy cannot be based on the currently available evidence. Additional 
research on the prognostic and predictive value of the MMR, BRAF, KRAS and CMS parameters has the 
potential to reduce this decision uncertainty and improve decision-making on the use of molecular 




Early cost-effectiveness analysis: the potential of molecular features
149602 Jongeneel BNW.indd   173 04-06-2021   13:48
 
Table 1. Overview of resource use, costs and utilities. All costs were standardized to 2020 Euros, 
using the consumer price index.50  
    







Biomarker tissue test 
  MMR 
  BRAF and KRAS mutation status 









Treatment cost per full regimen    
 CAPOXc 
 % quitting before end regimen 
€5,925  
0.25 
4, 23, 27 
24 
Adverse event cost per cased    
 Grade 3/4 neutropenia €99  23, 27, 51 
 Febrile neutropenia €3,459  23, 27, 51 
 Grade 3/4 diarrhea €50  23, 27, 51 
Absenteeism costs per cycle e 






Travel costs per cycle €9  27 
Surveillance costsf    
 Colonoscopy €888  4, 28 
 Colonoscopy with complications €1,494 0.028 28 
 Ultrasound scan € 87  4, 27 
 CEA determination € 8  4, 29 
Relapse costs €45,485  30 
 






 Before surgery (month 1) 
 After surgery/before chemotherapy (month 2 to 3) 
 During chemotherapy (month 4 to 6) 
 First year after chemotherapy (month 7 to 18) 



















 Recurrence month 1 to 60 after recurrence 0.45 0.45 52-54 
 
a The cost parameters were randomly assigned in the probabilistic sensitivity analysis using a normal distribution 
b DBC tariffs from 24 hospitals in the Netherlands were averaged.  
c The treatment with CAPOX consisted of 4 cycles of 3 weeks.4  
d The TOSCA trial was used to determine the adverse event rates.51 Costs were based on follow-up care per adverse event 
category. For neutropenia follow-up care was defined as a visit to the outpatient clinic, for febrile neutropenia as a hospital 
stay of 5 days and for diarrhea as oral rehydration medication.23,27  
e To calculate the absenteeism costs we assumed that; 1) the male to female ratio was 0.47/0.53, 2) number of hours 
worked per week was 40 and 38 for men and 28 and 25 for women in the age groups <55 and 55-65, respectively,50 and 3) 
patients do not work during chemotherapy. The absenteeism costs were calculated according to the friction cost approach. 
f Surveillance costs were calculated according to the Dutch guideline for colon cancer surveillance. 
g The utility parameters were randomly assigned in the probabilistic sensitivity analysis using a beta distribution. 
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Supplementary A. PATTERN model 
The PATTERN model distinguishes 72 clinical and pathological subgroups based on age (50-95 in nine 
5-year categories), number of lymph nodes evaluated (<10 and ≥10), pT stage (pT3 and pT4), and tumor 
site (left and right) (Supplementary Figure A1). Note that the subgroups in the PATTERN model are 
weighted such that the distribution of baseline clinical and pathological features is comparable to that 
of the 2015-2017 NCR database.  
The PATTERN model is extended with both biomarker subgroups as well as consensus molecular 
subtype (CMS) subgroups. It distinguishes 3 biomarker-based subgroups (MSI, MSS in combination 
with BRAF and KRAS wildtype, and MSS in combination with a mutation in BRAF and/or KRAS). The 
distribution of these features is based on the QUASAR trial.1 The PATTERN model also distinguishes 2 
CMS categories (CMS1-3 and CMS4). As the chance to develop a recurrence over time was comparable 
for the subgroups CMS1, CMS2 and CMS3 (Supplementary Figure A2),2 we decided to merge these 
subtypes in the PATTERN model. The distribution of the CMS subtypes in the PATTERN model was 
based on external patient-level data available from the study of Guinney et al.3  















Supplementary Figure A1. The flowchart of the Personalized Adjuvant TreaTment in EaRly stage 
coloN cancer (PATTERN) model.
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Supplementary Figure A2. Kaplan Meier curves reflecting disease free survival per CMSs.  
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Supplementary Table A2. Patient characteristics of stage II colorectal  
cancer patients included in the pooled analysis of Guinney et al.2  












pT stage  
   pT3 255 (59.6) 
   pT4 49 (11.4) 
   unknown 124 (29.0) 
  
CMS classification 
  CMS1 
  CMS2 
  CMS3 
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Supplementary Table A3. Additional information about the high risk patient selection in the 3 
evalauted strategies. 
 Selection criteria Total % of cohort 
treated 
Percentage that was 
selected based on 
pT4 
Dutch guideline strategy MSS AND pT4 3.2% NA 
CMS strategy CMS4 OR pT4 10.0% 3.0% 
Mutation strategy MSS and BRAF and/or KRAS mutation OR 
MSS and pT4 
13.2% 1.7% 
Abbreviations: NA = not applicable 
7
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Scenario analysis 
As mentioned in the method section, we assumed a treatment effect of 1 for patients with the CMS4 
subtype in the scenario analysis. Subsequently, we adjusted the treatment effect for the other 
subgroups to 0.65, so that the weighted mean was in line with the treatment effect of 0.73 that was 
estimated in the general stage II colon cancer population.4  
To allow simulation of this scenario, it was necessary to differentiate in the PATTERN model between 
patients with CMS1-3 and patients with CMS4 among the MSS double wild-type subgroup in 
combination with a pT4 and the MSS mutation subgroup as these are the subgroups which receive 
adjuvant treatment in the Dutch guideline strategy and in the mutation strategy. For this purpose, we 
used the overlap in subgroups observed in the data included in Guinney et al. (Supplementary Table 
B3). That is, we assumed in the Dutch guideline strategy that 23.1% (6 out of 26) of the patients with 
an MSS tumor in combination with a pT4 stage were classified as CMS4. For the mutation strategy, we 
assumed that 30.1% (28 out of 91) of the patients with an MSS tumor in combination with a mutation 
in BRAF and/or KRAS OR a pT4 stage were classified as CMS4.  
Probabilistic analysis 
In the probabilistic analysis all parameters in the PATTERN model were varied simultaneously 
according to their most appropriate distribution. For the MMR, BRAF, KRAS and CMS parameters it 
was necessary to maintain the average risk of recurrence in the population, while drawing random 
numbers. Therefore, for the CMS1-3 and CMS4 subgroups, we only randomly draw the prognostic 
parameter for the CMS4 group. Subsequently, the prognostic parameter for the CMS1-3 subgroup was 
determined in such a way that the recurrence risk in the overall population maintained the same. For 
the prognostic parameters for the MSI, MSSdwt and MSSmut subgroups, we applied the same 
procedure; the parameters for the MSI and MSSmut subgroup were randomly drawn and the 
parameter for the MSSdwt subgroup was determined in such a way that the recurrence risk in the 
overall population maintained the same. In order to avoid negative hazard ratios for the MSSdwt 
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Supplementary Table B3. Overlap between CMS status, mutation status and pT4 status among the 
stage II patients included in the pooled study of Guinney et al.2  
  CMS1-3 CMS4 Total 
MSI pT3 45 4 49 
 pT4 8 2 10 
 Total 53 6 59 
MSSdwt pT3 92 21 113 
 pT4 12 2 14 
 Total 104 23 127 
MSSmut pT3 43 22 65 
 PT4 8 4 12 
 Total 51 26 77 
Abbreviations: MSI = microsatellite instability, MSSdwt = Microsatellite stability in 
combination with a wild type for BRAF and KRAS, MSSmut = microsatellite stability in 
combination with a mutation in BRAF and/or KRAS, CMS = consensus molecular subtypes. 
Note that the number of patients in this table is lower than the total sample size of the 
pooled cohort included in Guinney et al. due to missing values in either mutation status or 
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Incremental quality adjusted life years



















Incremental quality adjusted life years
Mutation strategy compared to the Dutch guideline strategy
WTP €50,000/QALY
Supplementary Figure B2. Incremental cost-effectiveness planes depicting the incremental discounted 
costs (€) and incremental discounted quality-adjusted life-years (QALYs) for the CMS strategy 
compared to the Dutch guideline strategy (a) and for the mutation strategy compared to the Dutch 
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This thesis focuses on the evaluation of the optimal allocation and duration of adjuvant chemotherapy 
in stage II colon cancer patients. We first estimated the effect of adjuvant treatment on disease-free 
survival in stage II colon cancer patients using pooled data from randomized clinical trials (RCTs). 
Subsequently, the RCT estimate was compared to estimates based on real-world data. Furthermore, 
the longitudinal influence of chemotherapy on a patient's quality of life was investigated. Using the 
findings of these studies, we developed the “Personalized Adjuvant TreaTment in EaRly stage coloN 
cancer” (PATTERN) model that describes disease progression and treatment of early stage colon 
cancer, taking pathological-, clinical- and biomarker features of the patient population into account. 
Using the PATTERN model, first the optimal duration of adjuvant chemotherapy in terms of quality 
adjusted life years and costs was evaluated. Subsequently, the cost-effectiveness of different 
strategies to allocate adjuvant chemotherapy in stage II colon cancer patients was assessed. This 
chapter will summarize and discuss the main findings of this thesis. We will end with future 
perspectives for the optimal allocation of adjuvant chemotherapy.  
Summary of main findings 
In Chapter 2, we estimated the treatment effect of adjuvant chemotherapy in stage II colon cancer by 
pooling summary survival data of 9 RCTs, which compared two of the following options: fluorouracil-
leucovorin (FU/LV) (6 months), fluorouracil in combination with oxaliplatin (FOLFOX) (6 months), or no 
chemotherapy. This study demonstrated a reduced risk of progression both for FU/LV versus control 
(hazard ratio of 0.77 (95% CI, 0.43;1.10)) and for FOLFOX versus FU/LV (hazard ratio of 0.93 (95% CI, 
0.72;1.15)). Although the estimates did not reach statistical significance, the hazard ratio for FU/LV 
versus control suggests a clinically relevant benefit of adjuvant chemotherapy in terms of disease-free 
survival. Given the ongoing discussion regarding the applicability of RCT data to the real-world 
population, we compared the RCT-based estimate to estimates based on observational data from the 
Netherlands Cancer Registry (NCR). To correct for differences in baseline characteristics between 
patients with and without adjuvant chemotherapy (confounding by indication) in the NCR data we 
used propensity score methods which enhance comparability of the patients in each pairwise 
treatment comparison. We applied matching, weighting and stratification. Patients treated with 
adjuvant chemotherapy were compared to patients who did not receive adjuvant treatment. None of 
the applied methods showed a statistically significant or clinically relevant effect of adjuvant 
chemotherapy; treatment effects were 0.95 (95% CI 0.50;1.80), 0.88 (95% CI, 0.24;3.21) and 1.05 (95% 
CI, 0.04;2.06) using matching, weighting and stratification, respectively. Due to the broad confidence 
intervals around the registry-based estimates, no significant differences were found between the RCT-
based estimates and the NCR-based estimates.  
In addition to the effectiveness of treatment, it is also important to include a patient’s quality of life in 
the decision-making process. In Chapter 3 we presented the longitudinal impact of adjuvant 
chemotherapy on a patients’ quality of life, summarized as a health utility. For this study, we used data 
from the Prospective Dutch ColoRectal Cancer cohort (PLCRC). In a mixed model adjusted for age, 
gender and education level, we found a small but statistically significant lower health utility of -0.039 
(95% CI, -0.062;-0.015) during chemotherapy and the first 12 months thereafter in patients who 
received adjuvant chemotherapy compared to patients without adjuvant chemotherapy. In addition, 
we evaluated the role of Chemotherapy Peripheral Induced Neuropathy (CIPN) on a patients’ health 
utility. CIPN is a severe side-effect of the adjuvant chemotherapy and can cause sensory, motor, and 
autonomic complaints. The difference in health utility between patients treated with and without 
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adjuvant chemotherapy seems to be partly related to the sensory and motor neuropathy-related side 
effects. To illustrate, the effect of -0.039 without including neuropathy side-effects decreased to -0.020 
(95% CI, -0.044;0.003) and -0.024 (95% CI, -0.046;-0.002) after including the sensory and motor scale, 
respectively.  
In Chapter 4 we described the development of the PATTERN model, i.e. model structure, model 
assumptions, data sources, quantification and internal and external validation of the model 
predictions. To parametrize the PATTERN model, we used data of the NCR, using only the subset of 
patients that did not receive adjuvant chemotherapy after their curative resection. Transition 
probabilities were estimated in parametric survival models including relevant covariates (age, pT stage, 
number of evaluated lymphnodes and tumor sidedness). Subsequently, biomarker status was included 
in the model using an independent data source. To incorporate treatment effect in the PATTERN 
model, we used the RCT estimates reported in Chapter 2. The findings of Chapter 3 were used to 
incorporate health utilities for each of the health states in the PATTERN model. Subsequently, we used 
the PATTERN model to conduct the cost-effectiveness studies described in Chapter 5, Chapter 6 and 
Chapter 7. 
In Chapter 5 we assessed the impact of the recent revision of national and international guidelines for 
colon cancer treatment from 6 to 3 months for oxaliplatin-based chemotherapy. The cost-
effectiveness of 3 versus 6 months of adjuvant chemotherapy was compared for CAPOX and FOLFOX 
separately in a high-risk stage II colon cancer population. This study demonstrated that a 3-month 
regimen is the optimal treatment duration for CAPOX as the model predicted higher quality adjusted 
life years (QALYs) and lower costs compared to 6 months. For FOLFOX, our findings showed that 6 
months is the most favorable treatment duration, given the higher health effects for a 6-month 
regimen compared to a 3-month regimen.  
As there is no consensus on which high-risk stage II patients to select for adjuvant chemotherapy, we 
evaluated in Chapter 6 the effectiveness and cost-effectiveness of 5 risk-based selection strategies. 
We demonstrated that all evaluated strategies in which (part of the) patients were treated with 
adjuvant chemotherapy were more effective and costlier compared to a strategy in which none of the 
patients receives adjuvant chemotherapy. Based on a willingness-to-pay of 50,000 €/QALY, current 
selection of stage II colon patients for chemotherapy in The Netherlands can be improved by either 
including biomarker status in the selection strategy or improving adherence to current Dutch guideline 
recommendations. 
To evaluate the potential of including Consensus Molecular Subtypes (CMS) in the treatment decision 
for stage II colon cancer, we conducted an early cost-effectiveness study which is described in Chapter 
7. A CMS-based selection strategy was compared to the current Dutch guidelines as well as to a 
selection strategy based on MMR, BRAF and KRAS status. Based on the limited evidence available, the 
optimal use of resources would be to allocate adjuvant chemotherapy based on MMR, BRAF and KRAS 
status assuming a willingness-to-pay threshold of 50,000 €/QALY. However, a value of information 
analysis showed that the CMS, MMR, BRAF, and KRAS model parameters were the biggest drivers of 
uncertainty. Thus, additional research is needed to reduce decision uncertainty for these parameters.  
Reflection on main findings 
The studies described in this thesis have provided additional evidence concerning chemotherapy 
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chemotherapy after surgical resection of the primary tumor. These topics are considered as three 
important knowledge gaps for the stage II colon cancer population (Chapter 1). We also gained new 
insights into the burden of adjuvant chemotherapy. However, we encountered several challenges 
along the way, which will be discussed in the following section.  
The parametrization and validation of a decision analytic model 
The PATTERN model is mainly quantified based on data of the NCR (Chapter 4). Although registry data 
is not considered as the highest level of evidence, registry data is discussed in the literature as a data 
source with high potential to guide complex medical decisions, provided that limitations due to the 
observational nature of registry data are taken into account in the analyses.1-3 The most common 
challenges in registry data as input for model-based cost-effectiveness studies are missing information, 
confounding by indication, and insufficient numbers of comparable patients.1 The extent to which 
these challenges occur differs per registry. Thus, an unambiguous answer to what extent registry data 
is valid to use as input for models aimed to support decision making does not exist. To assist 
researchers in determining the value of registry data, several studies have provided guidance for 
assessing the reliability of observational data to inform decision making.3-6 According to these 
guidelines, the most important point of focus is the design of observational prospective studies. During 
the design of the study, extensive consideration should be given to the purpose of the data collection. 
Based on the purpose, it should be determined which covariates to include in the dataset in order to 
meet the strict condition of unconfoundedness for future analyses to correct for confounding by 
indication. Notwithstanding the challenges with registry data, there is one major advantage; a decision 
model that is informed by registry data delivers predictions that are probably better generalizable to 
daily clinical practice than a RCT-based model, and thus provides better insight into an intervention's 
value for money in daily practice.1 
In addition to model parametrisation, model validation is also an important part of model 
development. The PATTERN model is extensively validated both internally and externally (Chapter 4). 
In particular the external validation proved challenging. There is a considerable body of literature 
available with guidelines for performing an external validation, such as the Assessment of the 
Validation Status of Health-Economic decision models (AdViSHE) tool and the Good Research Practices 
Task Force for model transparency and validation developed by the ISPOR and SMDM.7-9 However, 
there is no clear guidance or criterion for determining when the model is able to satisfactorily 
reproduce external data. Moreover, when the model performance in the external validation exercise 
is considered as insufficient, there are no guidelines on how to “refit” the model. The reason for this 
lack of guidance is presumably two-sided. First, external validations are rarely performed during the 
development process of a health-economic model due to the lack of suitable data. Indeed, all relevant 
and available data is often already used to inform the model. Second, the methods for performing an 
external validation strongly depends on the type of model and the available data. This makes it difficult 
to capture all possible approaches in guidelines. The lack of guidance allows for a broad interpretation 
of the results of an external validation, which can lead to an overly optimistic interpretation of model 
performance. To illustrate, the PATTERN model was externally validated using the 2015 data of the 
Netherlands Cancer Registry. Overall, 78% of the model predictions fitted within the 95% confidence 
interval of the estimates based on the 2015 NCR data. In our case, we rated this percentage as 
sufficient, but the lack of guidance leads to a subjective character in the assessment of the external 
validation.  
200
8      Chapter 8
149602 Jongeneel BNW.indd   200 04-06-2021   13:49
 
Overestimation of the performance of a decision model is undesirable, especially in view of the 
increasing role that outcomes of decision models have in the development of health policy.10 Given 
the rising healthcare costs in the Netherlands due to the aging population and the increasing 
availability of new medicines, policy makers are focused on distributing health care as efficient and fair 
as possible within the available budgets.11 Model-based cost-effectiveness research can support the 
government to make responsible choices in terms of health effects and costs. However, it is hard to 
determine when the quality of cost-effectiveness research is good enough to use as input for policy 
making. The National Healthcare Institute has formulated several requirements for cost-effectiveness 
studies. In this requirements attention is paid to the methodological quality of the analyses, the 
uncertainty surrounding the study results and the question if more research is needed and/or useful.10 
Predictive treatment effects 
In the economic evaluations described in Chapter 5, Chapter 6 and Chapter 7, we assumed in the main 
analyses that treatment effect is equal across patient subgroups differing in clinical, pathological and 
biomarker characteristics. Although this assumption is in line with current literature14,15, there are 
investigators that hypothesize that there is heterogeneity in treatment effect, especially for subgroups 
of patients stratified on the basis of genetic features. Although significant differences in treatment 
effect between these subgroups (predictive treatment effect) have not yet been demonstrated so far, 
this does not necessarily mean that they do not exist. Estimating predictive treatment effects is 
extremely difficult and involves fundamental and conceptual problems,16 which are explained in more 
detail below. 
RCTs are considered as the golden standard to estimate treatment effect.17 However, the results of an 
RCT only provide insight into the average treatment effect for the trial population. The impact of the 
treatment in a specific individual is unclear as individual patients have many characteristics that might 
affect the benefits and harms of a specific treatment. Thus, determining the treatment effectiveness 
for a specific patient differs from determining the treatment effectiveness on average, which is often 
the main goal of a RCT.16 To gain more insight in the treatment effect in a group of patients with certain 
characteristics, subgroup analyses are often performed in trials. In such an analysis, the results are 
stratified for one specific variable, for example young versus old. Whether the treatment effects for 
these subgroups are comparable is often evaluated by studying the overlap in the confidence intervals 
for both subgroups. Another commonly used technique is the inclusion of an interaction term in the 
regression model between the subgroup variable and the treatment variable. The statistical 
significance of this interaction term determines whether the treatment effects is considered different 
between the subgroups. However, RCTs are usually powered to detect a main treatment effect rather 
than to detect differences in treatment effect between subgroups. To illustrate, to evaluate an 
interaction effect at least four times the sample size is needed to provide similar power as for the main 
treatment effect.18,19 The evaluation of treatment heterogeneity should therefore already be included 
in the design of the RCT and in the sample size calculation. However, when using conventional analysis 
methods, this will lead to unrealistically high sample sizes, in particular when aiming to test interaction 
effects for many different (genetic) features simultaneously. 
Estimating predictive treatment effects from existing RCT data is an upcoming field that requires new 
expertise and approaches. Many studies focus on both machine learning and regression based 
methods.20-27 However, clinical application of these methods is very limited due to the lack of validation 
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art techniques and to indicate which of these are adequate techniques to estimate predictive 
treatment effects.  
In addition to RCT data, observational data could also be a promising source to estimate predictive 
treatment effects in the future, especially since the introduction of the electronic patient record. Due 
to the sometimes extremely large sample size, observational data can achieve much more statistical 
power than (pooled) RCTs.29,30 However, researchers are also hesitant about using observational data 
to estimate predictive treatment effects. Due to the non-randomized nature, such datasets are very 
sensitive to confounding by indication. In order to properly correct for this, the data must meet the 
not formally testable condition of unconfoundedness, which is a strict requirement. More knowledge 
is needed to assess whether and how observational data can be used to estimate predictive treatment 
effects.16,31,32 
Guideline development and adherence to the guidelines 
In 2019, the recommended treatment duration in the Netherlands for CAPOX was revised from 6 
months to 3 months for stage II colon cancer patients.33 This guideline adjustment was primarily based 
on the findings from the IDEA collaboration.34,35 No cost-effectiveness study from the Dutch 
perspective was conducted to inform this decision.  
In the Netherlands, a guideline for the optimal development of clinical guidelines has been developed 
on behalf of the Ministry of Health, Welfare and Sport.36 According to this guideline, insight into the 
financial consequences of recommendations during the development process is necessary to make 
socially responsible choices when spending resources in health care. However, in the case of 
shortening a treatment duration, while assuming that the effectiveness of the treatment remains the 
same, it is clear that this will save costs and provide health benefits in terms of reduced treatment 
toxicity. Nevertheless, it is still important to gain insight into the amount of cost savings and health 
benefits as well as to understand the impact of uncertainty. In Chapter 5 we concluded that a 3-month 
regimen should be considered as standard of care in high-risk stage II colon cancer patients for CAPOX, 
but not for FOLFOX. Thus, the adaptation of the Dutch guidelines is supported by the findings in this 
thesis. However, our study also indicated that a relatively small change in hazard ratio for treatment 
effectiveness for 3 versus 6 months of CAPOX will lead to a QALY loss instead of gain. This small change 
in treatment effect was within the confidence interval of the IDEA trials, which we used as input for 
the cost-effectiveness analysis. The current Dutch guideline recommendation of 3 months of CAPOX 
does not include this uncertainty around the effect difference between 3 and 6 months of treatment. 
Therefore, it is advisable to discuss treatment continuation after 3 months per patient based on a 
patients’ preference and clinical condition.  
After adjusting clinical guidelines, the new recommendations should be implemented in clinical 
practice. The implementation of new guidelines is preferably done in close collaboration with involved 
organisations, such as professional organisations and patient federations. These organizations are 
expected to make an active effort to apply the guideline in practice.36 However, literature shows that 
clinical guideline adherence in the field of colon cancer is not optimal in the Netherlands37, while the 
cost-effectiveness of adjuvant chemotherapy would improve considerably if adherence to the current 
Dutch guidelines increased (Chapter 6). An important reason to deviate from the guidelines is poor 
clinical condition of the patient. But ignorance and disagreement with the clinical guidelines by medical 
specialists are probably also reasons to deviate. For these medical specialists, clear communication of 
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the rationale behind the adaption of the guidelines is a key component to increase the willingness to 
follow the revised guidelines.38,39 Given the imperfect adherence to the guidelines, it is important to 
evaluate adherence in the coming years in order to prevent the harms of over- and undertreatment 
for colon cancer patients. Data of the NCR and the Prospective Dutch ColoRectal Cancer cohort (PLCRC) 
are suitable data sources to evaluate guideline adherence in clinical practice in this patient 
population.40,41 
Future perspectives 
Predictive and prognostic value of molecular markers 
BRAF, KRAS and CMS status are strong prognostic factors in stage II colon cancer patients in terms of 
disease-free survival. Therefore, the cost-effectiveness of different risk-based strategies including 
these factors was evaluated in Chapter 6 and Chapter 7. However, little is known about the predictive 
value of these markers. Better insight into which patient characteristics lead to a better or worse 
response to adjuvant chemotherapy would be valuable in further optimizing patient selection for 
adjuvant chemotherapy.  
In addition to BRAF, KRAS and CMS status, the presence of circulating tumor DNA (ctDNA) is also 
recognized as a strong prognostic factor for disease-free survival.42,43 To illustrate, a prospective 
observational study of 230 stage II colorectal cancer patients demonstrated an increased risk of 
recurrence for patients that were tested positive for ctDNA compared to patients that were tested 
negative, with a hazard ratio of 18 (95% CI, 7.9;40).42 Due to this strong prognostic value, ctDNA is 
considered as a promising factor to guide adjuvant chemotherapy decisions in the stage II population. 
However, ctDNA is only present in a very small proportion of the population; 14 patients tested positive 
in the abovementioned study, which is equal to 6% of the stage II colorectal cancer population. Thus, 
additional prospective randomized studies, such as MEDOCC-CrEATE, are needed to further expand 
the knowledge of the prognostic (and predictive) value of ctDNA in early stage colorectal cancer. The 
MEDOCC-CrEATE study uses a trial within cohorts (TwiCs) design, which allows for randomizing 
patients before ctDNA measurement for adjuvant chemotherapy. The trial aims to investigate whether 
adjuvant chemotherapy will prevent recurrence of disease in patients which were positive tested for 
ctDNA.40,43 The inclusion for this study is ongoing and the first results are expected in 4 years.  
Before ctDNA could be implemented as a prognostic biomarker in daily clinical practice, a couple of 
challenges have to be overcome. The detection of ctDNA in a sensitive way can be highly complex, 
especially in early stage colon cancer patients. To illustrate, if ctDNA is present in early stage colon 
cancer patients, the amount of ctDNA, also known as the mutant allele frequency, is extremely low.44 
In addition, the different steps for ctDNA analysis can be conducted in a variety of manners, each with 
their own advantages and disadvantages.44,45 Thus, standardization of the analytical procedure is 
warranted. Although the publication output focused on ctDNA analysis has increased the last years, 
additional research is ongoing to optimize the diagnostic procedure. To illustrate, in the Netherlands, 
the COIN consortium has been recently formed to investigate the essential steps to use ctDNA in a 
controlled, cost-effective and validated way in daily clinical practice in the future. 
The PATTERN model as a framework for future cost-effectiveness research  
The PATTERN decision model is a multi-applicable model; it can be used to evaluate the cost-
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selection of stage II colon cancer patients for adjuvant chemotherapy in the current thesis. In the 
future, the PATTERN model will be used for the evaluation of patient selection strategies based on new 
genetic features, such as ctDNA. In addition, the structure of the PATTERN model will be used as a basis 
for the PersonAlization and opTimizaTion of follow-up after curativE coloRectal caNcer treatment 
(PATTERN-2) model, which focuses on the evaluation of personalized follow-up schedules in stage II 
and III colorectal cancer.  
Especially for the second purpose, rigorous adjustments to the PATTERN model will be required. That 
is, the model needs to be expanded with new health states as the follow-up schedule is not yet 
included in the PATTERN model. Furthermore, the model will be re-parameterized with updated 
registry data as the targeted population is broader than only the stage II colon cancer population. 
Besides, the PATTERN model was parametrized using data collected in 2002-2008, while in the 
meantime more recent data became available. After making these rigorous changes, the internal and 
external validation of the model should be repeated. It is important to keep evaluating the validity of 
the model.7 Ideally, the validation procedure should take place for every application of the model.7 An 
example of a multi-applicable decision model that has already been used for many different purposes 
and that follows the good practice of repeated validation is the Archimedes diabetes model. 46-48 To 
illustrate, the Archimedes model was, among others, used to evaluate the cost-effectiveness of 
lifestyle modifications to avoid diabetes type 2 as well as to evaluate the optimal screening strategy to 
detect diabetes type 2.48,49 For both purposes, the developers conducted external validations after 
modifying the model to answer the specific research questions. In total, more than 50 clinical trials 
have been used to validate the Archimedes model.46,50 In addition, the developers used cohort follow-
up studies, registries and national databases for the external validation.50 
Concluding remarks 
The studies presented in this thesis provide new insights into the optimal allocation and duration of 
adjuvant chemotherapy in stage II colon cancer patients. The findings support the recent Dutch 
guideline adjustment to shorten the treatment duration from 6 months to 3 months for CAPOX in high-
risk stage II colon cancer patients. Furthermore, our findings indicate that selection of stage II colon 
patients for chemotherapy can be optimized by either improving adherence to Dutch guideline 
recommendations or by including biomarker status in the selection strategy. However, more research 
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Nederlandse samenvatting  
Dit proefschrift richt zich op de evaluatie van de optimale duur van adjuvante chemotherapie, alsmede 
de optimale selectie van patiënten voor adjuvante chemotherapie bij stadium II dikke darmkanker. 
Adjuvante chemotherapie is een aanvullende behandeling die gegeven wordt aan dikke darmkanker 
patiënten na een in opzet curatieve operatie. Het doel van deze aanvullende behandeling is om de 
kans op terugkeer van de ziekte te verkleinen. In dit proefschrift hebben we eerst het effect geschat 
van adjuvante behandeling op de ziektevrije overleving bij stadium II dikke darmkanker patiënten met 
behulp van gepoolde gegevens uit gerandomiseerde klinische onderzoeken. Daarna voerden we een 
studie uit gericht op de invloed van adjuvante chemotherapie op de kwaliteit van leven van patiënten. 
Met behulp van de resultaten van deze twee studies hebben we het "Personalized Adjuvant TreaTment 
in EaRly stage coloN cancer" (PATTERN) model ontwikkeld. Het PATTERN-model beschrijft de 
ziekteprogressie van stadium II dikke darmkanker, rekening houdend met pathologische, klinische en 
moleculaire kenmerken van de patiëntpopulatie. Met behulp van het PATTERN model werd eerst de 
optimale duur van adjuvante chemotherapie geëvalueerd in termen van voor kwaliteit gecorrigeerde 
levensjaren (‘quality adjusted lifeyears’ oftewel QALYs) en kosten. Vervolgens werd de 
kosteneffectiviteit geëvalueerd van verschillende strategieën om patiënten te selecteren voor 
adjuvante chemotherapie in de stadium II dikke darmkanker populatie.   
In hoofdstuk 2 schatten we het behandeleffect van adjuvante chemotherapie in stadium II dikke 
darmkanker door data over terugkeer van ziekte van negen gerandomiseerde klinische onderzoeken 
samen te voegen. Alle geïncludeerde studies vergeleken ten minste twee van de volgende drie studie 
armen: fluorouracil-leucovorine (FU/LV), fluorouracil in combinatie met oxaliplatine (FOLFOX) of 
controle (geen chemotherapie). Onze gepoolde studie toonde een verminderd risico aan op terugkeer 
van de ziekte voor zowel FU/LV versus controle (hazard ratio van 0.77, 95% BI 0.43; 1.10) als voor 
FOLFOX versus FU/LV (hazard ratio van 0.93, 95% BI, 0.72; 1.15). Hoewel de schattingen niet statistisch 
significant waren, suggereert de hazard ratio voor FU/LV versus controle wel een klinisch relevant 
effect van adjuvante chemotherapie in termen van ziektevrije overleving. Omdat in gerandomiseerde 
klinische studies vaak sprake is van strenge in- en exclusiecriteria heerst er discussie over de 
toepasbaarheid van de data uit deze studies op de de gehele stadium II darmkanker populatie. Daarom 
hebben we de gerandomiseerde schattingen vergeleken met schattingen op basis van observationele 
data afkomstig uit de Nederlandse Kankerregistratie (NKR). Om in de NKR-data te corrigeren voor 
verschillen in kenmerken tussen patiënten die wel een niet adjuvante chemotherapie ontvingen, 
gebruikten we geavanceerde analyse methoden, namelijk propensity score matching, weging en 
stratificatie. Geen van de toegepaste methoden toonde een statistisch significant of klinisch relevant 
effect van adjuvante chemotherapie aan met hazard ratio’s van 0.95 (95% BI 0.50; 1.80), 0.88 (95% BI 
0.24; 3.21) en 1.05 (95% BI 0.04; 2.06) respectievelijk voor matching, weging en stratificatie. Er werden 
geen significante verschillen gevonden tussen de schattingen gebaseerd op de gerandomiseerde 
studies en de schattingen gebaseerd op de NKR-data. Dit was vermoedelijk vanwege de brede 
betrouwbaarheidsintervallen rondom de op de NKR gebaseerde schattingen. In Hoofdstuk 2 
concludeerden we op basis van de bevindingen in de klinische gerandomiseerde onderzoeken dat, 
hoewel de schatting niet statistisch significant waren, de hazard ratio voor FU/LV versus controle wel 
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Naast de effectiviteit van adjuvante behandeling is het ook belangrijk om de invloed van deze 
behandeling op de kwaliteit van leven mee te nemen in het besluit om adjuvante behandeling al dan 
niet voor te schrijven aan een patiënt. In hoofdstuk 3 beschrijven we de impact van adjuvante 
chemotherapie op de kwaliteit van leven van een patiënt samengevat als gezondheidsutiliteit. Een 
gezondheidsutiliteit is een maat om levensjaren te corrigeren voor kwaliteit van leven, waarbij een 
utiliteit van 1 gelijk staat aan perfecte gezondheid en een utiliteit van 0 aan dood. Voor het uitvoeren 
van deze studie maakten we gebruik van gegevens van het Prospectief Landelijk ColoRectal Cancer 
(PLCRC) cohort. In een mixed model, gecorrigeerd voor leeftijd, geslacht en opleidingsniveau, vonden 
we een statistisch significant lagere gezondheidsutiliteit van -0.039 (95% BI -0.062; -0.015) tijdens 
chemotherapie en de eerste twaalf maanden daarna bij patiënten die behandeld werden met 
adjuvante chemotherapie ten opzichte van patiënten die niet behandeld werden met adjuvante 
chemotherapie. Daarnaast hebben we de rol van chemotherapie geïnduceerde perifere neuropathie 
(CIPN) geëvalueerd in de associatie tussen chemotherapie en gezondheidsutiliteit. CIPN is een ernstige 
bijwerking van de adjuvante chemotherapie en kan sensorische, motorische en autonome klachten 
veroorzaken. Het verschil in gezondheidsutiliteit tussen patiënten behandeld met en zonder adjuvante 
chemotherapie lijkt gedeeltelijk verband te houden met de sensorische en motorische neuropathie-
gerelateerde bijwerkingen. Ter illustratie, het effect van -0.039 dat we vonden zonder het includeren 
van CIPN nam af tot -0.020 (95% BI -0.044; 0.003) en -0.024 (95% BI -0.046; -0.002) bij het includeren 
van de sensorische en motorische bijwerkingen, respectievelijk. 
In hoofdstuk 4 hebben we de ontwikkeling van het PATTERN model beschreven, dat wil zeggen de 
model structuur, de model aannames, de gebruikte databronnen, de model parametrisatie en de 
interne en externe validatie van de model predicties. Om het PATTERN model te parametriseren 
gebruikten we data uit de NKR, waarbij we alleen de patiënten includeerden die geen adjuvante 
chemotherapie kregen na hun curatieve operatie. De overgangskansen werden geschat door middel 
van parametrische overlevingsmodellen inclusief relevante covariaten (leeftijd, pT stadium, aantal 
geëvalueerde lymfeklieren en tumor zijde). Vervolgens werd het voorkomen van verschillende 
biomarkers in het model opgenomen op basis van een externe, onafhankelijke databron. Om het 
behandeleffect van adjuvante chemotherapie in het PATTERN model op te nemen hebben we de 
schattingen op basis van de gerandomiseerde studies uit hoofdstuk 2 gebruikt. De bevindingen uit 
hoofdstuk 3 zijn gebruikt om gezondheidsutiliteiten op te nemen in het PATTERN model. Vervolgens 
hebben we het PATTERN model gebruikt om de kosteneffectiviteitsstudies uit te voeren die worden 
beschreven in hoofdstuk 5, hoofdstuk 6 en hoofdstuk 7. 
In hoofdstuk 5 evalueren we de impact van de recente aanpassingen van nationale en internationale 
richtlijnen voor de behandelduur van adjuvante chemotherapie, welke is bijgesteld van zes naar drie 
maanden voor oxaliplatine-gebaseerde behandelingen, namelijk CAPOX en FOLFOX. De 
kosteneffectiviteit van drie versus zes maanden adjuvante chemotherapie werd voor CAPOX en 
FOLFOX apart vergeleken in een hoog-risico stadium II dikke darmkanker populatie. Deze studie 
toonde aan dat een behandelduur van drie maanden optimaal is voor CAPOX, aangezien het PATTERN 
model hogere QALYs en lagere kosten voorspelde in vergelijking met een behandelduur van zes 
maanden. Voor FOLFOX vonden we dat zes maanden de optimale behandelduur is, gezien de hogere 
gezondheidswinst voor een behandelduur van zes maanden in vergelijking met een behandelduur van 
drie maanden. 
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Aangezien er geen consensus bestaat over welke stadium II patiënten geselecteerd zouden moeten 
worden voor adjuvante chemotherapie, hebben we in hoofdstuk 6 de effectiviteit en 
kosteneffectiviteit van vijf risico gebaseerde selectiestrategieën geëvalueerd. We toonden aan dat alle 
geëvalueerde strategieën, waarbij (een deel van de) patiënten werd behandeld met adjuvante 
chemotherapie, effectiever en duurder waren in vergelijking met een strategie waarbij geen van de 
patiënten adjuvante chemotherapie kreeg voorgeschreven. Op basis van een willingness-to-pay 
drempelwaarde van €50.000/QALY, welke vaak gebruikt wordt in Nederland voor beleidsmatige 
beslissingen, kan de huidige selectie van stadium II dikke darmkanker patiënten voor chemotherapie 
verbeterd worden door ofwel biomarker status op te nemen in de selectiestrategie, ofwel de naleving 
van de huidige Nederlandse richtlijnen te verbeteren. 
Om de potentiële rol te evalueren van moleculaire subtypes (consensus molecular subtypes (CMS)) in 
de behandelbeslissing voor stadium II dikke darmkanker patiënten hebben we een vroege 
kosteneffectiviteitsstudie uitgevoerd die wordt beschreven in hoofdstuk 7. Een selectiestrategie 
gebaseerd op de moleculaire subtypes werd vergeleken met de huidige Nederlandse richtlijnen en met 
een strategie op basis van mismatch repair (MMR), BRAF en KRAS status. Uitgaande van een 
willingness-to-pay drempelwaarde van €50.000/QALY bleek het voorschrijven van adjuvante 
chemotherapie  op basis van de MMR, BRAF en KRAS mutatiestatus optimaal te zijn. Echter, een ‘value-
of-information’ analyse toonde aan dat de CMS, MMR, BRAF en KRAS parameters de grootste 
aanjagers waren van onzekerheid in onze studie. Er is dus aanvullend onderzoek nodig om de 
beslisonzekerheid voor deze parameters te verminderen. 
In conclusie, de studies die in dit proefschrift worden gepresenteerd bieden nieuwe inzichten in de 
optimale duur van adjuvante chemotherapie, alsmede de optimale selectie van patiënten voor 
adjuvante chemotherapie bij stadium II dikke darmkanker. De bevindingen ondersteunen de recente 
aanpassing in de Nederlandse richtlijnen om de behandelduur van CAPOX te verkorten van zes 
maanden naar drie maanden bij patiënten met hoog risico stadium II dikke darmkanker. Bovendien 
laten onze bevindingen zien dat de selectie van stadium II dikke darmkanker patiënten voor adjuvante 
chemotherapie kan worden geoptimaliseerd door ofwel de naleving van de Nederlandse richtlijnen te 
verbeteren ofwel door biomarker status op te nemen in de selectiestrategie. Echter, er is meer 
onderzoek nodig om de mogelijke rol van biomarkers bij de optimale toewijzing van adjuvante 
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